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Summary
This study investigated the potential of flow cytometry for assessment 
of both the immunology and oncology of breast cancer and explored the 
possibility of correlation between the two.
The T cell receptor y/8 expression was studied in lymphocytes found in 
the tumour (TILs), in the tumour draining lymph nodes and in the blood. 
During this study the T lymphocytes were divided into CD3, CD4 and CD8 
phenotypic subsets to assess differences. Tumour Infiltrating Lymphocytes 
(TILs) were observed to have a greater median expression of CD3+ CD8+ 
y/8+, whereas in contrast the lymph node lymphocytes (LNL) are shown to 
have a higher median expression of CD3+ CD4+ y/8+ lymphocytes. 
Interestingly the majority of y/8+ lymphocytes were double negative (CD4- and 
CD8-) which may indicate a role for this subset in immunology of breast 
cancer. Breast tumours often have reduced MHC class I expression, which in 
effect means that normal cytotoxic T cell mediated tumour killing is inhibited. 
Consequently other non MHC mediated killing methods, possibly mediated by 
the double negative y/8 T cell subset, may be important in tumour 
immunology.
The immune response was assessed in a tumour invaded and a tumour 
free lymph node removed from the same patient. The phenotype and activation 
of these lymphocytes was measured by flow cytometry to study the effect of 
metastatic tumour on the nodal immune response. The most significant 
difference was noted in the T lymphocyte phenotype, with the tumour invaded 
lymph node having an increased percentage of CD8+ cytotoxic T cells
XVI I
(pcO.OOl) which were replaced in the tumour free node, by CD4+ T helper 
cells (p=0.008). The trend was clearly shown as aj/i decreased CD4/8 ratio in 
the tumour invaded node, increasing significantly in the tumour free node 
(p<0.001). Significant changes were also observed for activation marker 
expression with HLA DR levels significantly higher in the tumour invaded 
nodes for both CD8+ T cells (p=0.023) and CD4+ T cells (p=0.036). The 
interleukin-2 receptor expression however was only significantly increased in 
the tumour invaded nodes for CD8+ T cells (p=0.029) these trends possibly 
being indicative of the effect of tumour invasion on the immune system.
Low and high axillary nodes which had been removed from each breast 
cancer patient were used to assess which of the observed lymphocyte 
phenotype and activation differences were local and also to compare stage I and 
II nodal responses. The stage II patients were then further subdivided into 4 
subsets on the presence or absence of metastatic tumour within these lymph 
nodes. Phenotypic changes were observed in the 22 stage I patients only with 
a j  significant increase in CD3+ T cell percentage in the low node (p=0.042), 
with a concomitant decrease in the high node. The opposite was observed for 
CD 19+ B cells (p=0.036), with a lower percentage in the low node. This trend 
was reflected in the significant decrease in the CD3/CD19 ratio (p=0.036). No 
significant phenotypic trends were noted for pooled stage II patients. However 
when the subsets of stage II patients were analysed a significant trend for T 
cells was noted in the subset with low node tumour invaded and the high node 
tumour free with a higher CD4/8 ratio in the low invaded node, decreasing in 
the high node (p=0.05). Lymphocyte activation trends were observed in the 22 
paired stage II nodes only. The low nodes showed significantly higher 
percentages of CD4+ HLA DR+ lymphocytes (p=0.01) and of interleukin-2
XV111
receptor (Tac) expression on both CD8+ T cells (p=0.05) and CD4+ T cells 
(p<0.001). The stage II subsets showed significant changes in activation, with 
the low node tumour invaded and high node tumour free showing significantly 
higher percentages of CD8+ HLA DR+ lymphocytes in the low node compared 
to the high node (p=0.05). Trends of increasing interleukin-2 receptor (Tac) 
expression in the low node were observed for CD4+ T cells (p=0.005). A 
trend of increasing expression of IgG on CD 19+ B cells was observed in the 
subset with both low node and high node tumour free (p=0.05). The general 
conclusion was that the invasion of the node was reflected primarily in the 
HLA DR response on CD8+ (T cytotoxic) cells while distance from the tumour 
was reflected by the interleukin -2 receptor (tac) response on CD4+ (T helper) 
cells.
Two oncoprotein markers were then analysed in the primary and 
metastatic tumour. p53 and c-erb B-2 expression y/£s measured in primary and 
metastatic breast cancer by dual parameter flow cytometry (oncoprotein and 
DNA). Interestingly almost all tumours had a detectable number of cells 
positive for both oncoproteins and no tumour had 100% of the cells positive. 
This was true even in the node where there was no possibility of "normal" 
epithelial cells being present in the sample. There were no significant trends for 
either c-erb B-2 and p53, although the c-erb B-2 expression tended to increase 
in stage II patients compared to stage I. In addition aneuploid tumours tended 
to have an increased expression of c-erb B-2. The level of both c-erb B-2 and 
p53 had little variation when primary tumour was compared to matched 
metastasis.
p53 and c-erb B-2 expression and tumour ploidy were then related to the 
nodal immune response to deduce the effect of tumour type on the immune
xix
system. No trends were evident for c-erb B-2 expression and the nodal 
immune response, whereas increased p53 expression tended to be related to 
increasing levels of the interleukin-2 receptor (tac) on CD4+ T cells (p=0.009). 
The ploidy of the tumour was related to the level of lymphocytic activation in 
the lymph nodes, with generally higher levels in the nodes draining aneuploid 
tumours. The only significant trend observed was for increased levels of slgG 
on CD 19+ B cells in nodes draining aneuploid tumours (p=0.04).
Overall the data illustrate inter and intra patient heterogeneity of both the 
tumour and the immune response to it. Thus, as each patient is unique, only a 
limited subset of patients are likely to respond to immunotherapy.
CHAPTER 1 
INTRODUCTION
11.1. Cancer
There exists in animals a delicate balance between cell death and cell 
renewal. As cells die they are replace by new cells generated by proliferation. 
Under normal circumstances the production of new cells is so regulated that the 
numbers of any particular type of cell remain constant. Occasionally cells arise 
which do not respond to normal growth control mechanisms. These cells will 
divide and give rise to a group of cells collectively known as cancer.
1.1.1. The history of breast cancer and treatment
Breast Cancer is an ancient disease, being first described by the 
Egyptians five thousand years ago (Donegan, 1988). The Romans were the 
first to attempt surgery as a treatment. However it was a Greek, Galen, who in 
the second century A.D described Breast cancer as "Like a crab, with the 
appearance of large veins from the sides giving the appearance of legs " thus 
the term cancer was coined. Galen at this time described breast cancer as being 
a "systemic disease" attributed to an excess of black bile in the body for which 
there was no cure.
Until the nineteenth century the practice of breast surgery was extremely 
ill advised and barbaric often resulting in death during the operation. It was 
only when Descartes discovered the lymphatic system and specifically the 
axillary lymph nodes draining the breast that Galen's black bile systemic 
disease theory was questioned. Le Dran offered the first alternative theory of 
breast cancer being a local disease which would begin in the breast, then 
metastasise to the nodes and from there finally enter the general circulation.
2This pointed the way to early diagnosis and surgery to halt the disease. The 
advance in breast surgery came with Halsted and the radical mastectomy 
(Halsted, 1894). This novel surgery at this time was based on an anatomical 
understanding of the disease, which involved the en bloc removal of the 
breast, pectoralis muscle and the axillary draining lymph nodes in all patients. 
The radical mastectomy was performed in its entirety unchanged until the early 
1960's. The acceptance of the radical mastectomy was due to the surgeons 
being convinced that no improvements could be made, as the limit of radical 
surgery had been reached. Eventually there was an irresistible stimulus for 
reassessment of treatment, as, although the limit of surgery had been reached, 
one third of all women were still succumbing to the disease. The greater 
understanding of the biology of cancer and the study of the metastatic process 
had shown that the confinement of the disease to the lymph nodes had come to 
an end long before surgery was attempted. Studies initiated on the effect of 
surgery suggested that the radical mastectomy was perhaps too radical and 
more conservative surgery could well be advocated in many cases. The type of 
surgery was altered and combined with new secondary treatments such as 
radiation and chemotherapy. Resultant trials have shown this to be just as 
effective as the radical mastectomy.
1.1.2 Treatment of breast cancer
The treatment of breast cancer is continuously evolving and throughout 
the U.K. variable surgical and post operative therapy regimes exist. In the 
Western Infirmary, Glasgow the surgery consists of two main types, 
lumpectomy and mastectomy.
3Lumpectomy involves the removal of the tumour when the tumour is 
less than 3 cm in size. With mastectomy there is removal of the whole breast 
down to the pectoralis major muscle when tumour size is greater than 3 cm. 
Simultaneously in both cases the axillary tumour draining nodes are removed 
and are assessed for the presence of tumour (Section 1.1.6.1.).
Post-operative therapy in the Western Infirmary is of two types 
depending on the presence of tumour metastases in the axillary lymph nodes.
(A) No tumour present in the axillary nodes: post-operative therapy is not 
given
(B) Tumour present in the axillary nodes: post-operative therapy given.
Pre menopausal women receive chemotherapy in a combination of 
chemotherapeutic agents known as CMF (cycloheximide, methotrexate and 5- 
fluorouracil) over a set period after surgery (Bonadonna, 1979).
Post menopausal women receive tamoxifen an anti-estrogen drug if the 
tumour has been shown to be estrogen driven or CMF due to failure of 
tamoxifen treatment. As well as chemotherapy the lumpectomy patients receive 
wide field radiation therapy to the breast. The function of these therapies is to 
stop rapidly dividing cancer cells by inhibiting DNA synthesis the major 
drawback being that other fast dividing cells such as lymphocytes are affected 
and this may curtail any immune response to the tumour.
There are no guide lines on breast cancer treatment and due to this fact 
many differences in surgery are observed between treatment centres. It is for 
individual surgeons to decide on what they perceive to be the optimal patient 
treatment. Surgical views are often opposing and generate much debate around
4topics such as the requirement for removal of the axillary nodes (Fentiman and 
Mansel, 1991) especially if these nodes are generating an immune response 
against the tumour. However in contrast, the USA has specific treatment 
guidelines on surgery and therapies. An example of this is the widespread 
practice to give pre-operative chemotherapy to shrink the tumour and to reduce 
tumour cell shedding during surgery. Eventually in this country regimes must 
be rationalised since treatment goes hand in hand with a greater understanding 
of the biology of the disease. This hopefully will make clinicians evaluate and 
question treatment regimes more often than the blind acceptance found in the 
past.
1.1.3. Anatomy of the Breast
1.1.3.1. Cellular composition of normal breast
The size, structure and function of the human breast is determined by 
complex interactions of hormones and other signals, resulting in differentiation 
of the epithelial cells to produce an organ capable of milk secretion.
The mammary gland, or breast, is a modified sweat gland that has 
developed the specialised function of secreting milk instead of sweat. The 
gland overlies the pectoralis major muscle and is a complex arrangement of 
inter-connected secretory units surrounded by fat and connective tissue, and 
serviced by an extensive blood, lymphatic, and nervous system. The mammary 
gland has an epithelial component, which constitutes the essential glandular 
tissue (parenchyma), and a connective tissue component, which forms the 
supporting and enclosing framework, called stroma. Overlying the glandular
5tissue is a layer of adipose tissue. The breast is highly vascularised and well 
provided with lymphatic drainage, leading towards the axilla.
The epithelial components are arranged as lobes, each with 15 to 20 
interconnected lactiferous ducts, which run radially from the base of the nipple 
and branch repeatedly (Figure 1.1.). Each of these ducts dilate to form a
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Figure 1.1 The human mammary gland and its constituent parts.
lactiferous sinus, before opening separately on the nipple. Each lobe is made 
up of the glandular tissue that develops from a single duct and is subdivided 
into lobules corresponding to the branchings of the duct system. Each 
functional lobe is a separate gland operating within the environment of the 
adjacent fat and stromal cells. The gland does not have a definite capsule, and
6its connective tissue component consequently merges with the subcutaneous 
connective tissue. The fundamental secretory units of each lobe are the many 
alveoli of the lactiferous ducts. These secretory units are responsive to 
hormonal modulations and, as such, show maximum growth and regression 
during various hormonal changes of puberty, pregnancy, and menopause. The 
alveoli are surrounded by a mesh of myoepithelial cells which show some of 
the properties of epithelial and muscle cells and are involved in milk ejection. 
The whole structure is surrounded by the basal lamina which acts as a 
boundary between epithelium and stroma. The boundary is permeable to 
growth factors and metabolites but is normally breached only by migratory 
blood cells.
1.1.3.2 Lymphatic drainage of the breast
The breast has a well developed lymphatic system that drains mainly 
towards the axilla (Figure 1.2). The major lymphatics include a superficial 
group draining the skin (Rotter nodes) and a deep group draining the mammary 
lobules. In addition, there are the internal mammary nodes which accompany 
the internal mammary artery. Although the lymphatics pass in all directions 
from the breast, the main direction of lymphatic flow is towards the axilla with 
about 97% of the lymphatic drainage to the axillary nodes, with the remaining 
passing to the internal mammary nodes (Donegan, 1988). The axilla can be 
further subdivided into three positions. They include the apical, which are 
located farthest away, the central (mid) axillary nodes, and those nearest to the 
gland, the anterior axillary nodes.
The axillary lymph nodes play a very important role in breast cancer with 
metastatic spread of the disease frequently involving the axillary nodes.
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Figure 1.2 The lymphatic drainage of the breast A= low axillary nodes and 
B= high (apical) axillary nodes.
The status of these nodes is, therefore, an important feature in assessing the 
prognosis of a breast cancer patient. In effect, the surgical management of 
breast cancer includes not only the removal of the primary tumour but removal 
and examination of the axillary lymph nodes. Whether nodes are involved in a 
cancer and the number of nodes involved is, at present, the most important 
prognostic indicator (Section 1.1.6.1.). If there is metastatic tumour in the 
nodes it can be direcdy compared with the primary to deduce the changes and 
interactions with the immune system within these axillary nodes.
81.1.4. Biology of the breast and breast cancer
1.1.4.1. Cellular components
The main four cell types in the breast are the glandular epithelium, 
myoepithelial cells, the fat cells and the stroma. These are involved in the 
interactions producing normal breast development or cancer formation, such as 
direct contact with the myoepithelium, secretion of growth factors from the 
stroma or activation of precursors (stromal and fat cells). These interactions are 
an essential part of complete breast development
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Figure 1.3 : Endocrine factors affecting breast development and function 
FSH (follicle stimulating hormone); TSH (thyroid stimulating hormone); LH 
(luteinizing hormone); PRL (prolactin); GH (growth hormone); HCS (Human 
chorionic somammotropin).
91.1.4.2 Hormones
Hormones have a crucial role in the the biology of the breast and also in 
breast cancer (Figure 1.3). The hormones involved are of two types; (1) the 
polypeptides, including growth hormone and prolactin; (2) the steroids 
including oestrogen, progesterone and glucocorticoids, some of which are 
involved in both normal and abnormal breast development.
1.1.4.2.1. Polypeptide hormones
Prolactin is a polypeptide hormone released from the anterior pituitary. 
The release is controlled by Prolactin inhibitory factor (PIF), assumed to be 
dopamine or a similar molecule. Prolactin is involved in the control of growth 
and differentiation of the mammary gland. Mitogenic effects of prolactin have 
been shown on MCF-7 cells and rat mammary cells (Shafie and Brooks,
1987). A role has also been implied in oestrogen receptor regulation and the 
transcription of the casein gene (Guyette et al 1979). However the specific 
effect of prolactin is dependent on the differentiation state of the breast 
epithelium and this can be modulated by the interaction of other hormones such 
as insulin (Ollivier-Bousquet, 1978).
Oxytocin is produced by the hypothalamus and has the ability to interact 
with the myoepithelial cells located in the alveolus and the surrounding ducts. 
Oxytocin is involved with the phosphorylation of myosin causing contraction 
of the target cells for induction of milk ejection.
1.1.4.2.2. Steroid hormones
Oestrogen is a member of the steroid hormone family. In breast tissues,
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the oestrogens bind to specific oestrogen receptors (ER) in the cytosol and the 
bound receptor then moves to the nucleus (Shayamala and Nandi, 1972). In 
addition to its effect on the gland, the hormones also promote prolactin 
secretion. Interestingly, oestrogen is believed to be produced in normal breast 
tissue as well as in breast cancer tissues (Edwards et al 1979).
Oestrogens are associated with mitogenesis in the female reproductive 
epithelium, especially in ductal formation (Stroudemire et al 1975) with 
progesterone and prolactin stimulating formation of lobulo-alveolae similar to 
that seen in pregnancy. This effect of progesterone is not seen on mammary 
epithelial cells in culture. The main role of progesterone is thought to be in the 
prevention of terminal differentiation in mammary epithelium during pregnancy 
(Neville and Berga, 1983).
Thus although the full role of the steroid hormones remains undefined, 
they appear to have a significant effect on the initiation and maintenance of 
differentiation. The presence of the oestrogen receptor in breast tumours is 
now routinely evaluated as it has been linked with patient prognosis.
Insulin has also been demonstrated to be a pre-requisite for proliferation 
of mammary epithelium in vitro but the precise role is as yet undefined and is 
thought to involve regulation of fatty acid production in lactating epithelium.
1.1.4.3. Cell-Cell interaction
The understanding of cellular interactions and adhesion are now being 
investigated in greater detail. Adhesion molecules such as ICAM 1, and others 
have an important role to play in both normal and abnormal growth of the 
cellular epithelium. Cell junctions in the breast are an important part of the
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epithelium, giving it integrity. Gap junctions form between neighbouring cells. 
The small gaps which form are important for the exchange of small molecules 
and signals between neighbouring cell types. Tight junctions form due to the 
direct fusing of two different cell types together and these act as the major force 
in anchoring cells together (Gorby and Steinberg, 1981). Changes in cell-cell 
interactions has been shown to be associated with the increase in metastatic 
potential and long term prognosis. The presence of epithelial cells and stroma 
may indicate an interaction between these two types of cells involving the 
secretion of specific growth factors. This is dependent on the structure of the 
basal lamina and alterations occurring in this layer have been implicated in 
metastatic potential (Pitelka et al 1984).
I.I.4 .4 . Growth Factors
Growth factors have an important role to play for both positive and 
negative regulation of breast cellular development Two main factors implicated 
are Epidermal growth factor (EGF) and Transforming growth factora 
(TGFa).
EGF is a growth factor of between 48 and 53 amino acids which acts on 
the Epidermal Growth Factor receptor (Section 1.4.3.4.). The receptor is 
found on most mammalian cells with the exception of differentiated white 
blood cells. On binding of EGF the receptor is dimerised and then immediately 
endocytosed. Signalling from this receptor involves the phosphorylation of the 
tyrosine kinase portion of the receptor leading to protein kinase C activation. 
High levels of EGFR protein expression has been implicated in poor prognosis 
for the patient (Sainsbury et al 1987; Nicholson et al 1988).
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TGFa has a similar structure to that of EGF and can also bind to the 
EGF receptor and activate the receptor. The current speculation is that TGFa is 
the ligand for the EGF receptor during embryonic development and that EGF is 
the normal ligand produced during adult life. This would agree with the 
suggestion that a tumour cell has evolved into a more basic, rapidly dividing 
embryonic cell type with specific requirements for growth factors such as 
TGFa.
A third growth factor, TGF-p (Transforming growth factor p), although 
originally described as a positive growth stimulator, can also act as a growth 
inhibitor depending on the target cell type (Spom et al 1987). Furthermore, 
although many normal epithelial cells are inhibited by TGF-p, several 
transformed cell lines, including breast cancer cells have been found to be 
resistant to its inhibitory effect (Knabble et al 1987). This may support the idea 
that escape from negative control might be an important step during 
carcinogenesis (Roberts et al 1985). Although a post receptor mechanism and 
not a loss of receptors is likely to be involved (Manning et al 1991), the 
mechanism of inhibition of epithelial cell growth by TGF-P is currently 
unclear. TGF-p is also a powerful immunosupressant and this may have an 
effect on any immune response including that to a tumour (Shullef al 1992).
1.1.5. Epidemiology and Etiology
1.1.5.1. M ortality
The frequency of mortality of breast cancer was unknown by the Greek 
and Roman Physicians who described it. The cases of carcinoma of the breast 
in the USA in 1987 were 900 males and 130, 000 females with a mortality in
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the same year of 300 males and 41, 000 females. The age adjusted death was
27.1 per 100,000 women. The highest rate of mortality is found in England 
and Wales at 33.8 per 100,000 women and in the United States there has been 
no significant change in the incidence rate for the past 60 years (Donegan, 
1988). However, the latest study from the USA suggests that the rate of breast 
cancer is increasing and now affects 1 in 9 women during their lifetime. 
Whereas in Japan a highly industrialised nation, the rate of breast cancer is one 
of the lowest in the world.
1.1.5.2. Aetiology of breast cancer
The incidence of breast cancer is high, but varies amongst different 
groups throughout the population. The reasons for this have been attributed to 
many different epidemiologic factors which have possible roles in cancer 
development.
1.1.5.3. Sex
The most significant high risk factor in breast cancer is the sex of the 
patient. More than 99% of breast cancer occurs in women. Breast cancer in 
men is rare and involves only 7 in a million men.
1.1.5.4. Age
The age of the patient is an important factor with nearly 85% of all 
breast cancers detected in women over 40. Less than 1.5% occur in women 
under the age of 30 (Leis, 1978).
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1.1.5.5. Genetic predisposition
Female relatives of a women with breast cancer have a two-fold increase 
in their suceptibility, with the highest risk for their daughters. There is a 
difference observed between western and oriental women, but this seems to 
have an environmental rather than a genetic origin. Following immigration to 
the U.S. A, the daughters of oriental women show a rate of breast cancer equal 
to that of the indigenous population (Seidman, 1972).
1.1.5.6. Reproductive factors
A high incidence of cancer of the breast has long been noted in nuns 
and in childless women. The age of childbirth is also an important factor as 
women who have children before the age of 35 have a two-fold higher risk of 
breast cancer compared to women who have had children before the age of 20 
(MacMahon et al 1973).
1.1.5.7. Dietary factors and Obesity
The poor diet in certain areas of the country, such as the West of 
Scotland will undoubtedly have a great deal of influence on the susceptibility of 
women to breast cancer. Associations with the dietary intake of saturated fat, 
cholesterol and protein have been suggested (Gray et al 1979). However these 
relationships are very tentative and often inconsistent.
Mice made artificially fat have an increased risk of breast cancer and 
studies, in various countries, have shown a similar, increased risk of breast 
cancer in postmenopausal obese women (Boyle and Leake, 1988).
1 .1 .5 .8 .Viruses
Viruses have been commonly implicated with both benign and malignant 
neoplasms in animals and in mice the mouse mammary tumour virus (MMTV) 
has been associated with breast cancer. However, while virus like particles 
have been discovered in human breast milk, there has been no association 
between this and the incidence of cancer (Spratt et al 1988).
1.1.6. Prognostic indices in breast cancer
Evaluation of patient prognosis is an important aspect of breast cancer as 
an understanding of the biology has to be eventually related to clinical 
treatment.
1.1.6.1 Staging of the tumour
The stage of the cancer has been shown to be the most reliable 
prognostic indicator in breast cancer. Evaluation by the Tumour Node, 
Metastases (TNM) method has long been accepted. The presence of metastatic 
tumour within the axillary nodes surrounding the breast is evaluated and the 
number and types of nodal involvement are noted and a staging is given for 
each patient.
Stage 1: The cancer is small and localised to the breast. No metastases are 
present in the tumour draining axillary nodes
Stage 2: The cancer has metastasised to the axilla but is not widely 
disseminated through the whole axillary tail.
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Stage 3: The cancer is widely disseminated through the breast and has 
metastasised through the majority of the axillary nodes
Stage 4: There are widespread metastases to the bone and brain.
The 5 year survival of patients without nodal metastases varies between 67 to 
85% and on nodal involvement this then drops significantly from 63 to 73% 
for one node involved. (Silverberg, 1975; Fisher, 1983). For patients with two 
or three nodes showing tumour involvement the prognosis for survival is not 
further decreased but, when many nodes are involved the survival rate of 
patients is greatly decreased.
1.1.6.2. Tumour size
The diameter of the tumour has been related to the presence of axillary 
node metastases and shown to be an important independent variable in long 
term patient survival (McGuire, 1986).
1.1.6.3. Oestrogen Receptor Status (ER)
The presence of oestrogen receptors in tumour cells is a well established 
predictor of clinical response to endocrine therapy. (Section 1.1.2.). Also a 
positive ER status has been correlated to the patient prognosis (Shek and 
Godolphin, 1988) and seems to have an inverse relationship to the EGFR 
status, with the lack of the ER leading to bad long term prognosis. ER status 
has been implied to be an independent prognostic indicator, and related to the 
degree and presence of tumour in the axilla (McCarty et al 1980). The degree 
of differentiation of the tumour measured by histological grading is related to
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the presence of the ER protein (McCarty et al 1980) and it is likely that the 
biological significance may be due to this association.
1.1.6.4. Grade of the Tumour
The most common grading system for breast cancer was introduced by 
Bloom and Richardson (1957). The grading system looks at three features of 
the tumour: cytological differentiation; structural differentiation; mitotic figure 
frequency. To each of these figures a value of between 1 and three is given and 
points are then totalled. Points from 3 to 5 represent low grade (Grade 1). 6 to 
7 are intermediate grade (Grade 2) and 8 to 9 represent high grade (Grade 3). 
Grade 1 tumours are less frequent than high grade tumours (Bloom and 
Richardson, 1957) and have a better prognosis.
1.1.6.5. Tumour Type
There are many types of breast cancer due to the heterogeneous nature 
of the tumour. The main difference is if the tumour is in situ (non invasive) 
within the ductal system or invasive and has spread beyond this area. The 
invasive tumours include invasive carcinoma, medullary carcinoma, invasive 
lobular, comedo and tubular carcinoma. The majority of non invasive tumours 
consist of carcinoma of ductal or lobular regions. These non invasive tumours 
have a much better prognosis.
1.1.6.6. Overview of prognostic indices
All of these factors are in current use for the evaluation and treatment of 
breast cancer patients. The use of a single parameter should not be taken as 
100% reliable. Even the use of staging has drawbacks as up to 30% of all node
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negative women will eventually relapse and die of the disease. Thus the 
absence of lymph node metastases does not ensure that primary tumour has not 
metastasised to other areas of the body (Redding et al 1983). The validity of 
the pathology has also been called into question as often only two contiguous 
slices of node are taken and the possibility of micrometastases outwith these 
slices is possible. Thus pathological evaluation of patients can be very prone to 
observer subjectivity (Gilchrist et al 1985). A study illustrates this point, as 
when the same tumour samples were sent to five different laboratories for 
grading, results on comparison showed 100% agreement in only 14.5% of the 
cases (Delides et al 1982). The assessment of patient pathology must be 
standardised more carefully as possible variation may mask important trends. 
However, even if better standardisation is achieved, multiple factors eventually 
will have to be assessed to give a better understanding of the disease due to the 
heterogeneity of the tumour.
1.1.7. M etastasis
Breast cancer will initially grow as carcinoma cells in situ, as a group of 
cells linked together and contained within the basement membrane. Abolition 
of the cell to cell contact will eventually allow individual tumour cells to invade 
surrounding tissues and become metastatic.
The metastasis of tumour cells is not one process but multistep 
interlinked steps eventually allowing the cancer to spread (Figure 1.4).
Circulation Aggregation
Figure 1.4 The metastatic process
There are a number of steps for metastasis to occur succesfully
(1) Release from the primary tumour accompanied by proteolytic digestion of 
the basement membrane and surrounding tissues
(2) Blood vessel invasion and entry into the circulation
(3) Homing to secondary sites
(4) Infiltration of the target tissues
Within primary cancer patients there is a great heterogeneity of disease 
with the majority of tumour localised to the breast and this type of cancer can 
be cured by surgery. However in some patients metastases are widespread and 
often incurable by surgery.
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I .I .7 .I. Generation of metastatic potential
Cancer is believed to be clonal, i.e derived from one transformed cell. 
The genetic changes initiated within the growing cancer are often unstable and, 
especially since cancer cells are fast growing, the DNA will be in an open 
conformation which is more susceptible to damage. Thus the tumour will 
evolve due to environmental pressures, especially those from the immune 
system, allowing more malignant cells to emerge from the heterogeneous 
population (Figure 1.5)
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Figure 1.5 Development of tumour cell heterogeneity.
and eventually the tumour will become autonomous and escape from the host 
control mechanisms. Tumour heterogeneity was first noted in histology and
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now has been extended to genetic, biochemical and immunologic properties. 
The great degree of tumour heterogeneity dampened the enthusiasm for 
antibody therapy as one monoclonal will in theory only recognise a small 
fraction of the total tumour cell population. Within this evolving tumour cell 
environment a subpopulation is likely to emerge and dominate. Alam et al 
(1992) investigated the change in DNA index from the primary to the metastatic 
tumour found within the axillary tumour draining lymph nodes. A 
subpopulation with a specific DNA index was shown to have metastasised to 
the lymph nodes, which would indicate that different subpopulations of tumour 
cells have differing abilities for metastasis. This has also been shown in animal 
models? clones derived from one tumour possess differing metastatic ability 
when compared to clones from other tumours (Fidler and Kripke 1977). Steeg 
et al (1988) have now isolated a gene^NM23, overexpression of which 
indicates good patient prognosis and low metastatic capability.
1.1.7.2. A ngiogenesis
Tumours up to a certain size (usually a few millimeters) have an 
adequate blood supply . Greater than this size will require new capillary blood 
vessels and a micro circulation within the tumour. The induction of a tumour 
blood supply is called angiogenesis and requires a complex interplay of growth 
factors from the tumour and the surrounding normal tissues. The non 
tumourogenic cells have been reported to produce both angiogenic factors and 
inhibitors of angiogenesis (Rastinejad et al 1989). Loss of the inhibitor of 
angiogenesis due to either mutation or suppression can be seen in the increase 
in both angiogenesis and tumorigenicity. Weidner et al (1991) have implicated 
increased microvessel density surrounding the breast tumour to an increase in 
numbers of metastases and a decrease in patient survival. A similar relationship 
has also been reported for human melanomas. (Srivastava et al 1988).
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1.1.7.3. Proteolytic enzymes and their function in metastasis
During the metastatic process the tumour cell must pass through 
physical barriers, including membranes and extracellular matrices, which are 
composed of collagen, proteoglycans and other glycoproteins. To accomplish 
this, proteolytic enzymes must be produced by the metastatic tumour cells. It 
has been shown that the production of these enzymes is one of the initial 
changes during neoplastic transformation (Duffy, 1987). Thus various 
proteases which include cathepsin D, urokinase (plasminogen activator) have 
been studied as indicators of metastatic potential. Recent reports have 
implicated their secretion in metastatic spread in breast cancer. However a 
major problem with this measurement is that it is often difficult to distinguish 
between tumour associated enzymic activities and enzymes released from 
contaminating normal cells.
1.1.7.4. Evasion of host immune responses
As a tumour develops and metastasises, there will be a constant 
interaction with the immune system taking place within the tumour in the form 
of tumour infiltrating lymphocytes (TIL), in the blood and also in the tumour 
draining axillary lymph nodes. The development of the tumour in the first place 
would suggest that the immune response is ineffective in controlling tumour 
growth. For an effective immune response the MHC class I molecule which is 
found normally on all nucleated cells in the body will mediate a cytotoxic T cell 
response against the tumour (Section 1.2.3.4). This will be in the form of a 
peptide in the groove of the MHC molecule that will allow the immune system 
to distinguish between 'self and 'non self proteins. The MHC class II
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molecules would also be involved in the immune response (Section 1.2.3.5.), 
but unlike the MHC class I molecules they are expressed only on specialised 
antigen presenting cells such as B cells or macrophages.
In breast tumour cells both MHC class I and n  molecules are presented 
(Whitford et al 1992a; Goepel et al 1991) though not all cells in the tumour 
express them. When MHC expression on primary breast cancers is compared 
to the situation on the corresponding metastases, the expression of MHC class 
I molecules is even further reduced or eliminated. The lack of MHC expression 
in tumours has been linked to failure to express the P-2 microglobulin 
component and this interferes with the associated peptide generation 
mechanisms. The removal of class I expression will allow the tumour cells to 
escape CD8+ cytotoxic T cell restricted killing and thereby allow the tumour to 
move through immune tissues without generating an immune response.
I.I.7.5. Expression of adhesion receptors and metastases
Cell adhesion molecules are found on the surface of all cells and bind to 
ligands on other cells or in the extracellular matrix. Cell adhesion is an 
important part of immunological recognition and re-circulation (Reviewed by 
Dustin and Springer, 1991). Several adhesion molecules associated with 
lymphocytes have now been described (Section I.2.7.). Three of these 
adhesion molecules have been associated with metastases (Johnson et al 1989; 
Fawcett and Harris 1992). LFA-1( lymphocyte function antigen-1), ICAM-1 
(Intracellular adhesion molecule-1) and CD44.
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LFA-1 is expressed only on leucocytes (Krensky et al 1983), while its 
counter receptor ICAM-1 is expressed on a variety of cell types (Dustin et al
1988) including tumour cells but in widely differing amounts.
ICAM-1 is expressed at very low levels on normal tissues except 
endothelial cells where rather moderate levels are found. ICAM-1 is 
upregulated on initiation of a local immune response. Johnson et al (1989) 
indicated that a glycoprotein with the same sequence as ICAM-1 was expressed 
on advanced human melanomas, but absent on benign and early melanomas. 
The suggestion is that the expression of ICAM-1 will cause tumour cells to 
interact with lymphocytes causing a reduction in the adhesion of the tumour. 
Which would implicate the lymphocytic infiltration within the tumour as having 
a role in the metastatic spread of tumour.
The CD44 glycoprotein is widely expressed on a variety of different 
tissues and is thought to function as an adhesion molecule (reviewed by 
Underhill 1992, Herrlich etal 1993). The CD44 molecule has specifically been 
implicated in lymphocyte homing at the high endothelial venule (HEV) within 
the lymph nodes. The protein is normally present as numerous isoforms 
created by 'mRNA alternative splicing', a mechanism allowing cells to exclude 
or include specific segments of mRNA in the final transcript. Jt has been 
calculated that different splicing of the CD44 transcript could give rise to 1000 
different isoforms of the protein. This may indicate a functional role rather than 
a structural role for the CD44 glycoprotein (Screaton et al 1992; Screaton et al 
1993).
A variant of CD44 has been implicated in metastatic ability of tumour 
cells. Gunthert et al (1991) raised a monoclonal antibody (Mab) against 
metastatic cells and discovered a variant of CD44 which was expressed only in
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metastatic rat cell lines. Hoffman et al (1991) showed splice variants were 
expressed in human cancer cell lines. Arch et al (1992) showed that one variant 
(V6) was transiently expressed on B cells, T cells and macrophages after 
antigenic stimulation, with anti-CD44 antibodies inhibiting lymphocytic 
activation. The expression of this CD44 variant has been related to metastatic 
capability in breast cancer (Tarin and Matsumura 1992) and colorectal 
carcinomas (Tanabe et al 1993). However this is disputed (Jackson et al 1993).
Metastasis is multifactorial and many factors will be necessary before 
the tumour spreads through the body eventually to settle and grow in tissues 
other than the breast. To date only a small number of the relevant contributing 
factors have been described and much more work will be necessary before this 
extremely complicated process is fully evaluated.
1.2. The Immune response
The immune system is a defense mechanism which has evolved to 
protect against pathogenic organisms and possibly even cancer. A great amount 
of diversity can be generated by the wide variety of cells, with the capability of 
recognising and eliminating any foreign antigen. This immune response can be 
divided into two areas, recognition and response. With the body discriminating 
between 'self (body protein) and 'non self (foreign protein), eventually a 
response is elicited against the specific antigen.
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1.2.1. Lymphocytes
An immune response can be elicited by either the T cell or B cell subsets 
in conjunction with other lymphoid cells. The T cell will recognise mainly 
endogenous antigen whilst the B cell recognises cell surface or soluble antigen.
1.2.1.1. B lymphocytes
B lymphocytes mature in the bone marrow and express a unique antigen 
recognition molecule on the surface called an antibody, which is a membrane 
bound glycoprotein. After encountering cell surface or soluble antigen the cell 
begins to divide rapidly and differentiates into memory B cells and plasma cells 
to produce large quantities of soluble antibody.
1.2.1.2. T lymphocytes
T lymphocytes also arise from haematopoetic stem cell precursors in the 
bone marrow. T cells migrate to the thymus for maturation and during this 
migrationthe receptor known as the T cell receptor (TCR) is expressed. This 
receptor has a function similar to the antibody produced by the B cell. But the 
antigen recognition is mediated in conjunction with a major histocompatibility 
complex (MHC) molecule (Section 1.2.3.3).
1.2.2. Lymphocyte phenotypic markers
Proteins on the surface of lymphocytes can be used to define the 
different subsets of lymphocytes which can then be detected by monoclonal 
antibody. The method of monoclonal antibody (Mab) production by Kohler 
and Milstein (1975) led the way for specific recognition of an epitope.
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Monoclonal antibodies could thus be used to type lymphocytes and other cells 
by recognition of specific protein expression.
Prior to Mab's, studies involving lymphocytes were crude, involving 
the use of sheep erythrocytes to form non antigenic rosettes for purification and 
estimation of the T cell population. The use of Mab's along with flow 
cytometry has significantly simplified lymphocyte study.
Lymphocytes express a great number of proteins on their surface and in 
certain cases unique proteins are found for a specific cell type. Mabs have been 
generated against these leucocytic phenotypic proteins. A system has been 
developed to reduce confusion over the many Mabs generated. This is called 
the CD (cluster of differentiation) system for identification of human cells of a 
haematopoietic lineage by Mabs. The CD designation is decided by regular 
international workshops. During these meetings, Mabs are compared and those 
with the same epitope are assigned a "cluster" and a number. At the 4th 
international workshop (1989), the number of defined antigens was increased 
to CD78.
1.2.2.1. T cell phenotypic markers
The definitive marker of the T cell is the expression of the CD3 protein 
(Figure 1.11.) which is expressed only on T cells in conjunction with the TCR 
through which antigen recognition takes place. There are two TCR the oc/p 
(Section 1.2.4.1) and the less common y/5 (Section 1.2.4.2) which are stably 
associated with the CD3 protein. The CD3 protein is a complex of five proteins 
associated with T cell signal transduction from the TCR. The T cell population 
can be further divided into two main subsets based on phenotypic markers. 
The helper (Th) subset which expresses the CD4 protein and the T
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supressor/cytotoxic (Tc) subset which is CD8+. The CD4+ T cell recognises 
antigen in conjunction with the MHC class II molecule (Section 1.2.3.5.) and 
produces growth factors called cytokines to 'help' both the B and T cell 
immune responses. The CD8+ T cell recognises antigen with the MHC class I 
molecule (Section 1.2.3.4.) and functions, as the name suggests, to mediate 
cell killing.
The CD4+ T cell population can be further subdivided based on its 
secretion pattern of growth factors, known as cytokines, and the nature of the 
lymphocytic interaction. The CD4 Th cells have been subdivided into Th-1 and 
Th-2. The Th-1 subset 'helps' the T cell response by secreting IL-2 and INF-y. 
Th-2 subset 'helps' the B cell response by secretion of growth factors and 
involvement in isotype switching of antibody class (Mossman and Coffman,
1989).
I.2.2.2. B cell phenotypic markers
B cells have two main functions: that of antigen presenting cells to the 
CD4+ T cell subset presenting the MHC class II molecule on their surface 
(Section 1.2.3.5) and also as mediators of the humoral antibody response 
against cell surface or soluble antigen (Section 1.2.1.1.). The main phenotypic 
markers of B cells are the CD 19, CD20 and CD22 proteins.
1.2.3. Antigen processing and presentation
The recognition of antigen occurs by two main mechanisms involving 
the T and B cell compartments of the immune response. B cells are involved in 
the recognition of soluble or cell surface antigen whereas the T cells recognise
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mainly endogenous processed antigen in the form of peptides presented on 
MHC (Section 1.2.3.3.).
1.2.3.1. Antigen presenting cells
Antigen must be in a suitable form for recognition by either B or T cells. 
Specialist organelles and antigen presenting cells have evolved this function. 
The main antigen presenting cells include macrophages, dendritic cells and B 
cells. These cells endocytose the antigen which is then processed within the 
endosome to form peptides. These peptides combine with the groove of the 
MHC class II molecule (Section 1.2.3.6.2) and move to the surface of the 
antigen presenting cell. T helper cells then recognise the peptide and the MHC 
molecule presented. If the peptide is foreign the T helper cell will become 
activated and release soluble growth factors known as cytokines which expand 
the response against the antigen to bring in both the T cytotoxic and B cell 
response.
1.2.3.2. Organs of antigen presentation
The immune system has specialised organs involved in the presentation 
of antigen to lymphocytes. These organs provide suitable environments for 
lymphocyte maturation. Important structures are the lymph nodes,which are 
situated throughout the lymphatic system. Their primary function is to drain 
lymph fluid from defined tissues and vascular spaces. They also act as a trap 
for antigen draining into the lymph. Within each node are specialised areas for 
B or T cell activation. The B cells mature in the germinal centres before 
entering the general circulation and the T cells mature in the paracortex. In 
order for lymphocytes to enter the lymph node they must adhere to and pass
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between the endothelial cells lining the blood vessels. This most readily occurs 
in the regions called the high endothelial venules (HEV) and lymphocytes 
possess specialised adhesion molecules for this purpose. (Figure 1.6)
High Endothelial Venule (HEV) Afferent lymphat ic
Cortex
B cell zone -  
(germinal  cent re)
T cell zone — 
(paraco r tex )
Efferent lymphaticMedulla
Vein
Artery
Figure 1.6. The anatomy of a lymph node
B cells are found primarily in the germinal centres, where follicular 
dendritic cells present the antigen. Also present are T helper cells which on B 
cell activation release cytokines to supplement the antigen response. Similar 
dendritic cells are found in the paracortex, the T cell area. Here the dendritic 
cells present antigen via MHC class II molecules for T helper recognition 
(Section 1.2.3.5).
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1.2.3.3. Presentation of antigen via the MHC molecules
During the 1960s it became clear that T cell responses were restricted to 
allelic forms of a set of highly polymorphic glycoproteins called the Major 
Histo Compatibility complex (MHC). Only in the 1980's was the nature of the 
interaction of the T cell response with the MHC elucidated. It was found that T 
cells contained an oc/p receptor (Section 1.2.4.) which had specificity for both 
the MHC and the antigen it was presenting.
T cells recognise peptides processed from antigen and presented in the 
groove with either MHC class I or class II (Bjorkman et al 1987). The MHC 
itself must be autologous, otherwise it will be recognised as being foreign by 
the cell. The processing mechanisms are different for class I and n  MHC. The 
CD8 and CD4 proteins have a crucial role in this process in that they interact 
directly with the MHC (Figure 1.7). CD4 interacts with class II and CD8 
interacts with the a3 domain of class I.
[Cytotoxic
jed ^ /P roc e s se d  
^  antigen
MHC class II
MHC class I
Antigen present ing cell Antigen present ing cell
Figure 1.7 Antigen recognition by CD4+ helper and CD8+ cytotoxic T 
lymphocytes.
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1.2.3.4. Class I MHC antigen presentation
MHC class I molecules are present on all nucleated cells (Daar et al 
1984) and are involved in presentation of endogenous antigen such as those 
derived from viruses. A peptide derived from such an endogenous protein is 
formed and eventually associates with the MHC molecule. Evidence suggests 
that the peptide charging of the MHC class I molecule occurs in the 
endoplasmic reticulum (ER). This association will allow stabilisation of the (3-2 
microglobulin with the MHC molecule allowing entry into the secretory 
pathway. In the absence of peptide binding the class I heavy chain (la) and the 
(3-2 microglobulin will undergo degradation in the ER.
1.2.3.5. Class II MHC antigen presentation
The method of presentation of class I and class II antigen is similar, in 
that antigen is presented in the form of a peptide fragment. However the MHC 
class II molecule uses specialist antigen presentation cells with an entirely 
different method of peptide generation and presentation.
The MHC class Ila  and Dp assemble in the ER along with the invariant 
chain (Ii), forming a trimeric complex. The presence of Ii prevents peptide 
binding and it is not until the eventual loss of the Ii and the gain of a peptide 
that the Da -DP complex transits to the cell surface for TCR recognition.
1.2.3.6. Structure of the MHC molecules
The structure of the antigen presentation molecule, the MHC, is crucial 
to the immune response elicited. As the MHC class I and II molecules have
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similar structures, great differences occur in the groove involved in the 
presentation of peptide antigen.
1.2.3.6.1. Class I
The class I molecule is membrane bound consisting of a heavy chain of 
46Kd and a soluble subunit of P-2 microglobulin (Figure 1.8).
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Figure 1.8.. The structure of class I MHC
The heavy chain consists of two main areas, a membrane domain and a 
peptide binding domain. Crystallography of the peptide binding domain has
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shown that the a la 2  domain unit forms the peptide binding site, supported by 
a p pleated sheet making up the floor, (Bjorkman et al 1987) (Figure 1.9).
Figure 1.9.. Overhead view of the protein groove involved in the 
presentation of peptides by an HLA A2 molecule.
Surrounding this are found two a  helices, one each from a l  and a2. 
The P~2 microglobulin contacts the P-floor but not the peptide binding 
domain. A number of pockets have been identified for peptide binding and 
have been given the designation A through to F.
1.2.3.6.2. Class II
Class II molecules are heterodimeric membrane proteins with each 
protein consisting of an a  subunit and a p subunit (Figure 1.10.). Like the 
class 1 heavy chain, the a  and P chains each consist of two regions: an 
extracellular hydrophilic region, a transmembrane hydrophobic region and an
a l , a 2  /
P sheet
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intracellular hydrophilic region. The crystal structure of HLA DR1 has recently 
been elucidated by Brown et al (1993). There is similarity with the MHC class 
I molecule with a  chains having close homology with the corresponding a l  
and (3-2 microglobulin of the MHC class I molecule. The peptide binding 
groove floor consists of 8 strands of anti parallel (3 pleated sheets open at both 
ends allowing peptides of between 12-24 amino acids to bind. The crystal 
structure indicates possible dimerisation of the MHC class II receptor and this 
may be important in stabilisation of the CD4+ TCR recognition with an antigen 
presenting cell.
G
termini
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MEMBRANE Transmembrane  (hel ica l)
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Class II MHC antigen  
Human HLA DR,DP,DQ 
Mouse l - A J - E
Figure 1.10. The structure of the MHC class II molecule.
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The processed peptides are presented in the groove and the CD4 T cell 
will simultaneously recognise the MHC class II molecule and the peptide 
within the groove.
1.2.4 Recognition of antigen by T ceils
After the discovery of the mechanism for antigen recognition of B cells 
utilising a specific receptor which undergoes gene rearrangement to generate 
diversity, it was thought that T cells would possess a receptor with a similar 
rearrangement for antigen recognition. Initial studies involved examining 
cDNA generated from T cells and, firstly, identifying genes able to somatically 
rearrange within the T cell population and then, secondly, identification of the 
protein and its structure (Hedrick et al 1984a). A (3 chain was discovered and 
shortly afterwards a y and an a  chain were found. The a  and (3 were found to 
associate and form an immunoglobulin type receptor. Later a 8 chain was 
found and shown to associate with the y  chain. This y/5 protein was identified 
and shown to have a receptor structure similar to the cx/p TCR and was also 
designated a TCR (the y/8 receptor is distinct from the y and 8 subunits of the 
CD3 component of the T cell receptor).
1.2.4.1. cx/p T cell receptor
The a/p  TCR is a disulphide linked heterodimeric transmembrane 
protein with considerable homology with IgG. It is composed of both a  and P 
chains, each containing two main domains, a variable amino acid sequence (V 
region) found at the N terminus and a constant amino acid sequence found at 
the carboxy terminus (C region). These domains interact with each other to 
form the area of recognition (Hedrick et al 1984b).
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The p chain locus was mapped to chromosome 7 in humans (Figure 
1.13.) and chromosome 6 in mice. Genomic sequences for the a  locus are 
found on chromosome 14 in both mice and humans. The genes are formed 
from separate genetic elements: a  from the V region and J region; p from the V 
the Diversity (D) regions and the J regions. The rearrangement of these genes 
gives a substantial potential for diversity (Geliebter et al 1986; Vega et al 1985; 
Seeman et al 1986).
The a /p  TCR recognises peptides presented in conjunction with the 
groove of the MHC (Section 1.2.3.3.). In most cases both the a  and p chain 
are involved in recognition of the peptide/MHC complex. The expression of 
CD3 is stably associated with the TCR and the expression of CD4 with the 
CD3 complex results in a MHC class II mediated antigen recognition. CD8 
with the CD3 complex elicits a MHC class I recognition.
The association of the TCR with the CD3 complex is a crucial part of the 
recognition mechanism. The CD3 complex has been shown to be responsible 
for the transduction of signals to the nucleus and consists of five proteins 
(Figure 1.11.).
In humans, the V a genomic sequence of the gene segments is estimated 
to contain approximately 100 members and the VP pool approximately 70 
members which can be assembled with D, J and C regions. This leads to a 
very considerable potential for diversity in the TCR.
The study of autoimmunity (Zamvil 1985; Oksenberg et al 1990; 
Oksenberg et al 1993) and allograft rejection (Miceli and Finn, 1989) has 
indicated a very limited usage of the TCR genes. This restricted usage has been
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implied in other disease states, such as multiple sclerosis (Oksenberg et al 
1990; Oksenberg et al 1993).
TCR: CD3 complex
CD3 CD3
C2 s C2
Cell
Membrane
Figure 1.11. The TCR:CD3 complex of T lymphocytes.
The circles signify domains; V and C domains show homology with Id V and 
Ig C domains respectively. Presumed N-linked carbohydrate sites are shown 
by symbol ■#. A sixth member of the complex, CD C, is not illustrated.
However, in contrast to the limited usage of the TCR found in other 
diseases, cancer stimulates oligoclonality on the TILs found within tumours. 
(Belldegrun et al 1989). This oligoclonality is restricted when TIL are grown 
in IL-2 culture leading eventually to a dominant V(3 expression (Karpati et al 
1991).This oligoclonality for TIL is found also in eye and breast cancers 
(Durie et al 1992).
39
The term superantigen was first proposed by White et al (1989) 
describing novel T cell stimulation (Figure 1.12.). The superantigens 
described, expanded specific T cell subsets instead of the more usual 
polyclonal stimulation noted for mitogens such as concanavalin A. The specific 
superantigen stimulus binds a variable portion in the P chain of the TCR to 
activate a specific V subset of T cells. Two main types of superantigen are 
known, the bacterial toxins such as Staphylococcal
T CELL
a P '
J JDI
( MHC
Super-
Antigen
ANTIGEN 
PRESENTING 
CELL
Figure 1.12. Interaction of a superantigen with the a/p TCR.
enterotoxin A (Acha-Orbea and Palmer, 1991) and the products of the mouse 
mammary tumour virus (MMTV).
In lymph nodes draining the tumours of pancreatic cancer patients, T 
cells tend to express the a /p  rather than the y/8 TCR. It has also been
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postulated that the mucin polypeptide core may be acting as a superantigen, 
(Jerome et al 1991).
1.2.4.2. y/8 T cell receptor
The second TCR to be discovered was the y/8. Like the oc/p TCR it is a 
heterodimeric immunoglobulin type receptor. The y chain locus was mapped to 
the short arm of chromosome 7 in humans (Figure 1.13) and on chromosome 
13 in mice, while the 8 locus is unusual in that it lies within the a  genomic 
region in both species. The great diversity shown by the receptor is due to the 
significant junctional diversity in the y (Jones et al 1986) and particularly the 8 
V domains. This suggests that the y/8 TCR is as diverse as the cx/p receptor 
(Chien et al 1987; Elliot et al 1988)
Murine y/8 T cells can be divided into four main subsets of y/8 T cells 
according to the usage of Vy segments V5, V6, V4, and V7. Each subset
localises in a specific area, which would suggest specific adhesion molecules 
are involved in targeting these subsets (Section 1.2.7.). Two subsets localise 
in the epithelia, V5 in the epidermis and V6 in the mucosa surrounding the 
uterus, vagina and tongue (Asamow et al 1988; Itohara et al 1990). These y/8 
T cells originate from the thymus (Itohara et al 1989; Lafaille et al 1989) and 
seem to have no role in the lymph nodes. However other y/8 T cells (V7) 
originate outwith the thymus and localise in the intestine (Bandeira et al 1991).
In humans there are two main subsets of y/8 T cell V81 and V82 
predominant in the post natal thymus (Casorati et al 1989). Most V82. express 
CD45RO, a probable marker for memory cells, wheras the Vyl CD45 cells are
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CD45RO negative (Hayward et al 1989). Unlike mice there is no dominant 
selection for epithelial areas of the body (Groh et al 1989; Bucy et al 1989).
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Figure 1.13. The human genomic location of the T cell receptors a/p and y/8
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The majority of y/8 T cells in both mice and human do not appear to 
recognise classical MHC molecules. The few that have classical recognition 
have shown specific recognition for both class I and class II antigens (Matis et 
al 1989; Rellahan 1991), with cross reactivity for different alleles (Ciccone etal 
1989; Spits et al 1990).
Along with the MHC presentation, a peptide is presented in the groove 
for TCR y/S recognition (Section 1.2.3.3.). Recently it has been shown that a 
peptide presented on HLA DR was derived from tetanus toxins was able to be 
recognised by y/8 T cells (Holoshitz et al 1992). However this recognition of 
MHC is only found in a small subset which would suggest that this type of cell 
does not have the same bias for MHC molecules.
Instead of recognition of MHC it is possible that these cells may 
recognise other antigen presenting proteins on the surface of cells. A molecule 
implicated in antigen recognition is CD48 (T cell target antigen), a member of 
the immunoglobulin superfamily (Mami-Chouaib et al 1990) since direct 
involvement of the molecule is seen in a mumber of cases in the recognition of 
y/5 T cells. It seems that the y/5 cells can recognise both MHC and non MHC 
molecules which would give a great variation in function as the location in 
different areas of the body would suggest and possible involvement of 
differing classes of antigen presenting cells.
y/5 T cells have been implicated in a number of disease states such as 
rheumatoid arthritis and leprosy. Synovial fluid of rheumatoid arthritis patients 
and leprosy patients have been shown to react against heat shock proteins, with 
th V8l and V82 subsets of the y/8 TCR expanded in the synovial fluid from 
rheumatoid arthritis patients (Modlin et al 1989; Holoshitz et al 1989). Elevated
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levels have also been observed in coeliac disease (Raulet 1989; Spencer and 
Isaacson 1989).
In humans the considerable junctional diversity in Vy9 and Vg2 would 
indicate possible superantigen involvement. When superantigen stimulation of 
both y/8 and a /p  T cells was studied using Staphylococcal enterotoxin A 
(SEA) (Flesher et al 1991; Abe et al 1991). It was discovered that SEA coated 
cells were lysed by a/p and y/8 T cells (Vy9 y/8 subset). However, unlike a/p
cells, y/8 cells do not proliferate in vitro in this response to SEA. The role of 
superantigens and their interactions with presenting molecules and the y/8 
receptor have yet to be fully elucidated.
y/8 T cells have similar surface protein marker expression to a/p T cells 
and to date only the T19 protein on sheep lymphocytes is unique to y/8 T cells. 
The CD3 protein has been shown to be stably associated with the y/8, 
(Goodman and Lefrancois 1988; Janeway 1988).
y/8 T cells due to their diverse nature could have a role in the immune 
response to tumours, since y/8 cells have been isolated from different human 
cancers. In Burkitts lymphoma y/8 T cells have shown specific lysis of 
autologous tumour (Wright et al 1989), the interaction involving y/8 TCR and 
surface IgG of the tumour, y/8 expressing TILs have also been isolated from a 
variety of tumours. TILs isolated from lung tumours have shown lysis of 
autologous tumour. This cytotoxicity could be inhibited by an anti MHC class I 
antibody (Zocchi et al 1990), implying class I restricted antigen recognition. 
However no other TILs isolated have since shown cytotoxicity against 
autologous tumour (Nanno et al 1992) and to date the role of y/8 T cells in 
immunosurveillance of cancer has not been proven.
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The question of the role of the y/8 T cell receptor remains as yet 
unanswered The receptor hayn theory more possible combinations than either 
a /p  or even IgG molecules, and this could be useful in the diversity of 
recognition and distribution shown by y/5 T cells. Infiltrates of y/8 expressing 
cells found in many disease states have implied possible functions but to date 
the role of the y/8 T cell receptor still open for debate.
1.2.5. T cell activation
The activation of the T cell results from the TCR peptide/ MHC complex 
interaction, transducing a signal across the plasma membrane eventually 
allowing resting T cells to move from GO to G1 phase of the cell cycle.
The biochemical events of T cell activation have been studied (Abbas et 
al 1991) using a T cell line (Jurkat) which has been stimulated with mitogen 
(Concanavalin A). Within 15 minutes transcription of cellular oncogenes such 
as c-fos and by 30 minutes c-myc can be detected. The c-fos binds to the IL-2 
gene enhancer and by 45 minutes IL-2 is secreted, with the receptor 
upregulated within 2 hrs. Later signals include the MHC class II molecule 
HLA DR 3-5 days later.
I.2 .5 .I. HLA DR
HLA DR like other MHC class II molecules has a heterodimeric 
structure of four glycoprotein domains (Brown et al 1988; Brown et al 1993). 
Antigens are presented to CD4+ T cells (Guillet et al 1986) via the groove in 
the structure of this molecule (I.2.3.6.2.). Expression of this molecule is 
restricted to certain specialised antigen presentation cells including both B cells 
and macrophages (Hammerling 1976). Apart from this role in antigen
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presentation, HLA DR is expressed on antigen stimulated T cells 3-5 days after 
initial stimulation. (Table 1.1) but is absent on resting T cells (Reinhertz et al 
1979). The exact role of this molecule is unknown, but may be part of a 
CD8/CD4 interaction.
1.2.5.2. IL2-R
The IL-2-R consists of three glycoprotein chains, a low affinity p chain 
of Mr 55,000 (Urdal et al 1984; Cushley and Harnett 1993) and an 
intermediate affinity a  chain (75,000), which is involved in signal 
transduction.
Table 1.1
Representative molecules expressed by activated T cells
Molecule Function Appearance Increase in
expression
c-fos Nuclear binding protein 15 min <100
c-myc proto oncogene 30min 20
INFa cytokine (secreted) 30 min >100
IL-2 cytokine (secreted) 45 min >1000
TGF-P cytokine (secreted) < 2 hrs >10
IL-2R p55 receptor 2 hrs >50
Transferrin receptor 14hrs 5
HLA DR Class II MHC 3-5 days 10
Best documented is the acquisition of the receptors allowing interaction 
between cells of the immune system. These include the Interleukin-2 receptor 
(IL-2R) and the MHC class n  molecule HLA DR.(Tseudo et al 1986; Cushley
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and Harnett 1993). When oc/p associate they form the high affinity IL-2 
receptor. There has also been shown to be a third chain y  which has been 
shown to associate with the receptor (Cushley and Harnett, 1993). The 
binding of the ligand a cytokine growth factor (IL2) to the receptor causes 
progression of the cells from the G1 into the S phase of the cell cycle 
(Herzberg and Smith 1987). When stimulated, T cells express the low affinity 
chain to a greater extent (5 or 10) than the a  chain and IL-2 binding to the high 
affinity receptor increases the expression of the (3 chain 10 or 20 fold. The use 
of the (3 chain (CD25 or Tac) as a measure of T cell activation is a standard test
Figure 1.1.4. Structure of the high affinity Interleukin-2 receptor (IL-2R).y 
chain not illustrated
a  75kD
Membra
(3 55kD
TAC
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for T cell activation. However IL-2 bound to the high affinity receptors 
undergoes internalisation leading to eventual down regulation of the surface IL- 
2 receptor (Duprez et al 1988).
1.2.6. B cell activation markers
B cells like T cells carry markers which are produced during activation. 
MHC II molecules are found on the surface, their function being to present 
antigens to CD4+ T helper cells (Section 1.2.3.5). Other markers may include 
the CD5 protein (Vande Velde etal, 1991; Hayakawa and Hardy, 1988) which 
is expressed on both T cells and a subset of activated B cells believed to be 
involved with B-T interaction and activation. B cells have had their activation 
defined by the presence of endogenously produced IgG on their surface. In the 
initial stages of a B cell response the cells express surface IgM which is 
polyvalent with low affinity for antigen. The isotype is then switched to the 
high antigen affinity IgG which marks the onset of the secondary response 
(Tonegawa, 1983). During antigen recognition CD4+ T helper cells secrete 
growth factors called cytokines to help generate the primary and secondary 
responses. Thus B cell maturation can be measured by the B cell marker CD 19 
and the presence of IgG.
1.2.7. Adhesion molecules and antigen presentation
Interaction of lymphocytes with antigen presenting cells or target cells 
found in a specific area of the body is an essential part of the immune 
recognition and activation process. Adhesion molecules play an important role.
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However only a few have been identified and have been given a CD 
designation (Section 1.2.2.).
Adhesion molecules possess a lectin-like N terminal domain which 
mediates binding to a carbohydrate ligand molecule. The similarity with lectins 
has resulted in the the designation 'se-lectins' for this specific group. There are 
three families of cell adhesion molecules, integrins, the immunoglobulin super 
family and selectins (Springer 1990).
Selectins can be split into three subgroups
(1) E - selectins
(2) P - selectins
(3) L - selectins
L- selectin (lecam) is found on both the endothelium and the lymphocyte 
allowing binding during lymphocyte recirculation through peripheral lymph 
nodes.
P- selectin also known as CD62 has a similar function to L - selectin but 
allowing neutrophils and monocytes to bind to endothelial cells at sites of 
injury (Larsen et al 1989).
E- selectin (Elam 1) is predominantly found in activated and inflamed 
endothelium, promoting binding of neutrophils, monocytes and a lymphocyte 
subpopulation (Bevilacqua et al 1989).
In addition to CD4 and CD8 which are involved in antigen recognition 
and activation (Section 1.2.3.3.), there are other important molecules involved 
in mediating the immune response.
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LFA-1 (lymphocyte function associated antigen -1) is expressed on 
virtually all leucocytes and has been implicated in cytotoxic T cell killing and 
lymphocyte adhesion to high endothelial venules (HEV) (Section 1.2.3.2.) 
(Springer et al 1987). The LFA ligand is intercellular adhesion molecule -1 
(ICAM-1) (Marlin and Springer 1987) which is expressed on a variety of cell 
types (Dustin and Springer 1988). LFA is believed to be associated with other 
molecules such as CD2 and CD8, to form a stable interaction during MHC 
class I recognition.
Other molecules included in this group include CD28 and CD44. CD28 
is a member of the immunoglobulin superfamily. The corresponding ligand is 
the B7 molecule. Signal transduction from this molecule has been shown to be 
independent of CD3 and loss of this interaction has been implied to cause T cell 
anergy. CD44 is expressed in a variety of cell types including both endothelial 
cells and leucocytes. CD44 has been shown to associate with the cytoskeleton 
of most cells, which may be due to a role in the adhesion of the extracellular 
matrix.
I.2.7.I. Lymph node homing receptors
In order to enter the various lymphoid organs, circulating lymphocytes 
must first adhere to the specialised endothelial cells of the HEV. This binding 
is very specific (Butcher,1979). Evidence for homing was found in the murine 
system, when an antibody designated Mel-14 was raised against the HEV and 
showed in vitro to block the lymphocyte adhesion to the HEV in lymph nodes 
but not in other organs. The antigen for the antibody was of a lectin structure, 
probably interacting with a carbohydrate determinant. (Sanders et al 1988).
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The human homologue of MEL-14 was named Leu-8. (Camerini, 
1989). Expression of this molecule is down regulated upon activation. Within 
tumour draining nodes of breast cancer patients expression of Leu-8 was of a 
higher level in the blood than the nodes. Leu-8 has yet to be proven as the 
human equivalent of murine MEL-14.
1.3. Tumour immunology
The immunosurveillence theory for cancer (Burnet, 1964), states that 
tumours are continually developing and the abnormal characteristics generated 
will be detected by the T cell or the B cell immune system before a tumour 
becomes detectable. In the late 1970's the great hope for treatment was a 
directed immune therapy to the antigens presented on tumour cells. This was 
known as the "magic bullet" treatment. To date no well defined cell surface 
tumour specific antigens have been characterised, although a number of 
internal mutated onco-proteins such as H-ras and p53 have been implied 
(Section 1.4.). Evidence for the theory is conflicting. Against a theory of a 
generalised immune response to cancer is the fact that patients undergoing long 
term immunosuppressive treatment have shown exactly the same incidence of 
epithelial tumours, such as breast cancer, as have normal individuals. 
Secondly, patients with acquired immuno deficiency syndrome (AIDS) have a 
higher frequency of tumours associated with DNA viruses (Penn, 1988). 
However the studies involving immunosuppressed patients have been for no 
longer than over 10 years and long term clinical evidence by Fisher et al (1980) 
has shown long term survival of patients with the primary tumour removed and 
the tumour draining lymph nodes intact containing metastatic tumour. This 
would suggest an active immune response in these patients. The tumour itself
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contains a lymphocytic infiltrate in 60% of all breast cancers, mainly of a T cell 
origin. This T cell response in tumours has been used as an indicator of good 
prognosis and TIL have been used in immunotherapy trials (Rosenberg et al 
1988). (Section 1.3.8.2.).
1.3.1. The B cell response to cancer
If a tumour is producing cell surface or soluble antigen, then a clinically 
useful B cell immune response could be generated. If antibody producing cells 
generated from patients could be isolated they could be immortalised. This 
would be using two major techniques: immortalisation using the Epstein Barr 
virus (EBV) (Steinitz et al 1979) or the use of fusion techniques first developed 
by Kohler and Milstein,(1975). These methods would generate an immortal B 
cell clone to produce large quantities of antibody with an anti tumour potential. 
The antibodies generated have had little use in diagnosis or therapy (Campbell 
and Leake 1990; Campbell et al 1987). To date the existence of a specific and 
useful B cell response against breast cancer has still to be proven.
1.3.2. The T cell immune response to cancer
The T cell response is mainly restricted to internal antigens and until 
recently the nature of the response was unclear. Recently, however a better 
understanding of T cell function has expanded the understanding of T cell 
immune responses to cancer.
The immune response to breast cancer occurs in three areas of the body: 
a direct response within the tumour, the tumour draining lymph nodes and the 
blood.
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1.3.3. Tumour Infiltrating lymphocytes (TILs)
1.3.3.1. Phenotype of the TILs
The presence of TILs has long been observed in breast and other 
cancers. The presence of lymphocytes within the tumour has been reported to 
be a good prognosis (Bloom et al 1970; Black et al 1975; Ridolphi et al 1977; 
Underwood et al 1976) this is disputed by a number of groups (Roses et al, 
1982; Champion et al, 1972). Early studies indicated that T cells comprise the 
major component of the lymphocytic infiltrate (Eremin et al 1981; Eremin et al 
1982). However, not until the advent of flow cytometry that it became possible 
to determine more accurately the phenotype and mechanism of activation of 
these lymphocytes. Flow cytometric studies confirmed that T cells were 
predominant within the tumour (Bilik et al 1989; Whitford et al 1990) and 
using this technique the T cell subsets could be distinguished. The data has 
been conflicting with groups showing a CD4+ T helper cell (von Kleist et al 
1987; Underwood et al 1987; Ben Ezra et al 1987; Balch et al 1990) or a CD8+ 
T cytotoxic predominance (Bilik et al 1989; Belldegrun et al 1989; Whitford et 
al 1990). However, considering all tumour types the CD8+ T cells seem to be 
the more predominant phenotype (Itoh et al 1988; Rosenberg et al 1988; Heo et 
al 1987; Belldegrun etal 1988; Durie etal 1990).
1.3.3.2. Activation of the TILs
Most studies have concentrated on the two main lymphocyte activation 
markers (Section I.2.5.2.) HLA DR and the IL-2R (Tac) (Section 1.2.5.3). 
These studies have shown TILs contain many HLA DR positive cells (Rowe 
and Beverly 1984; Lwin et al 1985; Ben Ezra et al 1987) with a few studies 
showing the opposite. The IL-2R was shown to be expressed in variable
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amounts in the infiltrate. One study has looked extensively at TILs in breast 
tumours. Whitford et al 1992, found a predominance of HLA DR expression 
on T cells, with the CD4+ T cell subset showing the greater expression. 
Percentages of positive cells reported were consistently higher than those 
found in the patients peripheral blood. The Tac antigen of the IL-2 R was also 
expressed on more cells in comparison to the peripheral blood, with the higher 
expression again found on the CD4+ T cells rather than CD8+ T cells. In this 
study the tumour type was also compared to phenotypic and activation changes 
within the TIL population. The presence of HLA DR correlated with tumour 
grade (state of differentiation). This expression of HLA DR also correlated 
with MHC class I and II expression. This would indicate that antigen 
recognition is increased on poorly differentiated tumour (Whitford et al 1992a) 
and would agree with earlier findings that a specific tumour type such as the 
poorly differentiated medullary carcinoma, have a large lymphocytic infiltrate 
and a good prognosis. (Donegan and Spratt 1988).
Thus the presence of TILs and especially the presence of activated 
CD8+ T cells, indicates antigen recognition and possible tumour killing in a 
number of breast tumours.
1.3.4. Immune responses in the axillary tumour draining lymph 
nodes of breast cancer patients.
The axilla occupy an important position, as these secondary lymphoid 
tissues are usually the first defined area of the immune system to come into 
contact with tumour breakdown products or metastatic tumour. The nodes are 
ideally situated to interact and modulate an immune response against the 
tumour. The lymph nodes have defined areas for both T cell and B cell immune 
responses. (Section 1.2.3.2.). These nodes also have a great clinical relevance
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as tumour cells with the ability to metastasise are found within them. These 
lymph nodes are removed routinely during surgery for the for the presence of 
metastatic tumour as this is the best indicator of bad prognosis for the patient 
(Bloom et al 1970). Thus the nodes have a great importance to both clinician 
and immunologist and as such have attracted much attention.
1.3.4.1. Phenotype of lymph node lymphocytes
Early studies using immunochemistry showed the nodes to have a 
greater population of B cells in contrast to the greater number of T cells within 
the tumour (Eremin et al 1976; Heidenreich et al 1979). The two subsets of T 
cells were phenotyped by Mabs in conjunction with flow cytometry and initial 
studies by Morton et al (1986) agreed with earlier findings in that B cells were 
predominant. The proportion of B cells increased or decreased according to the 
stage of the disease. The T cell population indicated that CD4+ T cells were 
found predominandy in stage I disease. The increase in B cell population was 
also noted by Mantovani et al (1986) and Whitford et al (1992b). Morton et al 
(1986) showed that distance of the lymph node had no effect on the phenotype 
of either T or B cells.
1.3.4.2. Activation of lymph node lymphocytes
A substantial proportion of B cells in the nodes are expressing IgG 
(Whitford et al 1992b) indicating a mature immune response against unknown 
tumour antigens. Whitford et al (1992b) compared this expression of IgG to 
the peripheral blood and found the expression of IgG significantly higher in the 
nodes. HLA DR expression was shown to be higher in the nodes than the 
blood (Morton et al 1986; Whitford et al 1992b), with the same trend noted for 
IL-2R expression. The CD4+ cells expressed higher levels of the IL-2R.
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The increased proportion of CD8+ HLA DR+ T cells was related to the 
stage of disease.
When comparing distance from the breast tumour to activation in the 
axillary nodes Morton et al (1986) have shown that lymph nodes excised from 
close to the tumour were found routinely to be more activated with respect to 
both HLA DR and IL-2R than the apical nodes further from the tumour. This 
would suggest a differential immune response in the axillary nodes depending 
on distance from the tumour.
Overall the data suggest that the nodes are activated and responding to 
the tumour.
1.3.5. Comparison of immune response in cancer and non cancer 
patients
The comparison of cancer patients with normal controls is an important 
one, as even within the normal population there is wide variation due to 
different exposure with antigen and different HLA types.
The presence of TILs within the tumour is one of the few examples of a 
lymphocytic infiltrate found in a specific disease state. Blood and lymph nodes 
can also be obtained from cancer patients. Pattanapanyasat et al (1988) 
indicated higher levels of the activation marker HLA DR expression when 
compared to normal controls. To date only one study has attempted to compare 
both blood and nodes from cancer patients, Whitford et al (1992b) used nodes 
received from the illiac region of kidney transplant patients and nodes from 
patients undergoing vascular surgery. This was compared to the axillary nodes
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from breast cancer patients. The ratio of CD4+ T helper cells to CD8+ T 
cytotoxic cells was lower in the control nodes than in the cancer patients, with 
the control patients showing much less variation. This large variation was also 
noted when activation markers were measured IL-2 receptor and MHC class II 
molecule HLA DR were gready raised in the cancer patients.
This change in phenotype and activation may be due to an immune 
response within the patients in the absence of any other major disease. The 
wide range observed suggests a response in a subset of patients, whereas in 
the remaining the response may be impaired or undergoing active supression.
1.3.6. Metastasis and the immune response within the axillary 
lymph nodes
The presence of metastatic tumour within the lymph nodes is the most 
important indicator of bad prognosis to date. It is important to study the 
interaction of the metastases with the immune system to understand why the 
immune response is eventually defeated. The removal of the lymph nodes 
during surgery gives an ideal opportunity to study the tumour lymphocyte 
interaction. Early studies, compared the histology of normal and tumour 
draining lymph nodes. This indicated that the micro architecture of the tumour 
draining lymph nodes showed significant hyperplasia when compared to 
normal nodes (Hamlin, 1968; Tsakraklides et al 1974). Other studies indicated 
phenotypic changes were also occurring in the T/B cells within these nodes, 
related to nodal tumour spread (Eremin et al 1980). Later studies, utilising 
Mabs and flow cytometry showed little change. This disagrees with the 
findings of Tsakraklides et al (1986) showing significant differences, with a 
higher percentage of B cells and lower percentages of T cells in nodes with no 
metastatic tumour (Stage 1).
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The more recent reports utilised flow cytometry and specific monoclonal 
antibodies. Morton et al (1986) showed that tumour draining nodes contain a 
higher proportion of helper T cells than cytotoxic T cells, the level of helper T 
cells dropping significantly in stage II patients being replaced by a higher level 
of CD8+ cytotoxic T lymphocytes. The activation state of lymphocytes within 
stage II patients showed an increased level of HLA DR compared to tumour 
free stage 1 nodes.
1.3.7. Overall view of the nodal immune response
The major alterations of both architecture, lymphocyte phenotype and 
activation observed within the tumour draining nodes of breast cancer patients 
would suggest a host mediated response against their tumour.
It will be useful to study the interactions within the nodes at a differing 
distance from the tumour and the change within groups of nodes with respect 
to the change in immune responses due to tumour cell invasion.
1.3.8. Tumour antigens
An immune response will be elicited in an immunocompetent host by 
any cell component that is new to the system. During cellular transformation 
molecules are sometimes expressed that are unique to the cell and not normally 
found in the host. These are referred to as tumour specific antigens and may be 
located either on the surface or within the tumour.
The hope in the 1980's was that the generation of monoclonal antibodies 
against tumour specific antigens would mean a directed 'magic bullet' treatment
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for cancer. Mabs were raised against cancer cell lines, tumour or metastases. 
The optimism soon vanished when it became evident that although the Mabs 
were reactive against the tumour, they were also reactive against normal tissue, 
(Colcher et al 1981). The major problem associated with Mab generation is the 
use of animals which have to be hyperimmunised with pristane or another 
material before priming with the antigen. This procedure is of course unethical 
to carry out in humans.
A different approach was the immortalisation of the B cell response 
against cancer from the blood or the nodes of a breast cancer patient. This was 
even less successful as the antibodies generated were polyspecific and were of 
litde use for either diagnosis or therapy. (Campbell et al 1987).
The clarification of the mechanism of the T cell immune response along 
with the identification of the genetic changes within tumours greatly increased 
the knowledge of tumour immunology. T cells were demonstrated to 
recognise mainly intracellular antigen presented on the surface of the target cefi 
in the form of a peptide^by a MHC molecule.
With the identification of genetic changes it became clearer that all major 
changes occurred within the tumour cell and to date no mutated protein has 
been discovered on the surface. Intracellular genetic changes are often unique 
to that type of cancer and are potentially targets for T cell recognition. In breast 
cancer^mutations are found in two main proteins ras and p53 (Section 1.4). ras 
mutations occur as a point mutation in positions 12 and 13. Even a point 
mutation has the ability for immune recognition. p53 mutations are the most 
common found in human cancer, with mutation in over 50% of all breast 
cancers. Other possible antigens include bcr/abl and tpr/met. These are proteins 
formed by the fusing together of two genes during transformation forming a
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possibly antigenic protein. However the expression of these in breast cancer is 
still to be fully elucidated.
I.3.8.I. Evidence for T cell specific antigens
Early work by Crawford et al (1979) using the anti p53 antibody Pab 
1801 indicated that in the sera of 10% of breast cancer patients antibodies 
specific for p53 were present. The presence of these antibodies is unusual as 
normally B cells recognise cell surface or soluble antigen, For p53 recognition 
the tumour cell may have broken down releasing cellular contents into the 
body. A recent paper has suggested that this antibody response is dependent on 
the presence of heat shock protein (hsp) 70 complexes in breast cancer 
(Davidoff etal 1992).
T cell responses to mutated oncogene products have been tested in 
murine models by transfection of the mutant gene into cells and adding them 
back into the animal and looking for a specific cytotoxic T cell (CTL) response. 
A response has been noted for ras, p53 and bcr/abl for the mutant protein but 
not for the normal protein. However the response is not seen in all animals and 
is restricted to specific HLA types.
The mechanism for antigen recognition is via a peptide presented in the 
groove of the MHC molecule. A new method has been developed to isolate and 
sequence these peptides and compare them to the actual mutant protein within 
the cell. This involved an HPLC linked to a mass spectrometer, to isolate a 
picogram of peptide from 10^ cells. The large amounts of cells involved make 
it difficult to sequence peptides from fresh tumour cells. However, cell lines 
can supply the necessary number of cells for peptide isolation though to date 
the peptides isolated remain unidentified (Eisenbach, 1993).
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Van der Bruggen et al (1991) have defined a melanoma tumour antigen 
(MAGE) from the cell line M22-MEL. The antigen was isolated after an 
extensive screening of the cell line DNA within a cosmid vector and testing 
with a number of cytotoxic T cell lines derived from the melanoma patient. 
Eventually a 2.4kb Bam HI fragment was isolated and the gene was found to 
be a member of a family of three genes with 60-80% homology. MAGE is 
expressed in most melanoma lines and is not found in normal tissue except the 
testis.
The MAGE antigen is expressed in 25% of all cases of melanoma, and 
17% in breast cancer. The expression is higher in metastases. The epitope has 
now been mapped and the nona-peptide isolated is found in the third exon of 
the MAGE 1 gene. The expression of the peptide is however restricted to HLA 
Al. This makes it theoretically possible for an active immunotherapy within 
suitable patients expressing this antigen. Thus 25% of melanomas are positive, 
but only 40% of these patients are HLA Al. Only 10% of patients are suitable 
for treatment (Boon 1993).
1.3.8.2. Immunotherapies
Traditional techniques such as surgery, radiation and chemotherapy can 
cure or delay cancer. However, there are a large number of people who die of 
the disease.
A more directed approach to cancer therapy would be the use of the 
immune system to target the tumour as the immune system has been implicated 
in spontaneous regression of the tumour in a very small number of patients.
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It was not until the discovery of the important T cell growth factor 
interleukin -2 (IL-2 ) (Gillis et al 1978) and the introduction of methods of 
growing large quantities of T cells in culture that T cell immunotherapy became 
possible.
Initially lymphokine activated killer (LAK) cells were generated from the 
peripheral blood lymphocytes (PBL) removed from cancer patients and grown 
in IL-2. These cells possessed the capability for lysis of tumour but not normal 
tissue (Raynor et al 1985). These LAK cells were assumed to be derived from 
the "null" population, which make up 5% of the circulating lymphocytes. They 
are capable of non-MHC associated cytotoxicity. (Grimm et al 1985). On 
analysis the cells were CD3 negative, CD 16 negative and are thought to be 
natural killer cells.
These cells were cultured in IL-2 and transferred back into the patient 
along with large quantities of IL-2. Limited anti-tumour effects were noted 
with the highest response in malignant melanomas (Rosenberg et al 1988).
The response rates were not as good as expected and work then 
concentrated on the tumour infiltrating lymphocytes (TILs) as murine models 
had shown a 50 to 100 fold improvement in the capability for tumour 
regression (Rosenberg et al 1986). TILs were extracted from human tumours 
and grown in IL-2. They were then readministered into the patients with large 
quantities of IL-2 (Topalian et al 1987). Initial data indicated complete 
regression in 15% of renal carcinoma and maligant melanoma patients.
Immunotherapy has its drawbacks, the administration of large quantities 
of IL-2 can cause major side effects such as vascular leak syndrome, weight
62
gain, nausea and even death in 1% of the patients. Most of the side effects are 
only temporary and after therapy is completed they completely disappear.
Recent TIL therapy has utilised gene therapy technology to transfer a 
marker neomycin gene to the removed TIL. These have been infused into 
patients and shown to home into the tumour. This pilot study led the way for 
transduction of specific genes into the TIL. Tumour necrosis factor (TNF) 
gene has been transferred into the TILs in the hope that these lymphocytes will 
home into the tumour. However the TILs do not all home into the tumour and 
some may reach the liver where the secretion of TNF is extremely cytotoxic to 
the liver.
Eventually the antigens stimulating the immune system must be 
identified to give a more directed immune therapy designed for each individual 
patient.
1.4. Genetic factors and cancer
1.4.1. The cell cycle
The disruption of cell cycle control is one of the factors which may lead 
to the initiation of cancer.
Two main identifiable events that characterise the cell cycle: are mitotic 
cell division and DNA synthesis. (Figure 1.15). Mitosis is represented by M 
and the period of DNA synthesis is S. GO cells are in the quiescent, resting 
phase, whilst the phases G1 and G2 are gaps between M and S and S and M
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respectively. The term G1 and G2 were coined due to the absence of 
knowledge of other identifying markers at this time (Adams, 1990).
1.4.1.1. Cell cycle control
Cells in different environments spend variable amounts of time within 
the phases of the cell cycle. The majority of lymphocytes are in the quiescent 
phase (GO) and are out of cycle, requiring a stimulus to enter the cycle. For 
entry into G1 a single entry point has been reported (Pardee et al 1974) 
followed by movement through the different phases of the cycle (Figure 1.15). 
In cancer the Glphase of the cell cycle has been reported to be highly variable 
(McGuire and Dressier 1985).
Thus the loss of cell cycle control in cancer is evident, however the 
understanding of the normal processes involved in cell cycle control is still not 
clear. A universal mechanism for the control of M phase entry has been 
proposed (Nurse 1990; Murray A.W, 1992; Pines J, 1993; Sher C.J., 1993). 
The protein kinase p34, first identified as the product of the cdc 2/ CDC 28 
gene in yeast, is believed to function at the onset of S phase. (Mendenhall et al 
1987) and mitosis (Pines, 1993; Sher 1993). The p34c^c2 kinase 
phosphorylates key proteins which leads to the events in M phase. A second 
class of protein, "the cyclins" complexes with and activates p34°dc2  to regulate 
M phase (Moreno et al 1989). Cyclin binding modifies and activates the 
p34cdc2 .
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Figure 1.15. The regulation of the cell cycle by its associated proteins
S phase initiation involves the p34 kinase and G1 cyclins, which appear 
in G1 and are degraded in S phase. The G1 cyclins are essential at the decision 
to pass from G1 to S phase. This transition is known as START (Pines, 1993; 
Sher, 1993) and involves a class of regulatory proteins that are involved in the 
G1 phase of the cell cycle.
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1.4.2. Measurement of DNA content
The DNA content of a normal somatic cell with 46 chromosomes is 
referred to as diploid (Tijo and Levan 1956). A cell with fewer or more than 46 
chromosomes is described as aneuploid.
1.4.2.1. Flow cytometric DNA analysis
Flow cytometry is commonly used for the measurement of DNA content 
as the technique gives information on the DNA ploidy and S phase fraction 
(SPF), which is a measure of the proliferative rate of a growing cell 
population. With this method a large number of cells are analysed objectively. 
A DNA histogram is obtained from which ploidy and S phase can be 
determined. The ploidy is usually expressed in the form of DNA index which 
contrasts the differences from diploidy.
1.4.2.2. DNA ploidy and breast cancer
In a substantial proportion of all breast cancers the state of the DNA is 
aneuploid. Studies indicate between 53% and 73% of breast tumours have an 
aneuploid DNA content, with an average of 63% (Frierson 1988).
This change in DNA ploidy has been linked in a number of studies to 
lymph node involvement (Eskelinen, et al 1989; Toikkanen et a 1989; Hedley 
et al 1987). However no association has been found by others (Visscher et al 
1990; Moran et al 1984; Horsfall et al 1986; Thorud et al 1986; McDivitt et al 
1986; O’Reilly et al 1990). Studies involving larger numbers of patients have
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only shown weak correlations to stage parameters (Hedley et al 1987; Ewers et 
al 1984; Dressier et al 1988).
DNA content correlates significantly with histopathological tumour 
grade (Toikkanen et al 1989; O'Reilly et al 1990; Thorud et al 1986; Moran et 
al 1984; Kute et al 1985; Kallioniemi et al 1987; Feichter et al 1988; Dowle et 
al 1987; McDivitt et al 1986; Visscher et al 1990). Generally aneuploid 
tumours seem to have a worse prognosis.
I.4.2.3. Multiparametric flow cytometric DNA analysis
The major problem associated with the analysis of solid tumours such as 
breast cancer is the presence of contaminating cells such as lymphocytes which 
can contribute up to 80% of the tumour mass (Whitford et al 1991). 
Histochemical analysis can easily recognise the presence of non- tumour cells, 
whereas single parameter DNA flow cytometric analysis cannot
However Zarbo et al (1989) has described two colour multi parametric 
DNA analysis on intact cells, the second colour being anti-cytokeratin which 
stains only cells of an epithelial origin. Utilising this method Alam et al (1992) 
described the ploidy changes from primary to metastatic tumour cells showing 
a subpopulation which metastasised from the primary tumour to the tumour 
draining lymph nodes.
The use of multiparametric DNA flow cytometric analysis has been used 
to quantify oncogene expression in relation to the ploidy of the DNA. There are 
reports for p53 (Morkve and Hostmark 1991), erb B-2 (Kelsten et al 1990) 
and C-myc (Hendy-Ibbs et al 1987).
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1.4.3. DNA oncogenes and tumour supressors
1.4.3.1. Oncogenes and proto-oncogenes
The first evidence for the cause of cellular transformation came from 
experiments carried out on the Rous Sarcoma virus. Later it was discovered 
that the presence of cancer genes called oncogenes within the viral genome was 
responsible for cellular transformation. In the Rous Sarcoma virus this was 
identified as a region called v-src and in later experiments homologues of v-src 
were discovered in normal cells. From these experiments other genes^similar to 
oncogenes were identified and named proto-oncogenes.
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Figure 1.16. Some proto oncogenes and tumour suppressor in normal and 
abnormal cellular development
The cellular proto-oncogenes code for proteins which are believed to be 
normally expressed at low levels during precise stages of cell or embryo 
development but which become irreversibly and permanently expressed in 
tumour cells as a result of viral, chemical or radiation induced changes in the 
genome of the affected tissue. In some cases overexpression of the normal 
cellular proto-oncogene as a consequence of loss of regulatory control is 
sufficient to cause cell transformation. In others, the gene product itself carries 
a mutation and codes for a slightly altered protein. The early oncogenes (eg src 
) were isolated as a result of their ability to induce tumours in animals. Later 
strategies have detected new oncogenes (eg c-m et) by random irradiation of 
animal DNA followed by transfection, isolation of genes which cause cellular 
transformation and subsequent extrapolation to the similarly hybridizing 
sequences within the human genome.
Most characterised oncogenes appear to encode developmental proteins, 
growth factors, growth factor receptors, signal transducing factors, or nuclear 
proteins controlling gene expression and the cell cycle. Tumour suppressor 
genes ("anti-oncogenes") are negative regulatory elements whose inactivation 
causes uncontrolled cell growth.
I.4.3.2. Oncogenes implicated in breast cancer
Oncogenes which have clearly been associated with breast cancer are shown in 
Table. 1.2.
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Table 1.2 Oncogenes implicated in breast cancer
Oncogene Human
chromosome
location
Possible 
function of 
gene product
"Size and 
location
Possible alteration 
in breast cancer
myc 8q24 gene
expression 
or cell cycle 
control
439 amino 
acids nuclear
Amplification
(occasional
iteration)
H-ras l lp l4 GTP binding 
protein
189 amino overexpression 
acids
inner membrane Gene deletion
erb- -B-2 
(neu)
17q21 receptor 1260 amino Amplification 
acids Overexpression 
Transmembrane
hst and 
int -2
llq l3 Growth
factors
206 and 220 
amino acids 
secreted
Amplification
1.4.3.3 C~myc
The oncogene myc was first identified as the transforming element of 
avian myelocytomatosis virus-29 (Bister et al 1977) and subsequently the 
human equivalent cellular oncogenes were identified. In man, there are three 
related myc proto-oncogenes. N-myc is amplified and expressed in human 
neuroblastomas (Schwab et al 1983) while the L-myc is amplified in lung 
cancers (Nau et al 1985). C-myc, which is encoded by chromosome 8q24, 
contains three exons of which only exons 2 and 3 contain the protein coding 
sequence. The C-myc protein product is a 439 or 454 amino acid nuclear 
DNA binding phosphoprotein with a short half life. The precise function of 
this protein is unclear but it is thought to work in collaboration with other
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nuclear proteins (Cole, 1991) and could be involved in the regulation of 
transcription of other genes important for cell growth regulation.
The deregulation of the C-myc proto-oncogene can take place via three 
different genetic mechanisms. Adjacent retroviral insertion causes activation in 
avian bursal lymphomas (Hayward et al 1981) whereas, in human and murine 
leukemias and lymphomas, it may be activated by chromosome translocation 
into actively transcribing regions encoding the immunoglobulin or T cell 
receptor genes (Adams et al 1983; reviewed by Cole, 1991). Finally, 
amplification of the oncogene may occur and this has been reported in several 
types of human tumour (reviewed by Alitalo and Schwab, 1986). It is believed 
that the C-myc oncogene may have a role in the the progression of the disease 
rather than in tumourigenesis.
C-myc amplification in breast cancer has been reported by several 
workers. In a study of 121 human primary breast carcinomas, Escot et al 
(1986) observed an amplification of 2 to 15-fold in 32% of the samples 
analysed. Tavassoli et al (1989) reported a similar range of amplification (3-15 
fold) in a sample of 52 breast tumours and in addition, found a significant 
correlation between amplification of the oncogene and histological grade in 
these tumours. C-myc amplification has been correlated to early relapse and 
poor short term prognosis in breast cancer (Roux-Dosseto et al 1992; Borg et 
al 1991). Interestingly, in addition to carcinoma cells, tumour infiltrating 
lymphocytes (TIL) (Section 1.3.3.) also showed high levels of C-myc 
transcription. A possible reason for this high level is that C-myc was one of 
the first proto-oncogenes to be translated during T cell activation. The presence 
of this population expressing C-myc to high levels may call into question the 
results obtained for western blotting as TIL can make up to 80% of the tumour 
cell mass (Whitford et al 1990).
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There are few reports of alterations in C-myc in breast cancer. Escot et 
al (1986) reported rearranged C-myc in only 5 samples, representing a mere 
4% of the total cases studied. One patient with a particularly aggressive tumour 
was reported to have a deletion in exon 3 by Varley et al (1987b).
I.4.3.4. H -ros
H-ras is an oncogene first identified in transforming DNA from the 
human EJ bladder carcinoma (reviewed by Marshall, 1993) and shown to be 
the cellular homologue of the ras H gene of Harvey sarcoma virus (Der et al 
1982; Parada et al 1982; Santos et al 1982). It is a member of a family of ras 
oncogenes which also includes K-ras (the proto-oncogene corresponding to 
Kirsten sarcoma virus) and N-ras (from neuroblastomas). The three functional 
members of the ras gene family are similar in that they encode a protein of Mr 
21,000 in four exons (Lemione, 1990). The H-ras gene is situated at 
chromosome location l ip  1.4 and the gene product contains 189 amino acids. 
All known ras proteins are GTP binding proteins with substantial homology to 
the normal cellular G proteins which are known to act as regulatory elements in 
signal transduction systems involving raf and MAP kinase (Marshall, 1993)
Ras activation is by point mutation leading to single amino acid 
differences from the normal cellular proto-oncogene sequence. In the human 
tumours studied, amino acid substitutions have been found to occur at 
positions 12,13 and 61. Substitution of the normal position 12 glycine residue 
with any other amino acid except proline causes oncogenic activation (Seeburg 
et al 1984) and in the EJ bladder carcinoma, where the glycine is altered to 
valine, such a change is sufficient to cause transforming activity. A similar 
situation is observed for the glycine residue at position 13 although a few
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substitutions like Ser 13, may not be transforming (Bos et al 1985). Work with 
rodents has indicated that chemical carcinogens can cause such point 
mutations.
In breast cancer there have not been many reports of ras gene 
amplification. However two recent reports have suggested ras amplification, in 
relation to nodal positivity (Saccani-Jotti et al 1992) and no relationship to any 
prognostic indices (Spandidos et al 1992). Three groups have reported the loss 
of one of the two c-H-ras alleles in around 25% of breast cancers (Theillet et al 
1986; Ali et al 1987; Mackay et al 1988). These studies also found a good 
correlation with histological grade, with more than 74% of tumours with c-H- 
ras allelic deletion being grade 3 (Theillet et al 1986; Ali et al 1987). It has 
been suggested that the allelic deletion of c-H-ras may be indicative of the 
possible involvement of tumour suppressor genes located on the same 
chromosome. Overexpression of unmutated H-ras proto-oncogene as mRNA 
(Theillet et al 1986) has also been reported even in situations where one allele 
is missing. There have also been studies showing that the ras protein is 
overexpressed (Horan-Hand et al 1984; De Bortoli et al 1985) without gene 
amplification. These reports were based on early immunocytochemical studies 
where it is possible that the specificity of the antibodies was not as high as 
anticipated.
I.4.3.4. erb B
The erb B gene was originally identified in avian erythroblastosis virus 
as a cellular gene which had the capacity to induce avian leukemias due to 
integration of the virus leading to abnormal overexpression (Fung et al 1983). 
On subsequent analysis, it became apparent that the virus had led to the 
expression of a truncated form of a cellular proto-oncogene which was the
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gene encoding the Epidermal Growth Factor Receptor (EGFR). EGFR is a 
transmembrane glycoprotein of Mr 170,000 and is found on many epithelial 
cell types, including breast cancer cells. EGFR also binds transforming 
growth factor a  (TGF-a) resulting in a growth stimulatory effect similar to that 
observed with EGF. The receptor has a cysteine-rich cell external domain, 
which binds EGF and TGF-a, a transmembrane domain and an intracellular 
domain which contains a tyrosine specific protein kinase. The kinase is 
activated upon binding of EGF to the receptor (Reviewed by Carpenter, 1987). 
The truncation in v-erb B is such that the extracellular (N terminal) domain of 
the gene is lost but the transmembrane and internal domains are present. The 
erb B protein therefore, lacks the extracellular domain and is therefore not 
sensitive to EGF and the intracellular domain is permanently activated. It has 
been shown that over-expression of the normal EGF receptor gene itself is 
sufficient to confer an EGF dependent transformed phenotype on NIH/3T3 
cells (Di Fiore et al 1987a).
There are reports of amplification of the normal proto-oncogene (EGF 
receptor) (Liberman et al 1985). Amplification of EGFR gene accompanied 
by elevated levels of mRNA and protein have been reported in only about 3% 
of the primary carcinomas studied (Ro et al 1988; Lacroix, 1989). Many 
groups have also obtained data showing that the expression of EGF receptor is 
a relevant factor in breast cancer prognosis (Harris et al 1989; Sainsbury et al 
1987, Nicholson et al 1988). However a recent study (Reeves et al 1993) has 
shown that in many cases expression of EGFR on normal mammary ductal 
epithelium is higher than that found in breast cancer. This would call into 
question the efficacy of using EGFR overexpression in tumours as a 
prognostic marker.
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I.4.3.5. c-erb B-2 (neu, HER-2)
The erb B-2 oncogene was originally identified as a result of 
transfection studies in which NIH-3T3 cells were transformed with DNA from 
chemically induced rat neuroglioblastomas (Shih et al 1981). Shortly after this, 
two groups working independently, identified erb B-like genes, which they 
called c-erb B-2 and HER-2 respectively (Coussens et al 1985; Semba et al 
1985). In the same year, a third group found amplification of an erb B-like 
gene in a single mammary carcinoma (King et al 1985). All three of these are 
the same gene, which was shown to be the human homologue of the rat erb B- 
2 gene and found to have substantial homology (45%) with the EGF receptor, 
particularly in the tyrosine kinase domain (82% homology) (Schechter et al 
1984). Cells transfected with the gene, however, showed no response to EGF.
Although closely related to, the erb B-2 gene is distinct from the EGFR 
gene (Schechter et al 1985). It is encoded on human chromosome 17q21, as 
compared to band p ll-p l3  of chromosome 7, where the EGFR gene is 
located. The protein encoded by the erb B-2 gene is 1260 amino acids long 
with Mr 185,000, as compared to Mr 170,000 of the EGFR protein. Like 
EGFR, the erb B-2 protein has an extracellular domain, a transmembrane 
domain that includes two cysteine-rich repeat clusters, and an intracellular 
domain with tyrosine kinase activity. The ligand for the erb B-2 protein is as 
yet unknown. Six possible ligands for the erb B-2 receptor have recently been 
identified only two have been characterised: a factor of Mr 30,000 (gp30) 
secreted by the breast cancer cell line MBA-MB-231 (Lupu et al 1990; Lupu et 
al 1992) and a 40Kd glycoprotein from ras transformed cells (Peles et al 
1992). In cell lines overexpressing the erb B-2 protein, stimulation by the 
ligands was shown to initiate differentiation (Lupu et al 1992; Bacus et al
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1992) and also DNA polyploidy (Bacus et al 1992). TGFa like activity with 
agonist activity for both EGF and erb B-2 was noted for each ligand. 
However the role of the erb B-2 ligands in normal and abnormal cellular 
development is still to be fully elucidated.
erb B-2 can transform cells in two ways. Over-expression of the 
normal cellular proto-oncogene, erb B-2 is sufficient to transform NIH-3T3 
cells and, unlike, the erb B (EGFR) gene (Section 1.4.3.4), the transformation 
is not dependent on exogenous growth factors (Di Fiore et al 1987b). Gene 
amplification results in elevated levels of expression of both erb B-2 mRNA 
and protein (Venter et al 1987; Vijver et al 1988). However, this does not 
preclude the possibility that in some cases mutation may occur, for the erb B-2 
oncogene product itself carries a point mutation at position 664 in the 
transmembrane region where valine is replaced by glutamic acid. This leads to 
increased tyrosine kinase activity, probably through receptor dimerisation 
(Weiner et al 1989). However a recent report suggests that the mutation at 
position 664 is a relatively rare event in breast cancer (Zoll et al 1992).
The erb B-2 oncogene has been extensively studied in breast cancer 
since the report of Slamon et al (1987), suggesting that its amplification 
correlated with poor prognosis. A large number of studies have now been 
published involving both erb B-2 gene amplification and protein 
overexpression in human primary breast tumours. The reported gene 
amplification rates range from 10 to 46%, with an average amplification of 
20%. Variability between these reports probably reflects differences in patient 
groups, the samples used for DNA analysis, paraffin-embedded as opposed to 
frozen or fresh tumour, and the fact that DNA preparations from tumour 
samples often contain DNA from normal vascular, stromal or inflammatory 
cells in addition to malignant cells. Although studies in general have shown
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good correlation between gene amplification and relative expression of both 
RNA and protein (Slamon et al 1989), there are also reports of a significant 
percentage of tumours with a single copy of the gene that overexpress the 
protein product (Inglehart et al 1990; Hanna et al 1990; Tandon et al 1989). In 
consequence measurement of protein expression may be a better guide to the 
clinical relevance of alteration (Clark and McGuire, 1991).
A characteristic feature of this onco-protein expression is that generally 
the erb B-2 protein is overexpressed in an unmutated, normal form and the 
potential site of mutation lies in the transmembrane domain. 
Immunohistochemical studies or western immunoblotting therefore, record 
differences in the intensity of staining. In the majority of the studies, 
immunocytochemical analysis with polyclonal antibodies, specific for the erb 
B-2 protein and not cross-reacting with EGFR, has been used and often 
groups of investigators have used the same anti-serum from the same source. 
A group of investigators (Lovekin et al 1991; Winstanley et al 1991; Gullick et 
al 1991; O’Reilly et al 1991), using one such anti-serum (2IN- directed to 
peptides 1243-1255) reported overexpression in about 20% of breast tumours, 
which is similar to that reported for gene amplification. Using both polyclonal 
and monoclonal anti-erb B-2 protein antibodies, membrane or cytoplasmic 
staining has been found to correlate with erb B-2 amplification (Venter et al 
1987; Vijver et al 1988, Berger et al 1988).
Most of the studies have also correlated erb B-2 amplification with 
prognosis in patients. In general, patients with node-positive disease have 
greater frequency of amplification than patients with node-negative disease. 
Although the original study reported by Slamon et al (1987) and some of the 
more recent studies (Tandon et al 1989; Borg et al 1991; May et al 1990) 
showed a positive association between erb B-2 expression and the number of
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invaded lymph nodes, this has not been generally reproducible. Vijver et al
(1988) found large cells of comedo type in situ carcinomas were associated 
with more intense staining. None of the recently published papers report any 
significant relationship with nodal status. But the association with histological 
grade has been consistently reported (Garcia et al 1989; Paik et al 1990; Wright 
et al 1989; Parkes et al 1990) although, investigators vary in their reports of the 
level of significance. A few studies also report that erb B-2 expressing 
tumours are generally larger in size (Vivjer et al 1988; Borg et al 1991) and 
negatively associated with steroid receptor status (Borg et al 1991; Tandon et al 
1989) but others have failed to confirm this (Zhou et al 1989; Slamon et al 
1987).
Although the area has been widely investigated, reports regarding the 
correlations between erb B-2 amplification and clinical outcome of breast 
cancer patients differ considerably. Clinical and pathological characteristics of 
the patients included in these studies vary and in some, analysis is restricted to 
node positive and in others to node negative patients. Using a monoclonal 
antibody to stain erb B-2 protein, Vijver et al (1988) reported no significant 
correlation between erb B-2 expression and disease free survival or overall 
survival after adjustment for tumour size, while Thor et al (1989), studying 
over-expression of erb B-2 with a Mab (TA1), which interacts with the 
extracellular domain of the protein, reported clinical significance in certain 
patient subpopulations only. In general, however, a significant prognostic 
effect of erb B-2 in terms of survival and recurrence has been reported in a 
larger number of studies compared to the reports of those studies which show 
no, or only a limited, prognostic effect (Perren, 1991). In a more recent study 
(Clark and McGuire, 1991), erb B-2 oncogene amplification in breast cancer 
has been reported to be of marginal utility as a prognostic factor in indicating 
clinical outcome. Correlation with either disease-free or overall survival was
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marginally significant for node positive patients only, but was not retained in 
multivariate analyses. In contrast, in the analysis of Gullick et al (1991), who 
combined the results of three relatively small studies with the same polyclonal 
ab and thus improved the total number of cases, erb B-2 protein over­
expression was found to be significantly associated with both recurrence and 
survival and this has also been confirmed in a multivariate analysis. This 
association was observed for breast cancer patients with involved and 
uninvolved nodes. As more studies with higher patient number are analysed, a 
clearer relationship will perhaps appear. At present, however, it is unclear 
which antibody preparation, method of tissue fixation, immunocytochemical 
reagents or schemes for immunohistochemical scoring is most useful. 
Standardisation of these methods must take place to give reliable estimates 
between groups.
It is of interest that erb B-2 has been implicated in the initiation of breast 
cancer rather than progression of the disease (Allred et al 1992). Further 
evidence for this is the fact that there is little change from tumour to metastases 
with respect to erb B-2 expression. (Tommasi et al 1992).
1.4.3.6 Hst  and int -2
Hst and int-2 are members of the Fibroblast Growth Factor (FGF) 
family of genes. The hst gene (also known as kFGF and as int-5), now 
assigned the name HSTF1 for heparin-binding secretory transforming factor, 
was originally isolated by gene transfer experiments with DNA from human 
stomach cancers and Kaposi's sarcoma (Deli Bovi et al 1987; Taira et al 1987), 
while int- 2 is a proto-oncogene identified as being adjacent to one of the 
integration sites of the proviral DNA of mouse Mammary Tumour virus 
(MMTV) (Nusse and Varmus, 1982). Hst and int- 2 are closely linked and in
79
the human genome both are encoded on chromosome llq l3 . Activation of 
both genes is by transcriptional deregulation giving over-expression of the 
normal gene product. The product of the hst gene is 206 amino acids long and 
that of the int-2 is 220 amino acids long. They have sequence homology to 
basic and acidic FGF but, significantly, unlike the FGF genes, they carry a 
signal sequence which allows them to be secreted efficiently. Although the 
precise function of the gene product is not known, normal expression of int- 2 
is thought to be restricted to defined stages of embryonic development 
(Wilkinson et al 1988) and transfection with int- 2 constructs in cell lines has 
led to small but reproducible changes in cell morphology and growth rate 
(Vijver et al 1991). A receptor specific for the int- 2 protein has not yet been 
identified.
Hst and int- 2 have been reported to be co-amplified in stomach cancer 
(Yoshida et al 1988). In breast cancer, the degree of gene amplification is low, 
and is not paralleled by expression of the gene (Fantl et al 1989). Varley et al
(1988) reported an amplification of int- 2 sequences ranging from 2- to 20- 
fold in 23% of the studied 40 primary breast carcinomas. While Zhou et al
(1989) reported amplification in only 19% (9 out of 46) of the primary 
tumours. Other workers also report similar modest amplifications of int-2 DNA 
in human breast cancers (Lidereau et al 1988). In addition to reporting co­
amplification of int -2 and hst in about 20% of primary tumours, Fantl et al
(1989) and Roux-Dosseto et al (1992) observed no significant correlation with 
any histopathological factors. Moreover, they also concluded that amplification 
of int- 2 and hst genes is not accompanied by marked over-expression. Co­
amplification was also observed by Ali et al (1989) and Theillet et al (1989). 
Theillet et al (1989) also reported a correlation between RNA expression and 
gene amplification in the case of hst but not of int- 2, while Ali et al (1989) 
found a significant association between int- 2 amplification and subsequent
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Varley et al (1988) have reported that the int-2 gene is altered in several 
amplified tumours with loss of an ECo R1 site. In most of the tumours with 
int- 2 amplification, a whole cluster of adjacent genes, including the oncogenes 
hst and bcl-1 is co-amplified (Lidereau, et al 1988; Yoshida et al 1988).
I.4.3.7. Other oncogenes implicated in breast cancer
1 .4 .3 .7 .1 . c -erb B-3
The third member of the ERB family to be identified was a 148kDa 
transmembrane growth factor receptor given the designation erb B-3. Two 
groups simultaneously discovered the gene using reduced stringency 
hybridisation of a v- erb probe, due to the high levels of homology in this 
receptor family, c- erb B-3 has 40% homology to the outer portion of erb and 
erb B-2 and 82% homology with the tyrosine kinase receptor domains. The 
ligand binding region is structurally related to erb and erb B-2 and may indicate 
"cross talk" of ligands, as evidence has shown low ligand specificity between 
binding of the erb and erb B-2 ligands. However, to date, the ligand for erb 
B-3 has not yet been identified.
Only one study has investigated the prognostic significance of erb B-3 
in breast cancer, reporting 43/195 patients (22%) over-expressing the erb B-3 
receptor, and this correlated with the mRNA level in these tumours. The over­
expression of the erb B-3 protein correlated with the presence of lymph node 
metastases but not with the overall survival of the patients. Gastric and 
pancreatic cancer have shown greater overexpression of c-erb B-3 when 
compared to levels in breast cancer (Lemoine et al 1992).
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Only limited data has so far been generated for erb B-3 and like erb B-2 
more detailed studies with larger patient numbers are necessary to fully 
evaluate the importance of the erb B-3 protein and its prognostic utility.
1.4.4. Tumour suppressor genes ("Anti-oncogenes”)
There is evidence that normal cells are controlled by genes which 
regulate activity of transforming genes and oncogene products. These have 
been called tumour suppressor genes and deletions or mutations in these 
important genes may play an important role in the generation of tumours. In 
cancer, the suppressor protein may be mutated and over-expressed with loss of 
its cellular control mechanisms. Along with deletions of the gene these may 
play an important step in carcinogenesis.
1.4.4.1. Retinoblastoma gene (RB)
Retinoblastoma (RB) is encoded on human chromosome 13ql4 and is 
expressed as a nuclear phosphoprotein. It has long been implicated in the 
generation of childhood tumours of the developing retina, collectively known 
as retinoblastoma. This linkage with cancer susceptibility was confirmed with 
the cloning of the human RB-1 gene and the demonstration that the RB genes 
from sufferers of retinoblastoma contain mutations for both alleles. 
Transfection of the wild type retinoblastoma into transformed cells containing 
the mutant gene showed reinstatement of growth control. The retinoblastoma 
phosphoprotein is also able to bind various viral transforming gene products 
and inactivate them (De Caprio et al 1990) These early experiments suggested 
that RB was a member of a group of negative regulators of proliferation. 
Transfection studies indicated growth control involvement of RB and a central
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role in cell proliferation. This hypothesis was tested in a gene knockout mouse 
for the RB gene (Lee et al 1992; Jacks et al 1992). The knockout embryo does 
not survive gestation and is terminated at about 12 to 13 days. At this point 
millions of cell divisions will have been already made without the absolute 
necessity for the RB gene product Thus the hypothesis for a central role in cell 
division must be questioned. The results however indicate another possible 
role, that of controlling cell differentiation, as the embryo ceases cell division 
with terminal differentiated cells at the time of abortion. At this point it could be 
hypothesised that RB plays a crucial role for further decisions involving cell 
division.
It is of interest that the heterozygous knockout mouse develops pituitary 
tumours whereas the humans develop retinoblastoma.
In breast cancer and other cancers there have been reports of loss of 
expression of the RB gene (Spandidos et al 1992) but no linkage to the 
progression of the disease.
1.4.4.2 p53 tumour suppressor gene
p53 was first detected in SV40 transformed cells (Lane and Crawford, 
1979; Lizer and Levine, 1979) where the protein was found to form an 
oligomeric complex with the SV40 oncogene product, large T antigen. Thus 
initially p53 was classified as a tumour antigen. However subsequent 
experiments have shown transforming ability and immortalisation of primary 
cells (Jenkins et al 1984), p53 was then categorised as an oncogene. 
Subsequently all of the transforming clones of p53 cDNA were shown to have 
originated from mutant forms (Hinds et al 1989). Recent findings have 
indicated that p53 protein has properties of a tumour suppressor gene,
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negatively regulating the cell cycle and requiring loss of function mutations for 
tumour formation, as expression of cDNA or genomic clones of wild type p53 
suppress the transformation of cells in culture and the tumourigenic potential in 
animals (Mercer et al 1990).
The human p53 gene was localised to the short arm of chromosome 17 
at 17pl3.1 (Benchimol et al 1985, McBride et al 1986). The organisation of 
p53 on the genome of other species is conserved and forms 11 exons 
interrupted by 10 introns. The expression of the human p53 gene has been 
shown to be controlled by two promoters of differing strengths and disruption 
of these promoters or the introns within the gene can cause abrogation of p53 
expression (Reisman etal 1988; Reisman etal 1990).
p53 has been shown by immunofluorescence studies to be localised 
primarily in the nucleus although it has also been shown have cytoplasmic 
localisation in non transformed cells (Dippold.et al 1981). Using calf thymus 
DNA the p53 mutant protein derived from human tumours was shown to have 
a higher binding affinity for single stranded(ss) DNA rather than double 
stranded(ds) DNA which is the opposite to what is observed with wild type 
p53 (Steinmeyer et al 1988). DNA binding characteristics of p53 were studied 
and when the first 40 amino acids are removed from the amino terminal end of 
the protein the DNA binding is not affected. However an antibody with an 
epitope to the carboxyl end of the p53 protein also does not inhibit DNA 
binding. These results would suggest that the DNA binding domain lies 
between the two ends of the molecule (Steinmeyer et al 1988). This 
observation was strengthened when a 33 base pair sequence was identified that 
specifically bound to p53 (Kem et al 1991). These sequences are associated 
with DNA replication origins and this fact along with the role in gene
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expression may suggest a dual role for the p53 protein in the regulation of 
growth control.
As p53 binds to both ssDNA and dsDNA regulatory sequences, the 
obvious question arises, is p53 a transcriptional regulatory factor? P53 has 
been shown to enhance the activity of a 5' Long Terminal Repeat (LTR) 
promoter and in mice a p53 responsive element for the muscle specific creatine 
kinase could be activated 80 fold in the presence of wild type p53 (Luria and 
Horowitz 1986). In humans similar regulatory affects were seen in the control 
of IL-6 transcription (Santhanam et al 1991). The wild type p53 protein has 
shown the ability for repression of c-fos and c-jun (Ginsberg et al 1991). It 
was noted that the amino terminal portion of the protein is a stronger 
transactivator than the full length protein, indicating that other areas of the 
protein are important in regulation of the transactivation activity (Fields and 
Jang 1990).
The involvement of p53 in the cell cycle was first suggested as p53 
expression was not observed in quiescent (resting) lymphocytes (Milner and 
McCormick 1980), but was induced on mitogen stimulation of the cells. Using 
quiescent lymphocytes as a model, p53 expression could be followed during 
cell cycle progression using fluorimetry. p53 content was shown to increase 
from G1 to S and also between G2 and M phase suggesting that the expression 
of p53 may be correlated with cell growth rather than progression through any 
specific phases of the cell cycle (Danova et al 1990). However after 
microinjection of p53 specific antibodies into growth stimulated quiescent 
cells, the entry into S phase was inhibited, indicating that p53 is an essential 
part of the G1 to S transition (Mercer et al 1984) having no effect on the S to 
G2M transition. Other evidence of cell cycle involvement was shown by the 
addition of a potent inhibitor of G l, sodium butyrate, which blocked the
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synthesis of p53. These results were obtained for both mutant and wild type 
forms, which would suggest a role at two distinct points the GO to G1 and the 
G1 to S phases of the cell cycle.
Wild type p53 has a negative effect on the cell cycle, which is in direct 
contrast to the positive effect of mutant p53. Mercer et al (1990) have shown 
induction of wild type p53 in a variety of cell lines caused cell cycle arrest at 
GO/1 preventing the cells from entering S phase. At the protein level p53 can 
inhibit a cellular initiation protein essential to functioning of DNA polymerase 
a. (Gannon et al 1987). Thus p53 may affect both the proteins and the genes 
direcdy involved in cellular replication mechanisms.
Early experiments, as described above, have shown that p53 had 
transforming capacity. This would suggest that it may have a 
promoter/enhancer ability in cellular transformation (Rovinski et al 1988). 
However it was later realised that the mutant form of p53 had been used in 
immortalisation experiments (Hinds et al 1989). When the same experiments 
were repeated with wild type p53 transfections into primary or senescent cells, 
it was found that these cells could not be immortalised. The wild type p53 has 
been shown to reduce the effect of transformation (Finlay et al 1989) and the 
development of fast growing tumours (Shaulsky et al 1991).
The induction of apoptosis also known as programmed cell death, is a 
central part of normal cellular development, which involves a selective 
"editing" of cells. Work on mammalian cells had shown the importance of two 
oncogenes myc and bcl-2 in positive and negative control of this process 
(Evan, 1992).
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It has been shown that p53 expression can be induced by DNA damage 
and this would suggest a role in cellular repair mechanisms (Kastan et al 
1991). Over-expression of wild-type p53 in a number of culture systems has 
been shown to induce apoptosis. However other cells types have shown only 
growth arrest (Michalovitz, 1990). These two concepts of DNA repair and 
apoptosis were explored in the thymocytes of p53 gene knockout mice (Lowe 
et al 1993; Clarke et al 1993). Thymocytes are an ideal model as they are a well 
evaluated system for apoptosis and clonal selection of lymphocytes. The 
results indicate that thymocytes from the gene knockout mice have 20 fold 
greater resistance to radiation before undergoing apoptosis, than thymocytes 
from normal mice. When comparing heterozygous mice to homozygous, the 
heterozygous mice containing only one copy of the p53 gene are more resistant 
to radiation induced apoptosis than homozygous mice with two copies of the 
gene implying a gene dosage effect. Induction of apoptosis may act as a 
defence against mutations in the genome of these cells, selectively editing 
mutated cells.
The p53 gene has been examined in a wide variety of primary tumours. 
Mutations in and/or reduction of heterozygosity of the p53 gene locus appear to 
be very frequent in many human tumours, including breast cancer. p53 gene 
has been most extensively studied in colon carcinomas, where 75-80% show a 
loss of both p53 alleles. Similar reduction to homozygosity has also been 
reported for breast tumours (Mackay et al 1988). In approximately 65% of 
informative cases, a region (p i3.1) on the short arm of chromosome 17 which 
includes p53, has been reported to be lost in breast cancers (Mackay et al 1988; 
Devilee et al 1991). It has been hypothesised that the tumour may develop 
through loss of heterozygosity in one allele, and subsequently the other 
through point mutation, which gives rise to over-expression of an altered 
protein. The mutated protein is unable to exert the control function of the
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normal wild type protein. Like those in the H-ras oncogene, mutations in the 
p53 gene appear at "hot spots" on the encoding gene, with residues such as 
175, 248 and 273 being particularly significant. This complex data has only 
been rationalised by the proposition that the mutation of p53 on one allele, 
confers selective growth advantage on the cell even though the other allele 
expresses the normal wild type gene.
Studies on the p53 gene have involved the examination of human 
tumours for loss of gene sequences and immunohistochemical analysis for 
gene expression. In assessing gene expression advantage is taken of the fact 
that the wild-type p53 gene product has a short half life and low intracellular 
concentration, whereas most mutant forms appear to have a much longer half 
life and a high intracellular concentration. The identification of p53 in primary 
tumours by antibodies is therefore, taken to indicate that the gene has been 
altered. In the case of breast cancer, loss of one gene locus encoding p53, or 
over-expression of the mutated protein have been reported. Both Bartek et al
(1990) and Cattoretti et al (1988), using immunocytochemical methods found 
the protein to be expressed in about 50% of human breast tumours. In the 
study of Cattoretti et al (1988), the choice of antibody used was important as 
one antibody detected mutant proteins in more tumours than the other. In the 
more recent study of Varley et al (1991), both loss of heterozygosity and p53 
protein expression were examined. 8 6% of breast tumours exhibited either p53 
expression or loss of heterozygosity with only a smaller percentage of samples 
being positive for both. They also found three patients positive for p53 
expression but negative for loss of heterozygosity where clear mutations in the 
p53 gene could be mapped by the polymerase chain reaction (PCR).
Mutations in p53 gene are the most frequently observed in human 
cancers. Donehower et al (1992) attempted to investigate the role of p53 in
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mammalian development and tumouiigenesis by inserting a null mutation into 
the gene by homologous recombination in murine embryonic stem cells. Mice 
homozygous for the null allele appear normal but are prone to the spontaneous 
development of a variety of neoplasms by 6  months of age. These observations 
indicate that a normal p53 gene is dispensable for embryonic development, that 
its absence predisposes the animal to neoplastic disease, and that an oncogenic 
mutant form of p53 is not obligatory for the genesis of many types of tumours.
p53 has been implicated in a variety of functions from transactivation to 
induction of apoptosis. However the results from the gene knockout mouse 
would suggest that p53 is not as essential as previously thought. The large 
incidence of mutations of p53 would indicate a central role in tumourigenesis 
and use of the gene knockout mouse model will be in the future invaluable to 
test hypotheses for the function of the p53 protein.
I.4.4.3. Other tumour suppressor genes
Apart from the two well defined tumour suppressor genes there exist 
other tumour supressor genes. These include deleted in colon cancer (DCC) 
and WT-1 first discovered in Wilms tumour. To date, there are no published 
refereed reports of these being relevant to breast cancer.
1.4.5. Aneuploidy, oncogenes and tumour suppressor genes
In breast cancer changes in the DNA ploidy are observed in 
approximately 70% of all tumours. A few studies have compared expression of 
specific oncoproteins with DNA ploidy. Of these the c-erb B-2 protein and the 
c-myc have been related to aneuploidy in breast cancer (Tavassoli et al., 
1989). With some reports relating higher c-erb B-2 expression in tumours with 
tetraploid DNA (4N) (Bacus et al 1990; Lee et al 1992). There have been no
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1.5. Aim of the study
This study was designed to utilise flow cytometry to assess both 
immunological and oncological parameters in breast cancer and to relate these 
two areas together. Flow cytometry has certain advantages over other 
techniques in that cells are analysed objectively giving a quantitative result for 
fluorescence. Flow cytometry can also select for cell types of a defined size 
such as lymphocytes to either include or exclude them from the analysis.
The samples analysed in this study are important as the tumour can be 
compared to the corresponding lymph node metastases in patients. Flow 
cytometry can exclude the lymphocytes and thus analyse only metastatic 
tumour cells. The lymphocytes can then be analysed separately for immune 
responses due to the tumour.
The flow cytometric studies included
(i) The expression of the T cell receptor y/8  within the lymphocyte populations 
of a breast cancer patient
(ii) immune responses in tumour invaded compared with tumour free axillary 
nodes from the same patient.
(iii) immune responses in tumour draining lymph nodes taken from the low 
and high axilla
(iv) Expression of p53 and c-erb B-2 proteins in primary and metastatic breast 
cancer.
(v) Relationship of p53 and c-erb B-2 expression to the immune response in 
the tumour draining axillary nodes.
CHAPTER 2 
MATERIALS AND METHODS
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2.1. Materials
2.1.1. Human tissue
Peripheral blood, axillary lymph nodes and tumour were obtained from 
patients undergoing surgical resection for breast cancer at the Western 
Infirmary, Glasgow, Scotland.
2.1.2. Tumour cell and lymph node lymphocyte preparations
RPM I1640 Gibco, Paisley, Scotland.
Penicillin Streptomycin Gibco, Paisley, Scotland.
2.1.3. Peripheral blood lymphocyte preparations
Ficoll-Hypaque Pharmacia fine chemicals
2.1.4. Cryopreservation of lymphocytes and tumour cells
RPMI 1640
Uppsala, Sweden.
Gibco, Paisley, Scotland.
DMSO BDH chemicals Ltd, 
Poole, England 
Gibco., Paisley Scotland.Foetal Calf serum
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2.1.5. Plasticware
Centrifuge tubes and Universals Sterilin Ltd., Feltham, 
England
Falcon 2052 FACs tubes Becton Dickinson, 
Cowley, England.
2.1.6. Antibodies
All antibodies were obtained from Dakopatts Ltd., High Wycombe, 
England.
With the following exceptions:
Leucogate
Sheep anti-mouse IgG (Whole ab) 
FITC conjugated
Becton Dickinson, 
Cowley, England. 
Amersham International 
pic, Amersham, England.
Mouse anti-human c-erb B-2 Oncogene Sciences, 
Cambridge, England
Mouse anti-human p53 Pabl801 A kind gift from 
Lionel Crawford 
ICRF, Cambridge.
Mouse anti-human y/5 T cell receptor A kind gift from Dr J 
Borst, Netherlands
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2.1.7. Other Materials
Sephadex G25 column Pharmacia,
Cambridge, England
2.1.8. Buffers
Phosphate buffered saline (PBS) pH 7.2
170mM NaCl, 3.4mM KC1, lOmM Na2HP04> 1.8mM KH2P0 4
Sheath Fluid pH 7.2
1.3mM NaCl, 0.02mM KC1, 20mM LiCl, 15mM KH2 P 0 4> lOmM  
Na2 HP04>
lOmMEDTA
Carbonate Buffer pH 9.0 
0.25M Na2 C03s 015M NaC1
Citrate Buffer pH3.0 
O.IMNa Citrate
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2.2 Methods
2.2.1. Sample preparation of tumour and lymphocytes
Samples were obtained from the Western Infirmary, Glasgow, 
Scotland. None of the patients had received any pre-operative chemotherapy or 
radiation therapy. A central representative slice of tumour was taken, with the 
remainder sent to pathology for routine histology and grading. The lymph 
nodes collected were bisected, with one half collected for analysis and the other 
half sent to pathology for staging. The samples were transferred aseptically to 
sterile containers.
2.2.2. Cell harvesting
Tumour and lymph nodes were processed within 1 hour of collection to 
minimise turnover of the membrane receptors. 5ml RPMI was added to the 
sample to remove any traces of blood with 1ml of 104 units/ml penicillin, 
lOmg/ml streptomycin subsequently added to remove any traces of infection. 
The samples were transferred to a 90mm sterile petri dish containing 10ml 
RPMI medium. The tumour tissue was teased apart and disaggregated using a 
scalpel and a sterile needle. The spilled cells were then harvested, washed and 
centrifuged at 150g for 5 minutes. They were cryopreserved if not immediately 
used.
2.2.3. Isolation of peripheral blood lymphocytes (PBL)
10ml of venous peripheral blood taken during surgery was layered 
carefully on an equal volume of Ficoll-Hypaque. The tubes were centrifuged at 
1400g for 20 minutes and the lymphocyte layer was carefully removed. The
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lymphocytes were transferred to a tube containing 10ml RPMI and then 
washed once again. The lymphocytes if not used immediately were 
cryopreserved.
2.2.4. Cryopreservation
The cell pellet was resuspended in 3ml freezing medium containing 10% 
DMSO and 90% foetal calf serum. This cell suspension was divided into 1ml 
aliquots and transferred into cryopreservation vials which were placed in a 
-70°C freezer overnight prior to storage in liquid nitrogen.
On removal from liquid nitrogen the ampoules were thawed rapidly in a 
37°C water bath and transferred to a sterilin tube containing 1ml of PBS. This 
was centrifuged at 150g for 5 minutes and the cells were resuspended in PBS 
for FACScan analysis.
2.2.5. Flow Cytometry
The flow cytometer used was the Becton Dickinson FACScan 
(Fluorescence Activated Cell Scanner). This allows simultaneous 
measurement of five parameters on a single cell consisting of two physical 
parameters forward scatter (FSC) and side scatter (SSC) and 3 fluorescence 
parameters. (1) FSC is the measure of incident light scattered in the forward 
direction and (2) SSC measures the degree of sideways light scatter for an 
estimation of granularity. The two physical parameters make it possible to 
distinguish between different cell types such as lymphocytes and tumour cells 
allowing gating of populations.
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Fluorochromes
Three main fluorochromes fluorescein (FITC), phycoerythrin (PE), and 
propidium iodide(PI) are used for fluorescence channels 1, 2 and 3 
respectively.
Fluorescein (FITC) (C12H11NO5 S) is a commonly used conjugate and 
can be easily attached on proteins and immunoglobulins giving a stable 
complex. FITC is green on low density staining and yellow on high density 
staining. Excitation range is 400-530nm, emission maximum 530 nm (Figure 
2 . 1).
The second fluorochrome phycoerythrin (PE) (FL 2) is a member of the 
phycobiliproteins, consisting of highly fluorescent orange/red macromolecules. 
Coupling to immunoglobulins is achieved by protein-protein crosslinking 
methods by direct linking to thiol groups. Excitation range is 420-580nm, max 
480, 545, 565. emission maximum 580 nm (Figure 2.1).
The third dye is propidium iodide (PI) which intercalates into RNA and 
nuclear DNA for discrimination of live and dead cells. PI excitation max is 493 
nm and emission maximum at 630nm in the red part of the spectrum (Figure 
2 . 1).
2.2.6. General FACScan procedures
2.2.6.1. General lymphocyte staining
Cell suspensions of LNL or PBL were washed after cryopreservation to 
remove any traces of foetal calf serum. These cells were resuspended at a cell
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Figure 2.1 Emission characteristics of fluorescein (FITC), phycoerythrin 
(PE) and propidium iodide (PI).
density of lOfyml. Aliquots (50|il) were incubated for twenty minutes on ice 
with the relevant monoclonal antibody (Mab) to specific phenotypic and 
activation markers on the lymphocytic membrane (Table 2.1). This incubation 
was carried out in the dark to reduce photo-bleaching of the fluorochromes. 
Where the primary antibody was unconjugated the cells were washed with 1ml 
PBS and a suitable second antibody labelled with FITC would be added for a 
further 20 minute incubation. The cells were washed, centrifuged at 150g for 5 
minutes and resuspended in 0.5ml PBS. Propidium iodide (2pg/ml) was added 
to discriminate between live and dead cells by exclusion gating (Figure 2.2).
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Figure 2.2 PI gating to exclude cells with breached membranes which have 
taken up PI and are highly FL-3 fluorescent.
2.2.6.2. Lymphocyte scatter gate.
A lymphocyte gate was set based on cell size, forward scatter (FSC) and 
granularity, side scatter (SSC). The validity of the gate was checked by the 
leucogate antibody (Figure 2.3). An irrelevant anti-mouse IgG monoclonal 
antibody was used to assess the non specific binding. 5000 events were 
collected for statistical relevance and analysed on the FACScan research 
program.
2.2.6.3. Live cell discrimination by propidium iodide gating
During the freezing and thawing of human tissue a proportion of cells 
will rupture and become non-viable due to the fragility of the cell membrane or 
ice crystal formation. Data from the viable cells with intact membranes are
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Table 2.1. M onoclonal antibodies used for lym phocyte  
phenotyping and activation studies
First antibody Second antibody Co-expression
IgGl-FITC IgG2a-PE Control
Leucogate
Anti-CD45-FTTC Anti-CD 14-PE Staining of leucocyte 
sub populations 
(lymphocytes, monocytes, 
neutrophils)
Anti-Leu 4-FITC Anti-Leu 12-PE T-lymphocytes
B-lymphocytes
Anti-Leu 3a-FTTC Anti-Leu2a-PE CD4+ T helper cells, 
CD8+ T cytotoxic cells
Anti-Leu 3a-PE Anti-HLA DR-FTTC Activated CD4+ 
helper T cells
Anti-Leu 3a-PE Anti-CD25-FTTC IL-2 receptor on CD4+ 
helper T cells
Anti-Leu 2a-PE Anti-HLA DR-FITC Activated CD8+ cytotoxic 
T cells
Anti-Leu 2a-PE Anti-CD25-FTTC IL-2 receptor on CD8+ 
cytotoxic T cells
Anti-Leu 12-PE Rabbit F(ab>2 
anti-human 
IgG(y chain)-FITC
Surface IgG expressing 
CD19+B cells
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collected since cells with ruptured membranes can bind the staining antibody 
non specifically. To distinguish between the populations, propidium iodide is 
added. The PI intercalates into DNA and this is detected on the red channel on 
the FACScan (FL3). Thus the red cells can be gated out of the analysis (Figure 
2.2). The PI is also used for DNA staining of fixed cells (Section 2.2.6.7).
2.2.6.4. Analysis of lymphocyte staining
A quadrant was set on the G1/G2 non specific binding control to include 
99.5% of cells for statistical relevance. The X co-ordinate and the Y co­
ordinate of the quadrant were noted for gating. The quadrant analysis was used 
for T/B and H/C estimations (Figure 2.4). Analysis of lymphocyte subset 
activation required a dot plot gate to include only the positive staining 
lymphocytes (Figure 2.5a and b). A histogram was drawn and the X- 
coordinate from the G1/G2 (Figure 2.5c) non specific binding experiment was 
used as a mark to measure dual positive cells.
2.2.6.5. Lymphocyte staining method for the y/8 T cell receptor
TILs, LNLs and PBLs were selected by FSC/SSC gating.The 
lymphocytes expressing the y/5 T cell receptor (TCR) were identified with 
monoclonal anti-TCR-y/5 which recognises both the disulphide and non­
disulphide forms of the receptor (a gift from Dr J. Borst). For two colour FCM 
analysis, lx 10  ^ cells were incubated with the anti-y/8-TCR for 20 minutes, 
and washed twice before incubating with FITC-sheep anti mouse IgG for 20 
minutes. After two more washes, the cells were blocked with mouse sera 
(diluted 1:50) for 20 minutes, and washed twice again. PE-conjugated 
antibodies (CD4, CD8 , and CD3) were added to the cells for a 20 minute
1 0 0
Figure 2.3 Lymphocytic gating by forward scatter (FSC) and side scatter 
(SSC) parameters.
green= lymphocyte population, red=monocytes, cyan=non staining cells.
A illustrates the size parameters before forward scatter (FSC) and side 
scatter (SSC) befor^gating and C illustrates the lymphocyte population after 
gating. B illustrates the differential staining of the leucocyte populations 
before gating and D after lymphocyte gating.

1 0 1
Figure 2.4 Phenotypic analysis of lymphocytes from breast cancer 
patients
A The G1/G2 level of non specific staining in the bottom left quadrant 
B The CD3+ (T cell) staining in the bottom right quadrant and the CD 19+ 
(B cell) staining in the top left quadrant
C The CD4+ (T helper) staining in the bottom right quadrant and the CD8+ 
(T cytotoxic) staining in the top left quadrant.
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Figure 2.5 Analysis of lymphocyte activation marker expression
A Dot plot of anti-CD 19 (FL-2) and anti-IgG staining (FL-1). The double 
stained CD 19+ IgG+ show up on the upper right quadrant
B. The proportion of cells expressing an activation marker (in this case IgG 
expression on CD 19+ cells) is analysed by isolating the particular 
population on FL-2 (phenotype staining)
C. On a histogram on FL-1, the proportion of IgG + CD 19+ B cells is 
assessed by placing a marker, the position of which is based on the control 
sample.
1 B
. 1 3 ,  , , I 3P P ,  , K B P ,  , m a p ,  , m a p ,  , 1 1 b b b
I B  2 —
I B 2 —
I B 1 —
I B
. -------------------------------------------------------------------------------------
: > v : S , 4i . I
J  ry s V : ::» j
! • * ^ 1
n —i i 1 u n i-1—i i i miii-1—i i i  miii---------------- 1—i i 11 in
3 0  I B 1 I B 2 I B 2FI UDriscancB 1
T B B B
CBS
ETBB
T BB
CSS
1B
I g a p ,  , k b p , , m a p ,  , m a p
I B
I B  2 “
a
a
S'®2-
a
s. I 
a 2
L.
I B 1 "
I B rmj-
I BI BI BI B
F I  U D r B S E B n C t  1
I B
B B B
I I I Mill
I B tBe
n  uorBicsncB 1
I B I B
103
incubation before the final two washing steps. Antibodies with irrelevant 
specificities were used as negative controls.
2.2.6.6. Analysis of y/8  T cell receptor expression
Percentages of y/8  positive cells were calculated from histograms on 
FL1 (FITC) drawn after gating for CD3 positive cells (FL-2 channel) on an 
FL1 vs FL2 plot. Phenotypic analysis was performed by calculation from 
populations gated for CD4 and CD8 and expressing the result as a percentage 
of total CD3/4/8 + y/8  + cells (Figure 2.6).
2.2.6.7. Dual Colour Flow Cytometry of oncoprotein and DNA
The tumour cells were washed and resuspended in 0.5ml PBS to a final 
concentration of lOfyml. 0.5ml 70% ethanol was added dropwise slowly 
whilst vortexing, ensuring complete mixing.The ethanol fixed cells were 
incubated on ice for 30 minutes. The cells were washed and resuspended in 
100(4.1 PBS. The p53-FTTC, and the c-erb B-2 antibodies were added (10|Xg/ml 
final concentration) to the relevant tubes and incubated in the dark for 2 0  
minutes and subsequently washed. To the c-erb B-2 tubes a second anti-mouse 
FITC labelled antibody was added. The cells were finally washed and 
resuspended in 500(4,1 2 0 (4,g/ml propidium iodide to stain the DNA. The 
controls consisted of second FITC antibody added alone to the tumour cells 
and the p53 and c-erb B-2 staining of the PBLs.
2.2.6 .8 . Analysis of oncoprotein staining
The data was acquired on the Consort 30 program. The fluidics were set 
on the low mode to allow the nucleus of one individual cell to have the correct
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Figure 2.6 Analysis of y/8  T cell receptor expression
Two colour flow cytometry showing T cells expressing y/8  receptors in TILs from a 
breast cancer patient. Lymphocytes in the cell suspension were incubated with 
monoclonal anti-TCR y/8  (green fluorescence, FL-1) and or PE labelled monoclonal 
antibodies (orange fluorescence, FL-2) specific for the CD3 marker and the CD4 and 
CD8 subsets. The thresholds of positivity for green (horizontal line) and orange 
(vertical line) fluorescence were established by incubation with unrelated antibodies 
(Figure 2.4A).
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shape for DNA acquisition. Peripheral blood lymphocytes (PBLs) from the 
same patients were stained as a diploid control. For analysis of the tumour 
samples, the lymphocytes present in the tumour and lymph node lymphocytes 
were gated out using the forward scatter (FSC) and side scatter (SSC) 
parameters the competence of this gate being confirmed by analysis of a sample 
of PBLs from the same patient at the same time. The tumour cells were stained 
with a sheep anti- mouse IgG polyclonal antibody conjugated to FITC for 
assessment of non specific binding (Figure 2.7). Analysis gates were 
constructed on the lymphocyte samples and checked against the non specific 
binding to the tumour cell (Fig 2.7 B and E). The number of positive cells in 
the analysis gates of the control samples was usually 5% or less, this was not 
subtracted from the positive samples which may therefore contain up to 5% of 
cells showing non specific binding. For ploidy determination a simultaneous 
propidium iodide DNA stain was used.
2.2.7. FITC labelling of the p53 antibody
0.05mg of FITC was added to 1 mg/ml antibody in a maximum volume 
of 0.5ml 0.25M carbonate buffer /0.15M NaCl pH 9.0. Incubation was 
overnight at 4°C whilst shaking. Samples were eluted through a Sephadex G- 
25 column to separate bound from free FITC based on molecular size.
2.2.8. Fluorescence microscopy
For examination of p53 and c-erb B-2 staining 50}il of tumour 
cell suspensions (106/ml) were stained with lOjil (100 |ig/ml) of the relevant
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Figure 2.7 Dual parameter flow cytometric plot of oncoprotein staining 
(Fluorescence 1) and DNA amplification (ploidy) (Fluorescence 2) for 
patient 3 showing the gating for positive cells.
A and D represent monoclonal antibody staining of the patient peripheral 
blood lymphocytes (PBLs) for p53 and c-erb B-2 respectively. B and E 
represent control staining of tumour cells with a sheep anti mouse IgG 
(Fluorescence 1) antibody for assessment of non specific binding.
C and F correspond to positive staining of tumour cells for p53 and c-erb 
B-2 respectively.
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fluorescein conjugated antibody. This incubation was for 20 minutes on ice in 
the dark. The samples were washed in 1ml PBS and resuspended in lOOpl of 
PBS. The samples were applied in 10|il portions to a microscope slide which 
was then examined in a Leitz orthoplan microscope.
2.2.9. Statistics
All statistical analyses were carried out using Statworks software for the 
Macintosh computer.
For all comparisons non parametric tests have been used for the 
comparison of different groups. Statistical significance is taken at 5%, 
corresponding to less than or equal to p=0.05.
The Wilcoxon signed rank test was used for the comparison of tumour 
free and tumour invaded lymph nodes removed from the same patient in 
Chapter 4.
The Mann-Whitney U test was used for the comparison of two 
independent groups such as the expression of p53 and c-erb B-2 within the 
diploid and aneuploid tumour subsets in Chapter 6 .
The comparison of more than two independent variables was carried out 
using the Kruskal-Wallis test, such as for p53 and erb B-2 expression within 
the three gradings of tumour (Chapter 6).
The Spearman Rank test was used to assess the assess p53/c-erb B-2 
and the corresponding increase or decrease in the immune response (Chapter 
7).
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For comparison of small numbers the students T test was used (Chapter
5).
CHAPTER 3
T CELL RECEPTOR y/8 
EXPRESSION ON 
LYMPHOCYTE 
POPULATIONS OF BREAST 
CANCER PATIENTS
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3. T cell receptor y/5 expression on lymphocyte 
populations of breast cancer patients
Relatively little is known about the function of the gamma delta subset 
of the T cell receptor (Section 1.2.4.2.). Recent studies have revealed that like 
the cx/p receptor it is stably associated with the CD3 molecule and can also be 
associated with the CD8 and CD4 proteins on T cells. These y/8 T cells have 
been shown to have significant junctional diversity within the 8  gene, giving 
the y/8 T cell receptor the ability to be potentially as diverse as the a/p receptor 
and IgG. This wide diversity is suggested to contribute to the possible 
functions of this receptor, which has been shown to have increased expression 
in coeliac disease, rheumatoid arthritis and certain bacterial infections. This has 
led to the suggestion of the y/8 T cells playing a role in immunosurveillance.
In this study the quantitative distribution and phenotype of the y/8 T cell 
receptor was measured within the peripheral blood lymphocytes (PBL), lymph 
node lymphocytes (LNL) and tumour infiltrating lymphocytes (TIL).
The methodology of lymphocyte staining and gating procedures are 
described in Sections 2.2.6.5. and 2.2.6.6.
Lymphocyte phenotype was defined by flow cytometry and divided into 
three main categories. (1)CD3+ y/8 +, (2) CD8+ y/8+ as a percentage of CD3+ 
y/8+ and (3) CD4+ y/5+ as a percentage of CD3+ y/8+
The values obtained for CD3+ CD4+ y/8 + and CD3+ CD8+ y/8 + were 
expressed as a percentage of the total obtained for CD3+ y/8 +, as both CD8 
and CD4 glycoprotein molecules stably associate with the CD3 protein. The 
results are expressed in median form due to the skewed nature of the data.
110
3.1 Distribution of the y/S+ T cells in the TIL, LNL and 
PBL populations
The median percentages of CD3+ y/5+ cells in lymphocytes from each 
analysed source are shown in Figure 3.1 and Table 3.1. The results show TIL 
5.4% (quartile range 1.6 - 7.4%), PBL 3.0% (quartile range 1.3 - 6.0%), LNL 
3.6% (quartile range 3.5 - 12.5%). The greatest range of expression is found 
in the LNL, whereas the TIL and the PBL show much smaller ranges of y/5 
expression (Figure 3.1). With individual patients expression for TIL, PBL and 
LNL is illustrated in Figures 3.2a, 3.2b and 3.2c.
A small CD3- CD 19- population positive for y/5 was observed during 
analysis of TIL samples where the lymphocytes were not separated from non 
lymphocytic cells. This probably represents non specific binding of antibody to 
tumour cells within the TIL samples. All analyses of y/5 TCR expression were 
therefore directed to the CD3+ population.
No correlation was observed with the number of y/5 cells in the TIL 
population and the progression of disease as assessed by the grade of tumour 
and the stage of the tumour (lymph node involvement).
The overall expression of the receptor in the three tissues was similar 
with the exception of two patients with a higher proportion in the lymph node 
(33% and 25%) (Figure 3.1). Within the same patient the expression of y/5 
receptor in the TIL population did not correlate with that in peripheral blood 
and lymph node.
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Table 3.1
Percent expression of the y/5 T cell receptor within the CD3+, CD4+ and 
CD8+ T lymphocyte subsets of breast cancer patients.
Source TCR y/d 
CD3+ as a 
% of CD3+ 
lymphocytes
CD4+ y/8+ 
asa % 
of CD4+ 
lymphocytes
CD4+ 
asa %
of CD3+y/8+ 
lymphocytes
CD8+ y/5+ 
asa%  
of CD8+ 
lymphocytes
CD8+ 
asa%  
of CD3+Y/5 
lymphocytes
TIL 5.4 10.4 4.4 14.5 45.7
PBL 3.0 12.4 3.8 11.3 15.4
LNL 3.6 9.5 18.0 12.9 0.3
Fresh lymphocytes from peripheral blood (PBL), lymph node 
lymphocytes (LNL) and tumour infiltrating lymphocytes (TIL) were obtained 
from breast cancer patients. The cells were stained with mouse monoclonal anti 
TCR y/5 antibody and detected via a second anti mouse antibody conjugated to 
fluorescein (FITC). The CD4 and CD8 subsets were analysed using specific 
antibodies directly conjugated to phycoerythrin (PE). Values represent the 
median percentage obtained from analysis of 13 tumour and 11 peripheral 
blood and lymph node samples. Percentages of y/5+ cells were determined on 
gated CD3+ populations and percentages of CD4+ and CD8+ populations were 
calculated as a percentage of CD3+ y/5+ cells (Section 2.2.6.6.).
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Figure 3.1 Percent of CD3+ y/5+ T lymphocytes within the total gated 
lymphocyte populations from (1) TIL (2) PBL and (3) LNL
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Figure 3.2a Percentage expression of CD3+ y/8+ T lymphocytes within 
CD3+ gated TIL population.of 13 breast cancer patients.
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Figure 3.2b Percentage expression of CD3+ y/5+ T lymphocytes within the 
CD3+ gated PBL population of 11 breast cancer patients.
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Figure 3.2c Percentage expression of CD3+ y/5+ T lymphocytes within the 
CD3+ gated LNL population of 11 breast cancer patients
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3.2. Phenotypic marker expression of y/8 T cells
The only T cell phenotype consistently expressed within the CD3+ y/5 
population of the tumour infiltrate was the CD8 marker (Table 3.1; Figure 
3.3b) the median expression (45.7%) being greater than that of PBL and LNL. 
Patient expression in TIL, PBL and LNL is illustrated in Figure 3.4a, 3.4b and 
3.4c.
In the peripheral blood within the CD3+ y/8 + lymphocyte population a 
low percentage of y/8 + CD8+ (median 15.4%) and y/5+ CD4+ (median 3.8%) 
expression was observed in a few cases but otherwise the majority of y/5 cells 
were double negative (CD4- CD8-).
In the nodes within the CD3+ y/8  population CD4+ y/8  T cells were 
found to be predominant with a median value of 18% (Figure 3.3a). The CD4 
expression on y/8+ cells in the lymph node was higher than CD8 expression 
(median 0.3%), which is the opposite to that observed in the TIL population. 
The majority of y/8 + cells in the node are double negative. Each patient 
expression within TIL, PBL and LNL is illustrated in Figures 3.5a, 3.5b and 
3.5c.
115
+Tf
Q
U
o
0]
+a-w
"O
aa
So +
03
+ 2S 0)
«*- a ° a
^  So
40 n
30 -
20 -
10 -
oS°
o
o
O O
o
o
00o
1 2 3
Source of lymphocytes
Figure 3.3a Distribution of CD3+ y/5+ T lymphocytes also CD4+y/5+ 
within the total gated lymphocyte populations from (1) TIL (2) PBL and (3) 
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Figure 3.3b Distribution of CD3+ y/8 + T lymphocytes also CD8+y/5+ 
within the total gated lymphocyte populations from (1) TIL (2) PBL and (3) 
LNL
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Figure 3.4a Percentage expression of CD3+ y/8+ T lymphocytes also CD8+ 
y/8+ within the gated TIL population of 13 breast cancer patients
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Figure 3.4b Percentage expression of CD3+ y/8 + T lymphocytes also CD8 + 
y/5+ within the gated PBL population of 11 breast cancer patients
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Figure 3.4c Percentage expression of CD3+ y/8+ T lymphocytes also CD8+
y/8+ within the gated LNL population of 11 breast cancer patients
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Figure 3.5a Percentage expression of CD3+ y/S+ T lymphocytes also CD4+ 
y/8+ within the gated TIL population of 13 breast cancer patients
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Figure 3.5b Percentage expression of CD3+ y/5+ T lymphocytes also CD4+ 
y/S+ within the gated PBL population of 11 breast cancer patients
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Figure 3.5c Percentage expression of CD3+ y/8+ T lymphocytes also CD4+ 
y/8+ within the gated LNL population of 11 breast cancer patients
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3.3 Discussion
y/5 T lymphocytes represent a small subset found in both normal 
patients and in some disease states. However little work has been reported on 
cancer and the phenotype of lymphocytes within cancer patients.
Localisation of y/8  T cells in specific areas of the mouse such as the 
epithelia and mucosa has been reported depending on the Vy usage. The 
exposed nature of these tissues would suggest regular direct interfacing with 
external antigens. However in humans this preferential homing of Vy subsets 
is not seen with human y/8  T cells possibly having a different function. Recent 
studies have shown that y/8  T cells respond to heat shock proteins and also 
bacterial antigens which may suggest that there is a potential cytolytic role 
against both stressed and transformed cells, y/8  T cells in the TIL, PBL and 
LNL of breast cancer patients show no relation to the disease state and tumour 
dissemination. The level of expression in PBL is similar to levels reported for 
healthy individuals (Itohara et al 1990), however the expression of y/8  T cell 
receptor within the node and the tumour was shown to be elevated.
Within the TIL population the CD8 marker was consistently expressed 
on a substantial proportion of CD3+ y/8  cells (median 45.7%). Breast cancer 
TILs have been reported to be predominandy CD8+ (Whitford et al 1991) with 
the infiltrate highly activated as represented by the expression of HLA DR and 
the IL-2R when compared with the PBL (Whitford et al 1991). Cytotoxicity of 
y/8  TIL has been reported and in addition TIL T cell lines grown in IL-2 have 
been reported in certain lung tumours to have cytotoxicity for autologous 
tumour. However this is based on a small number of patients and so far no 
other isolated y/8  T cell line from TILs has shown this specific cytotoxicity 
(Zocchi et al 1990). Other specific y/8  T cell subsets have been shown to be
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cytotoxic for a number of cancer cell lines dependent on specific Vy usage. 
High expression of the y/5 T cell receptor on cytotoxic T cells within the 
tumour suggests that the marker may have relevance in the possible cytolytic 
function of these cells.
The LNL population contained a larger proportion of CD4 cells 
expressing the y/8  T cell receptor (median 18.0%).The expression within the 
tumour and the blood was confined to a much smaller population. The LNL 
which are found within the nodes of breast cancer patients have been reported 
to be predominantly of the CD4 phenotype (Whitford et al 1992) and to be 
highly activated compared to peripheral blood. If CD4 y/8  T cells perform a 
similar function to the oc/p T cells, the increase in expression of the CD4 y/8  
subset in the nodes may suggest that these may be also involved in the nodal 
immune response against the tumour.
The phenotypic analysis of the y/8  T cells from the three lymphoid 
tissues presents one particularly interesting feature. In agreement with previous 
reports, the majority of the y/8  T cells in both PBL and LNL were double 
negative. (CD4- CD8 -). The double negative cells would represent 
lymphocytes not utilising MHC recognition but rather recognition mediated by 
another method, involving possibly undiscovered antigen presentation 
molecules. The large percentage of these cells may suggest that they have a 
crucial role within specific areas of the body.
The changes observed within the y/8  T cell CD4+ and CD8 + subsets 
and more interestingly the presence of the double negative cells also reported 
by other groups would indicate that lymphocytes have an altered y/8  phenotype 
within breast cancer patients. The further understanding of the so far 
ambiguous functional role of the y/8  TCR in cancer and other disease states
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may answer the question of its role in immunosurveillance and the immune 
response.
CHAPTER 4
THE EFFECT OF 
METASTATIC TUMOUR ON 
THE IMMUNE RESPONSE 
WITHIN THE TUMOUR 
DRAINING LYMPH NODES
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4. The effect of metastatic tumour on the immune 
response within the tumour draining axillary lymph 
nodes
The immune response between two patients is extremely variable as 
noted in the study of Whitford et al (1992b), and it would be useful to reduce 
this interpatient variability to a minimum. As the tumour draining nodes have 
been shown to be eliciting an immune response against the tumour (Whitford et 
al 1992b), two lymph nodes were taken from the same patient. These lymph 
nodes are a site where the metastatic tumour can interact with the immune 
response and in consequence of this, activation and phenotype of lymphocytes 
within these nodes may be altered. Thus a comparison can be made within the 
axillary lymph nodes from the same patient, to show the changes occurring 
with tumour invasion in one node by comparing this with an uninvaded node, 
thus removing the considerable interpatient variability. Data in this chapter 
report such a study.
2 2  patients were entered in the study and from each a heavily tumour 
invaded lymph node and a tumour free lymph node were removed. Distance 
from the tumour was not assessed The methodology of staining and gating is 
described in Section 2.2.6.1 and Section 2.2.6.2
4.1. Phenotypic markers
4.1.1. T and B lymphocytes
Little change was noted in the mean percentage values of T and B 
lymphocytes between invaded and uninvaded lymph nodes (Table 4.1). The
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Table 4.1.
Distribution of phenotypic markers on lymphocytes from tumour invaded and 
tumour free lymph nodes of 22 stage II breast cancer patients.
Phenotypic
marker
STAGE D
Tumour
invaded
Tumour
free
Statistical
significance+
CD3 (%T cells) 44.8+7-3.9 43.8+/-3.9 p= 0.160
CD19 (% B cells) 42.9+/-4.5 45.8+/-3.6 p= 0 .1 2 0
CD8
(%CD8+T cells)
16.7+/-2.2
(12.7+/-10.6)*
9.1+/- 0.9 
(8.0+/-3.9)*
p<0 .0 0 1
CD4
(%CD4+T cells)
29.8+/-2.6 36.7+/-3.3 p= 0.008
CD4/CD8
RATIO
2.6+/-0.4 4.8+/-0.6 p< 0.001
Values represent mean % +/- standard deviation of lymphocytes expressing 
the phenotypic marker.
* values in bracket represents median +/- standard deviation (SD). Median 
values and SD are cited for cases where a distribution appeared to be skewed 
(marked with asterisk).
+Statistical test used: Wilcoxon signed rank, when comparing tumour invaded 
nodes from the same patient to tumour free nodes. Statistical significance is 
taken at a p value equal to or < 0.05. N.S. is not significant.
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Figure 4.1 CD 19+ B cell population within tumour free (un) and tumour
invaded (inv) lymph nodes from the same stage II breast cancer patients.
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proportion of CD 19+ B cells in tumour invaded lymph nodes (42.9%) was 
only slighdy lower than that in tumour free lymph nodes (45.8%) (Figure 4.1).
Proportions of CD3+ T cells in tumour invaded nodes (44.8%) were 
also very similar to tumour free nodes (43.8%) and a large variability was 
noted for the total numbers of T cells present (Figure 4.2).
4.1.2. T cell subsets
Although the overall proportion of T cells remains relatively constant 
between invaded and uninvaded nodes, analysis of the T cell subsets shows 
some significant changes. The mean percentage of CD8+ cytotoxic T cells in 
tumour invaded nodes (16.7%) was higher than the CD8 + population within 
the tumour free nodes (9.1%) (Table 4.1), the difference being highly 
significant. However the distribution of these cells was skewed (median 
12.7%) with only six patients having greater than 20% CD8+ T cells (Figures 
4.3 and 4.5). Within the remaining population the proportion of CD8+ T cells 
was confined to a much smaller range (Figures 4.3 and 4.5)
The CD4+ T helper cells on the other hand showed a decrease in the 
invaded nodes (29.8%) in comparison with tumour free stage II nodes 
(36.7%). This change was also shown to be statistically significant, the range 
of expression being wide in both subsets.(Figures 4.4 and 4.6)
4.1.3. CD4/CD8 ratio
The CD4/CD8 ratio agreed with the findings observed with a depressed 
ratio in the tumour invaded lymph nodes compared to the tumour free. Figures 
4.7 and 4.8 illustrate the extensive patient variability, with some patients
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Figure 4.2 CD3+ T cell population within tumour free (un) and tumour
invaded (inv) lymph nodes from the same stage II breast cancer patients.
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Figure 4.3 CD8+ T cell population within tumour free (UN) and tumour
invaded (INV) lymph nodes from the same stage n  breast cancer patients.
127
100  -
■  CD4/INV 
□  CD4/UN80 -
<Z)
1 2 3 4 5 6 7 8 9  10 1 1 1 2  13 14 15 16 17 18 19 2 0 2 1 2 2
Patient number
Figure 4.4 CD4+ T cell population within tumour free (UN) and tumour
invaded (INV) lymph nodes from the same stage n  breast cancer patients.
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Figure 4.5 Distribution of CD8+ T lymphocytes in tumour invaded (1) and
tumour free lymph nodes (2) from breast cancer patients.
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Figure 4.6 Distribution of CD4+ T lymphocytes in tumour invaded (1) and
tumour free lymph nodes (2) from breast cancer patients.
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Figure 4.7 CD4/CD8 ratio within tumour free (UN) and tumour invaded 
lymph nodes from the same stage II breast cancer patients.
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Figure 4.8 CD4/CD8 ratio of invaded and uninvaded lymph nodes 
showed as matched pairs for each patient.
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showing both a depression of the proportion of CD4+ cells and an increase in 
CD8 + T cells. In some patients a change was only noted within one of the T 
cell subsets with the depression of the CD4+T cell population occuring in the 
majority of cases. Figures 4.5 and 4.6 illustrate the individual changes within 
the CD8 and CD4 populations.
The ratios for the invaded node were within a more restricted range, 
between 0.8 and 5.42 whereas a much larger range was noted between 
uninvaded nodes from 0.4 to 9.16. The degree of change between individual 
patients is shown in Figures 4.7 and 4.8. Figure 4.9 illustrates the trend of a 
depression of the CD4/8 ratio within the invaded node.
4.2. Activation markers
The expression of the activation markers HLA DR and IL-2R (Tac 
antigen) on T cells and slgG on B cells are summarised in Table 4.2. These are 
surface activation markers which undergo upregulation upon antigen 
stimulation. Lymphocytes were gated based on size characteristics as described 
in Section 2.2.6.2.
4.2.1. HLA DR expression
HLA DR expression overall was higher in the CD8+ T cells (Table 4.2). 
When invaded nodes are compared with uninvaded nodes there is a significant 
trend towards increased HLA DR expression on CD8+ T cells and also CD4+
T cells, within the invaded lymph nodes (Figures 4.10 and 4.11). There is a 
wide range of expression of HLA DR on both T cell subsets within both the 
invaded and uninvaded lymph nodes (Figures 4.10 and 4.11).
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Table 4.2.
Distribution of activation markers on lymphocytes from tumour invaded and 
tumour free lymph nodes in 2 2  stage n  breast cancer patients.
Activation
Marker
STAGE II
Tumour
invaded
Tumour
free
Statistical
relevance
HLA DR on 
CD8+T  cells 50.6+/-4.1 47.2+/-3.5 p=0.023
HLA DR on 
CD4+T cells 38.2+/-4.0 31.0+/-3.7 p=0.036
IL2R(Tac) on 
CD8+T  cells 17.1+/-2.5
(15.7+/-12.0)*
12.9+/-2.1
(9.8+/-9.5)*
p=0.029
IL2R (Tac) on 
CD4+T cells 2 1 .2 +/-2 .8 22.5+/-2.4 p=0.075
slgG on 
B cells 37.6+/-4.6
(33.0+/-22.3)*
30.0+/-3.4 
(30.9+/-15.8)*
p=0.065
Values represent mean % +/- standard deviation of lymphocytes expressing 
the phenotypic marker.
* values in bracket represents median +/- standard deviation (SD). Median 
values and SD are cited for cases where a distribution appeared to be skewed 
(marked with asterisk).
+ Statistical test used: Wilcoxon signed rank, when comparing tumour invaded 
nodes from the same patient to tumour free nodes. Statistical significance is 
taken at a p value equal to or < 0.05. N.S is not significant.
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Figure 4.9 Representative flow cytometry diagram of (a) invaded and (b) 
uninvaded lymph nodes from the same patient using FITC labelled anti-CD4 
(FL-2) and PE labelled anti-CD8 (FL-2).
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Figure 4.10 Percentage of CD8+ T cells which also expressing HLA DR in
tumour free (UN) and invaded (INV) nodes from the same stage II breast
cancer patients.
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Figure 4.11 Percentage of CD4+ T cells which also expressing HLA DR in
tumour free (UN) and invaded (INV) nodes from the same stage II breast
cancer patients.
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4.2.2. IL-2R (Tac) expression
The expression of the Tac component of the IL-2 receptor was shown to 
be generally higher on the CD4+ T cells than on the CD8+ T cells (Table 4.2). 
The mean percentage of IL-2R expressing CD8+ T cells in stage II invaded 
nodes (17.1%) was significantly higher when compared to the paired 
uninvaded lymph node (12.9%) whereas the expression of IL-2R on CD4+ T 
cells showed little change between invaded (2 1 .2 %) and uninvaded lymph 
nodes (22.5%) (Table 4.2).
The patient variability within both groups of T cells was high, with 
some cases of higher percentages in invaded nodes and in others the reverse. 
(Figure 4.12 and 4.13)
4.2.3. Surface IgG
The percentage of slgG expressing B cells was higher in tumour 
invaded nodes (37.6%), compared to tumour free nodes (30.0%). This 
however failed to make statistical significance (Table 4.2).
The range of expression was variable and skewed. In a few patients a 
noticable feature was the major increase in expression in tumour invaded nodes 
(Figure 4.14).
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Figure 4.12 Percentage of CD8+ T cells also expressing the IL-2R(Tac) in
tumour free (UN) and tumour invaded (INV) nodes from the same stage II
breast cancer patients.
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Figure 4.13 Percentage of CD4+ T cells also expressing the IL-2R(Tac) in
tumour free (UN) and tumour invaded (INV) nodes from the same stage II
breast cancer patients.
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Figure 4.14 Percent of B cells (CD 19+) also expressing surface IgG in
tumour free (UN) and tumour invaded (INV) nodes from the same stage II
breast cancer patients.
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4.3. Discussion
The primary function of the axillary lymph nodes is to scavenge for 
antigen in the lymph fluid that drains from the breast tissues. Here they are 
ideally situated to encounter both metastatic tumour and tumour breakdown 
products possibly leading to a host mediated immune response. The metastatic 
tumour within these nodes may, however, have an adverse effect on the 
lymphocyte populations. An analysis of phenotype and activation state of nodal 
lymphocytes may reflect the response within the nodes and the eventual 
outcome of the tumour host interactions taking place.
Two previous studies have analysed lymph node lymphocytes from 
breast cancer patients by flow cytometry (Morton et al 1986; Whitford et al 
1992). However although nodes from both stage I and stage II patients were 
analysed in these studies, nodes largely free of tumour were preferred and 
significantly invaded nodes were omitted. In this study phenotypic and 
activation markers on lymphocytes from matched pairs of tumour free and 
tumour invaded nodes taken from the same stage n  patients were analysed for 
22 patients. Thus inter-patient variability which is considerable (Morton et al 
1986; Whitford et al 1992) is removed and only intra patient variation between 
the two types of nodes has been analysed.
Results obtained show that in breast cancer patients there are differences 
in phenotype and activation between nodes that are invaded and those that are 
not.
The most significant difference between tumour free and invaded nodes 
was the change observed within the CD4/ CD8 ratio. In invaded nodes this 
ratio was reduced in comparison to the tumour free nodes. The reduction in
1 4 2
CD4/CD8 ratio was due to an increase in the percentage of CD8+ T cells and a 
decrease in the CD4+ population. Within the invaded node the CD4+ T cells 
showed a greater decrease but also showed more variation. Similar alterations 
in the CD4+ and CD8+ populations have been reported within stage II breast 
cancer patients (Morton et al 1986) and melanoma patients (Farzad et al 1990).
The changes are most clearly illustrated in Figure 4.8. The majority of 
the patients show a decreased CD4/CD8 ratio within the invaded nodes but 
there are a small number of patients who do not show a trend.
The increased numbers of CD8+ T cells within the invaded node is of 
interest as tumour infiltrates mainly comprise CD8+ cells (Whitford et al 
1991), and the increase of these cells in invaded nodes is perhaps suggestive in 
both cases of activated cytotoxic cells within close proximity to their target 
cells.
Expression of the activation marker HLA DR has been reported to be 
related to stage of the tumour in breast cancer patients. Morton et al (1986) 
reported higher proportions of HLA DR expressing CD4+ and CD8+ T cells in 
stage II patients. Within these stage II patients the change in phenotype was 
measured between invaded and uninvaded lymph nodes. The expression of 
HLA DR on CD8+ T cells was shown to be greater in invaded nodes rather 
than tumour free nodes with this change showing significance. The expression 
of the IL-2R (Tac) on CD8+ T cells showed on average an increase within the 
invaded nodes this also being a significant difference. The large percentage of 
CD8+ activated T cells within tumour invaded nodes would suggest that these 
lymphocytes are responding locally to the tumour, possibly in a similar way to 
CD8+ T cells found within a primary breast tumour. The proportion of CD4+ 
HLA DR cells was found to be raised in the invaded nodes with this reaching
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significance. However the expression of the IL-2R (Tac) failed to reach 
significance.
In general the percentage of HLA DR positive T cells was higher in 
invaded nodes than in tumour free nodes. However the changes noted for the 
IL-2R must be treated with caution, as although an increased expression of the 
receptor indicates T cell activation, the lack of the receptor does not necessarily 
suggest an inactive state, as following activation the receptor undergoes down 
regulation (Duprez etal 1988).
The proportion of mature B cells expressing IgG although found to be 
raised in a number of patients, failed to reach statistical significance, between 
the two types of nodes. Thus the antibody arm of the immune response is 
erratic.
The results together indicate that the presence of metastatic tumour 
within a lymph node can cause specific alterations in both phenotype and 
activation status of T cells, while only affecting the B cell component in a few 
individuals. The differences observed in terms of phenotype can be correlated 
with respect to the activation status as in general it appears that a larger CD8+ T 
cell population and a smaller CD4+ population are present in the invaded 
nodes. Thus while certain T cell populations are being activated others appear 
not to be proliferating or are actively being suppressed by the tumour. The 
alterations which are observed here may have an important role to play in the 
metastatic process.
CHAPTER 5
INVESTIGATIONS ON THE 
EXTENT TO WHICH THE 
NODAL RESPONSE IS LOCAL
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5. Investigations on the extent to which the nodal 
response is local
The data in Chapter 4 suggest that the majority of breast cancers elicit a 
measurable and statistically significant immune response in both phenotype and 
activation status of the lymphocytes. This Chapter investigates the extent to 
which such a response is local to the tumour area. The aim of this chapter was 
to investigate whether various therapeutic regimes such as sampling of the low 
nodes, removal of the entire axilla, or local radiotherapy of the axilla remove 
the immune response and also to indicate whether these tissues, rather than 
blood, should be the focus for attempts to immortalise T or B cells for 
subsequent immunotherapeutic strategies. The low draining axillary nodes are 
as close as 5cm to the tumour. The higher ones are often 15* 20cm away (Fig 
1. 1 ). In this study, the degree of response in nodes close to the tumour as 
opposed to nodes distal from the tumour was analysed. The study included 44 
patients, 22 stage I and 22 stage II patients. The 22 stage II patients were 
selected during the operation to remove the primary tumour and axilla and 
further subdivided thereafter by pathological grading and by the flow 
cytometric analysis itself into the following groups.
A. Low node invaded and high node tumour free (n=8)
These patients are similar to those in Chapter 4. The difference is that, in the 
operating theatre, the nodes were removed on the basis of distance from 
tumour rather than invasion. On average, therefore, invasion was less 
advanced.
B. Low node invaded and high node invaded (n=7)
C. Low node tumour free and high node tumour free (n=5)
Several nodes were obtained from these patients. The particular pair analysed 
contained no tumour cells by either pathological or FACS analysis. However,
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other nodes, not used in the current study, were found by the pathologist to be 
invaded.
D. Low node tumour free and high node invaded ("skips") (n=2)
5.1 Phenotypic markers 
5.1.1. Stage I paired lymph nodes (n=22)
5.1.1.1. T and B lymphocytes
The results from stage I patients are illustrated in Table 5.1. The mean 
level of CD3+ T cells was significantly higher in the low node (47.0%) than 
the high node (41.4%) (p=0.042) the individual values being shown in Figure
5.1. The mean level of CD 19+ B cells show the opposite trend with the low 
node containing significantly lower (36.4%) than the high node (43.5%) 
p=0.036 the individual values being shown in Figure 5.2. This change is 
illustrated in the CD3/CD19 ratio in the low node (2.0) being significantly 
higher than the high node (1.2) p=0.036 the individual values being shown in 
Figure 5.3. The data are however biased by one patient with an abnormally 
high ratio in the low node
5.1.1.2. T cell subsets
Analysis of T cell subsets showed no significant trends within the stage 
I patients (Table 5.1) although the mean level of CD8+ T cells is on average 
higher in the low node (14.5%) than the high node (10.3%), whereas the mean 
level of CD4+ T cells shows no change between the low (40.8%) and high 
node (39.2%).
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Table 5.1
Distribution of phenotypic markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 22 stage I patients.
Phenotypic
marker
Stage I
Low node 
(n=2 2 )
High node 
(n=2 2 )
Statistical
significance+
CD3 (%T cells) 47.0+/-3.5 41.4+/-3.2 p=0.042
CD19 (% B cells) 36.4+/-4.5 43.5+/-4.1 p=0.036
CD8
(CD8+T cells)
14.5+/-3.3 10.3+/-1.4 p=0.080
CD4
(CD4+T cells)
40.8+/-3.5 39.2+/-3.6 p=0.076
CD3/CD19 ratio 2 .0 +/-1.0 1.2+/-0.3 p=0.036
CD4/CD8 ratio 5.5+/-0.8 7.6+/-2.0 p=0.090
Values represent mean % +/- standard error of lymphocytes expressing the 
phenotypic marker.
+Statistical test used: Wilcoxon signed rank, when comparing two lymph 
nodes from the same patient. Statistical significance is taken at a p value equal 
to or < 0.05. Only significant p values are given. N.S. is not significant.
147
Figure 5.1 The change in the percentage of CD3+ T cells between the low
(1) and high (2) axilla of the total 22 stage I patients.
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Figure 5.2 The change in the percentage of CD 19+ B cells between the
low (1) and high (2) axilla of the total 22 stage I patients.
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Figure 5.3 The change in CD3+ T cell/ CD 19+ B cell ratio in the low (1)
and high (2) axillary nodes of the total 22 stage I patients.
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5.1.2. Stage II paired lymph nodes (n=22)
5.1.2.1. T and B lymphocytes
There were no significant trends observed for changes in phenotype in 
stage II patients nodes (Table 5.2). However differences were noted. The 
mean level of CD3+ T cells was increased in the low node (47.0%) compared 
to the high node (43.0%). The mean level of CD19+ B cells was decreased in 
the low node (36.6%) to rise in the high node (43.0%). This was similar to 
what was observed in the stage I patients.
5.1.2.2. T cell subsets
No significant trends were observed for stage II patients (Table 5.2). 
However a slight increase was noted in the mean level of CD8+ T cells in the 
low node (13.0%) with respect to the high node (11.0%). This increase in the 
low node was also illustrated in the mean level of the CD4+ T cell subset 
within the low node (36.0%) compared to the high node (33.0%).
5.1.3. Stage II subset A: Low node tumour invaded, 
high node tumour free (n=8).
5.1.3.1. T and B lymphocytes
As with the total stage II patients a rise in the proportion of CD3+ T 
cells was observed in the low tumour invaded node (46.7%) compared to the
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Table 5.2
Distribution of phenotypic markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 22 stage II patients.
Phenotypic
marker
Stage II
Low node 
(n=2 2 )
High node 
(n=2 2 )
Statistical
Significance+
CD3 (%T cells) 47.0+/-4.1 43.0+/-3.2 p=0.121
CD19 (% B cells) 36.6+/-4.0 43.0+/-3.6 p=0.113
CD8
(CD8+T cells)
13.0+/-1.7 11.0+/-1.3 p=0.098
CD4
(CD4+T cells)
36.0+/-2.8 33.0+/-2.3 p=0.087
CD3/CD19 ratio 2.3+/-0.7 2.3+/-1.1 p=0.097
CD4/CD8 ratio 3.2+/-0.4 3.1+/-0.3 p=0.080
Values represent mean % +/- standard error of lymphocytes expressing the 
phenotypic marker.
+Statistical test used: Wilcoxon signed rank, when comparing two lymph 
nodes from the same patient. Statistical significance is taken at a p value equal 
to or < 0.05.
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high tumour free node (32.5%) although this was not statistically significant 
(Table 5.3). Within the CD 19+ B cell population there was a rise on the high 
tumour free node (54.8%) compared to the low tumour invaded node (40.8%). 
The CD3/CD19 ratio reflects this change (Table 5.3).
5.1.3.2. T cell subsets
Within the low tumour invaded node an increase (17.5%) was noted in 
the mean number of CD8+ T cells compared to the high node (8 .8%) although 
this was not statistically significant (Table 5.3). An increase was observed in 
the mean number of CD4+ T cells in the high tumour free node (35.7%) 
compared to the low tumour invaded node (28.4%) this change again not being 
statistically relevant (Table 5.3). However when the change in ratio of 
CD4/CD8 was considered the trend became significant p=0.05 (Table 5.3, 
Figure 5.4). This was in agreement with the results of chapter 4.
5.1.4. Stage II subset B: Low node tumour invaded, 
high node tumour invaded (n=7).
5 .1.4.1. T and B lymphocytes
There were no significant trends noted (Table 5.4) although a small 
decrease was noted in the mean number of CD3+ T cells in the high tumour 
invaded node (48.2%) compared to the low tumour invaded node (46.4%). 
Concurrently an increase in the mean CD 19+ population was noted in the high 
tumour invaded node (36.8%) compared to the low tumour invaded node 
(28.9%). These changes are illustrated in the CD3/CD19 ratio.
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Table 5.3
Distribution of phenotypic markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 8 stage II patients with the low lymph node tumour invaded and 
the high node tumour free (subset A).
Phenotypic
marker
Stage II
Low node 
Tumour invaded 
(n=8)
High node 
Tumour free 
(n=8)
Statistical
Significance+
CD3 (%T cells) 46.7+/-7.8 32.5+A4.3 p=0.072
CD19 (% B cells) 40.8+/-6.8 54.8+/-4.9 p=0.068
CD8
(CD8+T cells)
17.5+/-4.6 8.8+/-1.4 p=0.091
CD4
(CD4+ T cells)
28.4+/-3.7 35.7+/-3.0 p=0.67
CD3/CD19 ratio 2.5+/-1.6 3.1+/-2.4 p=0 .1 2 0
CD4/CD8 ratio 2.2+/-0.4 4.4+/-0.6 p=0.05
Values represent mean % +/- standard error of lymphocytes expressing the 
phenotypic marker.
+Statistical test used: Student T test as the number of paired lymph nodes has 
decreased due to division into stage II subsets. Statistical significance is taken 
at a p value equal to or < 0.05.
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Figure 5.4 The change in CD4+ T cell/ CD8+ T cell ratio in the low (1) 
and high (2) tumour free nodes of 8 stage II patients.
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Table 5.4
Distribution of phenotypic markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla(> 10cm from the 
tumour) of 7 stage n  patients with the low lymph node tumour invaded and the 
high node tumour invaded (subset B).
Phenotypic
marker
Stage II
Low node High node 
Tumour invaded Tumour invaded 
(n=7) (n=7)
Statistical
Significance+
CD3 (%T cells) 48.2+/-7.9 46.4+/-2.4 p=0.088
CD19 (% B cells) 28.9+/-6.4 36.8+/-1.9 p=0.078
CD8
(CD8+T cells)
10.2+/-1.9 1 0 .2 +/-1.8 p=0.116
CD4
(CD4+T cells)
39.4+/-5.4 38.9+/-2.3 p=0.130
CD3/CD19 ratio 2 .8 +/-0 .8 1.2 +/-0.1 p=0.089
CD4/CD8 ratio 3.4+/-0.6 3.2+/-0.6 p=0.111
Values represent mean % +/- standard error of lymphocytes expressing the 
phenotypic marker.
+Statistical test used: Student T test as the number of paired lymph nodes has 
decreased due to division into stage II subsets. Statistical significance is taken 
at a p value equal to or < 0.05.
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5.I.4.2. T cell subsets
There were no significant trends within the T cell population (Table 5.4) 
with little change noted in the mean values of both CD8 and CD4 lymphocytes 
in the low and high tumour invaded nodes.
5.1.5. Stage II subset C: Low node tumour free, high 
node tumour free (n=5).
5.1.5.1. T and B lymphocytes
No statistically relevant trends were observed within this stage II 
subsets although some trends were noted (Table 5.5). As with the total stage II 
mean values an increase was observed in the mean CD3+ T cell population in 
the low tumour free node (45.0%) when compared to the high tumour free 
node (37.5%). An increase in the mean number of CD19+ B cells was also 
found in the high tumour free node (55.5%) compared to the low tumour free 
node (45.0%). These changes were also reflected in the CD3/CD19 ratio.
5.1.5.2. T cell subsets
There were no significant trends noted within the T cell subsets (Table
5.5). However an increase was found in the mean percentage of CD8+ T cells 
in the high tumour free node (18.9%) compared to the low tumour free node 
(12.4%). The CD4+ T cells showed the opposite trend with the numbers 
increasing in the low tumour free node (39.7%) compared with the high 
tumour free node (24.0%). This was confirmed in the CD4/CD8 ratio.
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Table 5.5
Distribution of phenotypic markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla(> 10cm from the 
tumour) of 5 stage II patients with the low lymph node tumour free and the 
high node also tumour free (subset C).
Phenotypic
marker
Stage II
Low node 
Tumour free 
(n=5)
High node 
Tumour free 
(n=5)
Statistical
Significance+
CD3 (%T cells) 45.0+/-1.8 37.5+/-14.5 p=0.056
CD19 (% B cells) 45.0+/-1.8 55.5+/-9.0 p=0.067
CD8
(CD8+T cells)
12.4+/-1.9 18.9+/-7.4 p=0.062
CD4
(CD4+T cells)
39.7+/-6.2 24.0+/-3.9 p=0.071
CD3/CD19 ratio 6.3+/-5.9 2.1+/-3.2 p=0.059
CD4/CD8 ratio 5.7+/-2.4 2 .0 +/-1.0 p=0.078
Values represent mean % +/- standard error of lymphocytes expressing the 
phenotypic marker.
+Statistical test used: Student T test as the number of paired lymph nodes has 
decreased due to division into stage II subsets. Statistical significance is taken 
at a p value equal to or < 0.05.
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5.1.6. Stage II subset D: Low node tumour free, high 
node tumour invaded (n=2).
Due to the small sample size of n=2 no statistics were attempted on this 
stage II subset and any trends which were observed must be treated with 
caution.
5.1.6.1. T and B lymphocytes
Within the CD3+ T cell population there was a slight decrease in mean 
numbers from the low tumour free (57.6%) to the high tumour invaded node 
(54.3%) (Table 5.6). A rise in the mean number of CD19+ B cells was noted 
in the high node tumour invaded (23.7%) compared to the low tumour free 
node (20.2%) (Table 5.6).
5.1.6.2. T cell subsets
A slight rise was noted in the mean numbers of CD8+ T cells from the 
low tumour free node (8 .6%) to the high tumour invaded node (10.5%) (Table
5.6). There was a decrease in the numbers of CD4+T cells from the low 
tumour free node (52.7%) to the high tumour invaded node (47.9%) with these 
changes being reflected in the CD4/CD8 ratio (Table 5.6).
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Table 5.6
Distribution of phenotypic markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 2 stage II patients with the low lymph node tumour free and the 
high node tumour invaded (subset D).
Phenotypic Stage II Statistical
marker Low node High node Significance*
Tumour free Tumour invaded
(n=2 ) (n=2 )
CD3 (%T cells) 57.6+A6.9 54.3+/-3.7
CD19 (% B cells) 2 0 .2 +/-0 .6 23.7+/-9.7
CD8
(CD8+T  cells)
8.6+/-0.3 10.5+/-0.5
CD4
(CD4+T cells)
52.7+/-10.0 47.9+/-5.8
CD3/CD19 ratio 3.2+/-0.1 2.8+/-1.3
CD4/CD8 ratio 6 .8 +/-0 .8 4.6+/-0.8
Values represent mean % +/- standard error of lymphocytes expressing the 
phenotypic marker.
* Due to their being only 2 members of this stage II subset no statistics were 
performed.
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5.2. Activation markers
5.2.1. Stage I paired lymph nodes n=22
Table 5.7 summarises the expression of the activation markers HLA DR 
and IL-2 receptor (Tac) on T cells and slgG on B cells. In all cases, average 
levels were higher on the low node than the high node but the statistical 
difference of this is low
5.2.1.1. HLA DR
No significant trends in HLA DR expression were noted although 
differences were noted. HLA DR expression on CD8+ T cells tended to be 
greater in the low node (41.2%) than the high node (36.8%) (Table 5.7). A 
similar trend was observed for the expression of HLA DR on CD4+ T cells 
with a increased expression in the low node (28.8%) over the high node 
(23.1%) (Table 5.7).
5.2.1.2. Interleukin-2 receptor (Tac)
No significant trends were observed for the IL-2R. However some 
differences were noted (Table 5.7). The mean expression of the IL-2R on 
CD8+ T lymphocytes was higher in the low node (16.8%) compared to the 
high node (14.5%). The same was noted for the CD4+ T cells with the mean 
IL-2R expression higher in the low node (26.0%) than the high node (23.0%).
161
Table 5.7
Distribution of activation markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 22 stage I patients (low lymph node tumour free and the high 
node tumour free).
Activation
Marker
Stage I
Low node 
(n=2 2 )
High node 
(n=2 2 )
Statistical
Significance+
HLA DR on 
CD 8+ T cells 41.2+/-4.6 36.8+/-4.1 p=0.088
HLA DR on 
CD4+ T cells 28.8+/-4.4 23.1+/-3.2 p=0.057
Interleukin-2 
receptor (Tac) 
on CD8+ T cells 16.8+/-4.2 14.5+/-2.9 p=0.071
Interleukin-2 
receptor (Tac) 
on CD4+ T cells 26.0+/-3.8 23.0+/-3.2 p=0.099
slgG on CD 19+ 
B cells 24.9+/-2.4 25.2+7-2.9 p=0.101
Values represent mean % +/- standard error of lymphocytes expressing the 
activation marker.
+Statistical test used: Wilcoxon signed rank, when comparing two lymph 
nodes from the same patient. Statistical significance is taken at a p value equal 
to or < 0.05.
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5.2.I.3. Surface Immunoglobulin G (slgG)
No significant trends were noted and no difference was observed 
between the CD 19+ slgG mean expression in the low (24.9%) and high nodes 
(25.2%) (Table 5.7).
5.2.2. Stage II paired lymph nodes n=22
Table 5.8 summarises the expression of HLA DR and IL-2R on T cells 
and slgG on B cells. As with stage I, the average levels of all markers were 
higher on the low node nearest to the tumour
5.2.2.1. HLA DR
The mean expression of HLA DR on CD8+ T cells was found to be 
greater in the low node (46.0%) compared with the high node (42.9%) 
although this failed to reach statistical significance (Table 5.8). The mean 
expression of HLA DR on CD4+T cells was higher in the low nodes (31.2%) 
than the high node (25.0%) reaching statistical significance p=0.01 (Table 5.8, 
Figure 5.5). The mean expression of HLA DR, generally was found to be 
lower on the CD4+ T cells expressing this activation marker.
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Table 5.8
Distribution of activation markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 22 stage II patients.
Activation
Marker
Stage II
Low node 
(n=22)
High node 
(n=22)
Statistical
Significance+
HLA DR on 
CD8+ T cells 46.0+/-4.8 42.9+/-4.5 p=0.060
HLA DR on 
CD4+T cells 31.2+/-0.1 25.0+/-3.9 p=0.01
Interleukin-2 
receptor (Tac) 
on CD8+ T cells 16.0+/-3.3 12.6+/-2.3 p=0.05
Interleukin-2 
receptor (Tac) 
on CD4+ T cells 20.7+/-2.5 16.3+/-2.2 p < 0.001
slgG on CD 19+ 
B cells 30.0+/-4.8 22.9+/-3.7 p=0.073
Values represent mean % +/- standard error of lymphocytes expressing the 
activation marker.
+Statistical test used: Wilcoxon signed rank, when comparing two lymph 
nodes from the same patient. Statistical significance is taken at a p value equal 
to or < 0.05.
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Figure 5.5 The change in CD4+ T cell HLA DR+ population between the
low (1) and high (2) nodes of the total 22 stage II patients.
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5.2.2.2. Interleukin-2 receptor
The proportion of CD8+ T cells expressing the IL-2R was found to be 
higher in the low node (16.0%) than the high node (12.6%) with this trend 
being statistically relevant at p=0.01 (Table 5.8, Figure 5.6). A similar trend is 
noted with the CD4+ T cells expressing the IL-2R in the low node (20.7%) 
greater than the high node (16.3%) with statistical significance at p < 0.001 
(Table 5.8, Figure 5.7). The expression of the IL-2R was found to be 
generally higher on the CD4+ T cells.
5.2.2.3. Surface Immunoglobulin G
The mean level of expression of IgG on CD 19+ B cells was observed to 
be higher in the low node (30.0%) than the high node (22.9%). However this 
trend was not statistically relevant (Table 5.8).
5.2.3. Stage II subset A: Low node tumour invaded, 
high node tumour free (n=8).
In this subset, as with stage I and the pooled stage II patients the average for 
the low node was greater than the high for all parameters
1 6 6
Figure 5.6 The change in CD8+ T cell IL-2R+ population between the
low (1) and high (2) nodes of the total 22 stage II patients.
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Figure 5.7 The change in CD4+ T cell IL-2R+ population between the
low (1) and high (2) of the total 22 stage II patients.
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5.2.3.1. HLA DR
The mean expression of HLA DR on CD8+ T cells in the low tumour 
invaded node (65.1%) was found to be significantly greater than that found in 
the high tumour free node (56.8%) (p=0.05) (Table 5.9, Figure 5.8). A similar 
trend was observed for the CD4+ T cells expressing HLA DR with a higher 
mean expression in the low tumour invaded node (49.0%) than the high 
tumour free node (40.1%), this difference did not achieve statistical 
significance (Table 5.9). Here the HLA DR expression was found to be 
generally higher on the CD8+ T cell subset. The level of HLA DR on both 
CD8+ and CD4+ T cell subsets in this stage II subgroup was higher than the 
mean values in Table 5.8.
5.2.3.2. Interleukin-2 receptor
A higher mean expression of IL-2R was observed on the CD8+ T cells 
in the low tumour invaded (16.9%) rather than the high tumour free node 
(9.2%), but this failed to reach statistical significance (Table 5.9).The mean 
expression of the IL-2R on the CD4+ subset was higher on the low tumour 
invaded node (21.6%) than the high tumour free node (14.7%) with this trend 
being highly significant p=0.005 (Table 5.9, Figure 5.9).
5.2.3.3. Surface Immunoglobulin G
Higher mean expression of slgG was noted in the low tumour invaded 
(41.3%) rather than the high tumour free node (35.9%) the trend failing to
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Table 5.9
Distribution of activation markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 8 stage n  patients. With low node tumour invaded and high 
node tumour free (subset A).
Activation
Marker
Stage II
Low node 
Tumour invaded 
(n=8)
High node 
Tumour free 
(n=8)
Statistical
Significance+
HLA DR on 
CD8+ T cells 65.1+/-4.8 56.8+/-6.7 p=0.05
HLA DR on 
CD4+ T cells 49.0+/-6.4 40.1+/-7.8 p=0.089
Interleukin-2 
receptor (Tac) 
on CD8+ T cells 16.9+/-5.7 9.2+/-1.8 p=0.060
Interleukin-2 
receptor (Tac) 
on CD4+ T cells 21.6+/-4.1 14.7+/-3.0 p=0.005
slgG on CD 19+ 
B cells 41.3+/-9.9 35.9+/-8.0 p=0.055
Values represent mean % +/- standard error of lymphocytes expressing the 
activation marker.
+Statistical test used: Student T test as the number of paired lymph nodes has 
decreased due to division into stage II subsets. Statistical significance is taken 
at a p value equal to or < 0.05.
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Figure 5.8 The change in CD8+ T cell HLA DR+ population between the 
low (1) tumour invaded and high (2) tumour free nodes of 8 stage II 
patients.
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Figure 5.9 The change in CD4+ T cell IL-2R population between the low
(1) tumour invaded and high (2) tumour free nodes of 8 stage II patients.
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make statistical significance (Table 5.9). The level of expression in the nodes 
was found to be higher than the mean value obtained for stage II patients 
(Table 5.8).
5.2.4. Stage II subset B: Low node tumour invaded, 
high node tumour invaded (n=7).
The expression of activation markers is illustrated for this stage II subset 
in Table 5.10. No statistically significant trends were evident although some 
differences were noted. As with stage I patients and the pooled group of stage 
2 patients, the average percentages in the low node were greater than those of 
the high node.
5.2.4.1. HLA DR
There was no difference in the mean expression of HLA DR on CD8+ T 
cells in the low tumour invaded (33.0%) and high tumour invaded nodes 
(32.0%). The level of expression was lower in this subset than the mean for all 
stage II patients (Table 5.8). The expression of HLA DR on CD4+ T cells was 
slightly higher in the low tumour invaded node (20.3%) than the high tumour 
invaded node (16.6%). The values here were lower than the mean for total 
stage II patients (Table 5.8).
5.2.4.2. Interleukin-2 receptor
The mean expression of the IL-2R on CD8+ T cells was higher in the 
low tumour invaded node (19.2%) than the high tumour invaded node (15.2%) 
although not statistically relevant. The same was noted for IL-2R mean
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Table 5.10
Distribution of activation markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 7 stage II patients with both nodes tumour invaded (subset B).
Activation
Marker
Stage II
Low node High node 
Tumour invaded Tumour invaded 
(n=7) (n=7)
Statistical
Significance+
HLA DR on 
CD8+ T cells 33.0+/-6.6 32.0+/-4.9 p=0.110
HLA DR on 
CD4+ T cells 20.3+/-4.5 16.6+/-3.4 p=0.090
Interleukin-2 
receptor (Tac) 
on CD8+ T cells 19.2+/-4.2 15.2+/-3.3 p=0.067
Interleukin-2 
receptor (Tac) 
on CD4+ T cells 22.2+/-3.5 19.2+/-3.1 p=0.095
slgG on CD 19+ 
B cells 16.0+/-3.9 12.9+/-2.9 p=0.057
Values represent mean % +/- standard error of lymphocytes expressing the 
activation marker.
+Statistical test used: Student T test as the number of paired lymph nodes has 
decreased due to division into stage II subsets. Statistical significance is taken 
at a p value equal to or < 0.05.
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expression on CD4+ T cells in the low tumour invaded (22.2%) and high
tumour invaded nodes (19.2%).
5.2.4.3. Surface Immunoglobulin G
Although not statistically relevant a higher mean expression of slgG was 
noted in the low tumour invaded node (16.0%) than the high tumour invaded 
node (12.9%), the two values being lower than what is observed in the total 
mean stage II mean expression of slgG (Table 5.8).
5.2.5. Stage II subset C: Low node tumour free, high 
node tumour free (n=5).
5.2.5.1. HLA DR
There is no change in mean expression of HLA DR on CD8+ T cells in 
the low tumour free (31.0%) and high tumour free nodes (32.0%) (Table 
5.11). An increase is noted in the HLA DR CD4+ T cells in the low tumour 
free (31.0%) and high tumour free nodes (20.0%), but this is not statistically 
relevant (Table 5.11).
5.2.5.2. Interleukin-2 receptor
The mean percentage of CD8+ lymphocytes expressing the IL-2R does 
not significantly change between the low tumour free (8.7%) and the high 
tumour free nodes (10.3%) (Table 5.11) .The same is noted for the CD4+ 
lymphocytes in the low tumour free (11.8%) and high tumour free nodes 
(11.9%) expressing the IL-2R (Table 5.11). This contrasts with the greater 
levels of IL-2R found in the previous stage 2 subgroups.
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Table 5.11
Distribution of activation markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 5 stage II patients (subset C).
Activation
Marker
Stage II
Low node 
Tumour free 
(n=5)
High node 
Tumour free 
(n=5)
Statistical
Significance+
HLA DR on 
CD8+ T cells 31.0+/-9.4 32.0+/-7.7 p=0.109
HLA DR on 
CD4+ T cells 31.0+/-1.4 20.0+/-7.5 p=0.058
Interleukin-2 
receptor (Tac) 
on CD8+ T cells 8.7+/-2.9 10.3+/-3.7 p=0.103
Interleukin-2 
receptor (Tac) 
on CD4+ T cells 11.8+/-1.4 11.9+/-3.7 p=0.146
slgG on CD 19+ 
B cells 33.7+/-4.7 24.5+/-5.3 p=0.05
Values represent mean % +/- standard error of lymphocytes expressing the 
activation marker.
+Statistical test used: Student T test as the number of paired lymph nodes has 
decreased due to division into stage n  subsets. Statistical significance is taken 
at a p value equal to or < 0.05.
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S.2.5.3. Surface Immunoglobulin G
The expression of slgG was significantly higher in the low node 
(33.7%) than the high node (24.5%) (p=0.05) in this stage II subset (Table 
5.11, Figure 5.10). However, with only 5 patients, even a statistically 
significant result is very preliminary as Figure 5.10 shows one of the five 
patients displaying the opposite trend.
5.2.6. Stage II subset D: Low node tumour free, high 
node tumour invaded (n=2).
As there were only two patients in this stage II subset, no statistics were 
performed and any trends which are observed must be treated with caution 
(Table 5.12).
5.2.6.I. HLA DR
The mean expression of HLA DR on the CD8+ T cell population was 
higher in the low tumour free (27.7%) than the high tumour invaded node 
(24.5%). This trend of greater mean HLA DR expression was found for the 
CD4+ T cells in the low tumour free (15.1%) and high tumour invaded nodes 
(10.6%). The mean expression of HLA DR on both T cell subsets (Table 5.12) 
was less than the average for total stage II patients (Table 5.8).
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Figure 5.10 The change in slgG expression on CD 19+ B cells in the low 
(1) tumour free and high (2) tumour free nodes of 5 stage II nodes.
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Table 5.12
Distribution of activation markers on lymphocytes from lymph nodes taken 
from the low axilla (5cm from the tumour) and the high axilla (> 10cm from 
the tumour) of 2 stage n  patients with the low node tumour free and the high 
node tumour invaded (subset D).
Activation
Marker Low node 
Tumour free 
(n=2)
Stage II
High node 
Tumour invaded 
(n=2)
Statistical
Significance*
HLA DR on 
CD8+ T cells 27.7+/-1.8 24.5+/-1.3
HLA DR on 
CD4+T cells 15.1+/-2.9 10.6+/-1.8
Interleukin-2 
receptor (Tac) 
on CD8+ T cells 10.0+/-0.9 7.1+/-1.6
Interleukin-2 
receptor (Tac) 
on CD4+ T cells 17.5+/-2.9 8.8+/-2.1
slgG on CD 19+ 
B cells 12.3+/-9.4 9.5+/-6.8
Values represent mean % +/- standard error of lymphocytes expressing the 
activation marker.
* Due to only 2 members of this stage II subset statistics were not performed.
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5.2.6.2. Interleukin-2 receptor (Tac)
The level of mean IL-2R expression was greater for the CD8+ T cells 
within the low tumour free (10.0%) with decreasing levels found in the high 
tumour invaded node (7.1%) (Table 5.12). The same trend was observed for 
the IL-2R mean expression on
the CD4+ T cells in the low tumour free (17.5%) and high tumour invaded 
node (8.8%) (Table 5.12).
5.2.6.3. Surface Immunoglobulin G
slgG was found to be higher in the low (12.3%) node rather than the 
high (9.5%) node (Table 5.12) with values less than the total stage II means 
(Table 5.8).
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5.3. Discussion
The aim of this section was to investigate the extent to which the 
immune response was local. The overall conclusion is that the immune 
response, at least in terms of activation markers, decreases significantly in 
between nodes 5cm from the primary tumour and nodes 10cm from the 
primary tumour. Thus there is a substantive local response which will be 
removed by axillary sampling or clearance or destruction by local radiotherapy. 
In consequence, if cellular or antibody based immunotherapy is envisaged, 
such tissues should probably be stored in a manner which retains their 
suitability for this purpose immediately after the operation.
There are both significant phenotypic and activation changes occurring 
in the nodes of breast cancer patients in this study. Phenotype changes are 
observed in the overall levels of T and B cells within the nodes of stage 1 
patients. With greater levels of T cells in the low node than in the high node 
and the opposite trend noted for B cells. The presence of greater numbers may 
be due to the fact that T cells are responding locally to the tumour. The T cell 
immune response can be observed more clearly in the trend observed for stage 
2 node subset A with low node tumour invaded and high node tumour free. 
Here the trend was within the T cell subsets with a greater percentage of CD8+ 
T cytotoxic cells within the low tumour invaded node than the high tumour 
free. The presence of the CD8+ cells may be due to an immune response 
initiated due the close proximity of tumour which may be recognised by MHC 
class 1 restricted cytotoxicity, in agreement with the larger study in chapter 4.
However more interestingly the phenotypic trends were generally less 
significant than for the two activation markers HLA DR and the interleukin-2 
receptor (IL-2R;Tac). The two markers of activation are both independant and
181
are initiated at different times after initial antigen stimulation with the IL-2R 
being expressed after 2 hours and HLA DR after 3-5 days (Abbas etal 1991; 
Tadatsugu and Minami, 1993). In general higher levels of HLA DR were noted 
in the stage 2 nodes than stage 1 agreeing with both Morton et al (1986) and 
Whitford et al (1992b). Trends in lymphocyte activation were only noted in 
stage 2 patients, suggesting that close proximity of tumour may initiate a 
greater immune response with HLA DR reflecting tumour invasion and the IL- 
2R the distance from the tumour. But within the low node the percentage of 
activation marker was generally greater. When the 22 stage 2 patients are 
divided, new trends are noted, as each group may represent a different type of 
tumour. A more agressive tumour may suppress the immune response and 
initiate few changes in the lymph nodes. Sub group B with both nodes invaded 
and HLA DR generally lower than the stage 2 mean may indicate this type of 
tumour. Whereas group A has tumour in the low node and levels of HLA DR 
are higher in both nodes than the mean stage 2 level, which could correspond 
to a local immune response throughout the nodes inhibiting the tumour from 
further metastasising possibly due to the type of the tumour. The presence of 
tumour in the nodes of breast cancer patients has been reported not to be a bad 
prognosis in all cases (Fisher et al 1980) which would agree with these 
findings that stage 2 patients can be subdivided with respect to their immune 
response in the nodes. The nodes that contain no tumour and are from an axilla 
with tumour present elsewhere sub group C may be interesting as they might 
show the first signs of tumour invasion. The activation levels of HLA DR are 
below the average found in stage 2 patients, however a trend is noted for 
increased IgG expression in these nodes above the mean stage 2 level. 
Possibly indicating a surface antigen or an internal mutant protein such as p53. 
p53 may be released due to the tumour undergoing immune attack or necrosis. 
However a B cell response may not be useful if the protein is internal such as 
p53.
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In conclusion the percentage of cells bearing the activation markers 
HLA DR and H-2R was observed to be higher in the low nodes rather than the 
high nodes which would indicate a greater immune response occurring within 
these nodes. This was noted for stage 1 and the pooled stage 2 patients but 
significance was only achieved for stage 2 patients with HLA DR mainly 
associated with tumour invasion and the IL-2R with distance from the tumour. 
These differences were seen within the stage II nodes when they were further 
subdivided. The main differences seemed to be from the subset with low node 
tumour invaded and high node tumour free. The trends of activation could 
signify that there are immune responses in both stage 1 and stage 2 tumours. 
However the presence of overall greater levels of HLA DR in stage 2 nodes 
would suggest that these patients are stimulating the immune system possibly 
due to the presence of greater levels of antigenic determinants on these tumours 
of stage 2 subsets.
CHAPTER 6
DNA AND ONCOGENE 
EXPRESSION IN PRIMARY 
AND METASTATIC BREAST
CANCER
183
6. DNA and oncogene expression in primary and 
metastatic breast cancer
There is increasing evidence that breast cancer has a multi-factorial aetiology 
and that a variety of prognostic indicators may be employed to assess the 
aggressive capacity of a primary tumour. Among a number of parameters, those 
which have been shown to correlate strongly with prognosis are cell cycle analysis 
at the DNA level (Section 1.4.2.2.), and cellular oncogene or mutant tumour 
suppressor gene product estimation at the protein level (Section I.4.3.). Cell cycle 
analysis, usually performed by flow cytometry, makes it possible to estimate the 
extent to which the primary tumour has aneuploid cells with abnormal DNA 
content together with the percentage of cells in the S phase of the cell cycle. 
Among the oncogene related proteins, which have generally been assessed by 
immunocytochemical methods, recent interest has centred on the c-erb B-2 gene 
product over-expressed on the surface of 20-30% of primary breast cancers (Clark 
and MacGuire 1991; Varley et al 1991; Gullick et al 1991) and the p53 mutant 
tumour suppressor gene product over-expressed in 50% of breast carcinomas 
(Cattoretti et al 1988; Bartek et al 1990).
Primary breast tumours, like most solid tumours of epithelial origin, 
generally show a heterogeneous cell population. This may reflect genuine tumour 
cell heterogeneity where metastatic subpopulations of the primary are most relevant 
to tumour progression. In addition, it may also include normal epithelial cells, 
stromal fibroblasts, and lymphocytes infiltrating the tumour (Whitford et al 1990). 
Thus DNA cell cycle analysis and oncoprotein expression estimation may indicate 
that a tumour is positive for one or both parameters but it has not been possible to 
judge whether all those cells within the tumour which have such genetic
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abnormalities are also those which carry the mutant or aberrantly expressed 
oncoprotein.
Flow cytometry, routinely used in lymphocyte analysis, has the advantage 
that up to five parameters on the same cell may be measured at the same time 
(Butcher et al 1991). In addition, information from 10,000 cells can be objectively 
collected and quantitated. Flow cytometry may be used to simultaneously analyse 
DNA and structural protein within the same cells of primary breast tumours (Zarbo 
et al 1989; Alam et al 1992). This has been adapted to estimate oncoprotein 
products on tissue culture cell lines (Kelsten et al 1990; Remvikos et al 1990) and 
primary tumour (Kelsten et al 1990 ; Morkve et al 1991a; Morkve et al 1991b; 
Hendy Ibbs et al 1987; Remvikos et al 1990).
This study describes an analysis of the expression of both p53 and c-erb 
B-2 in primary breast carcinomas and correlates the data with their ploidy 
status and metastatic capacity.
63 breast carcinomas were analysed simultaneously for DNA and p53 
expression. In this group of patients 61 were analysed for stage of tumour and 
50 for tumour grade.
51 breast carcinomas were analysed simultaneously for DNA and c-erb 
B-2 expression. Of this group 39 patients were analysed separately for grade 
of the tumour and 51 patients for tumour stage.
51 tumours were directly compared for both c-erb B-2 and p53 
expression.
The procedure for oncogene estimation is described in Section 2.2.4.6.
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6.1. Expression of the p53 and c-erb B-2 oncoproteins
To test the efficacy of the anti-p53 antibody and the anti- c-erb B-2 
antibody stained with fluorescein (FTTC), immunofluorescence was carried out 
on primary tumour. Both nuclear and cytoplasmic staining was noted for the 
p53 tumour suppressor protein and membrane staining was found for the c-erb 
B-2 proto-oncogene receptor.
Figure 6.1 illustrates c-erb B-2 and p53 flow cytometry
6.1.1. Cell lines
Three cell lines were analysed for p53 and c-erb B-2 expression (Table
6.1), two breast cancer lines MCF-7 and ZR-75 with known p53 and c-erb B - 
2 expression. The other cell line HL-60 is of a neutrophil origin, with a null 
p53 mutation. p53 positive cells were shown to be greatest in the ZR-75 cell 
line (90%), with the MCF-7 cell line expressing slightly less p53 at 75%. The 
control HL-60 was shown to have only 1% p53 expression.
The c-erb B-2 expression was highest in the ZR-75 cell line at 40%, the 
MCF-7 having less expression at 20%. The HL-60 cell line expressed a very 
small proportion of c-erb B-2 at 5%.
The experiment for the cell lines was done in duplicate to test 
reproducibility, there was less than 5% variation in the result achieved. In 
addition, when ethanol fixed cells were compared to non ethanol fixed for c- 
erb B-2 staining, less than 5% variation was again observed in the results.
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Figure 6.1 Flow cytometric analysis of the expression of the p53 and c-
erb B-2 oncoproteins in primary breast cancer.
Diagram A: The control stained with an irrelevant antibody.
Diagram B: The p53 oncoprotein positive tumour cells.
Diagram C: The c-erb B-2 oncoprotein positive tumour cells.
Blue cells = Diploid tumour cells 
Red cells = Aneuploid tumour cells 
Green cells = Positive for the oncoprotein
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Table 6.1.
Percent positive cells for p53 and c-erb B-2 in cell lines
Cell line Percent p53 Percent
positive cells c-erb B-2
positive cells
ZR75 90 40
MCF-7 75 20
HL-60 1 5
The result is given as cells positive for p53 and c-erb B-2 within the total cells 
analysed.
Table 6.2.
Mean percent cells positive for p53 or c-erb B-2 in primary breast tumours 
using the data from Figure 6.4
Mean Percent
positive cells
p53 c-erb B-2
(n=63) (n=51)
29 30
The values in the table are given as mean cells positive for the p53 or c-erb B-2 
proteins
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6.1.2. Tum our
The percentage of cells positive for p53 ranged from 5% to 84% (Figure
6.2) in the 63 tumours analysed, with an average positivity of 29% (Table
6 .2).
The percentage of cells positive for c-erb B-2 ranged from 1% to 89% 
(Figure 6.3) in the 51 tumours analysed, with an average of 30% (Table 6.2).
6.2. Co-expression of c-erb B-2 and p53.
There was no strong correlation between the expression of p53 and that 
of c-erb B-2 (Figure 6.4). The patient with the highest expression of both 
proteins was patient 61 with 89% cells expressing c-erb B-2 and 60% cells 
positive for p53. Other patients had the opposite trend such as patient 10 with 
high p53 expression and low c-erb B-2 expression. Overall the expression of 
the two proteins was very variable (Table 6.2) and no correlation was found 
using the Mann-Whitney test.
6.3. DNA ploidy and oncoprotein expression
The simultaneous measurement of both DNA and oncoprotein gives the 
advantage of observing expression derived from specific DNA populations 
such as the aneuploid population. Figure 6.1 illustrates a tumour expression of 
both c-erb B-2 and p53 with ploidy. In the total group of tumours analysed 
47/63 were aneuploid (75%) and 16/63 were diploid (25%) (Table 6.3).
1 8 9
Figure 6.2 p53 positive cells in 63 primary breast cancers
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100
1 9 0
Figure 6.3 c-erb B-2 positive cells in 51 primary breast cancers (patient 
numbers 1-36 and 49-63)
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Figure 6.4 p53 and Q-erb B-2 positive cells in 51 primary breast cancers 
(patient number 1-36 and 49-63)
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Table 6.3.
Mean Percentage of cells positive for p53 in comparison to tumour DNA 
ploidy
Tumour cell ploidy Statistical
Diploid Aneuploid significance
(n=16) (n=47)
mean % cells 
p53 positive
28 35 p=0.157
The values in the table are given as mean cells positive for the p53 protein in 
the diploid and aneuploid tumours
For comparison of two independent groups the Mann Whitney test was used. 
With significance being less than or equal to p= 0.05
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6.3.1. p53 and tum our DNA ploidy
The 16 diploid tumours analysed for p53 expression had a range of 
between 6% to 64% (Figure 6.5) with an average p53 positivity of 28% (Table
6.3). The 47 aneuploid tumours analysed had a greater range of 5% to 84% 
(Figure 6.5) and also a higher average expression. However the change 
although tending to be higher in the aneuploid tumours was not statistically 
relevant.
6.3.2. c-erb B-2 and tum our DNA ploidy
The 14 diploid tumours analysed for c-erb B-2 expression had a more 
restricted range of 1% to 48% (Figure 6.6) and a lower average expression of 
15% (Table 6.4) than the diploid tumours analysed for p53 expression. The 37 
aneuploid tumours had a much larger range of expression 5% to 84% (Figure 
6.6) with an average expression level of 35% (Table 6.4). The increase in 
expression in the aneuploid population was found to be not statistically 
relevant.
6.4. Oncoprotein expression in relation to the stage of 
the tumour
The oncoprotein expression was divided into stage 1 (no nodal 
metastases in the tumour draining lymph node) and stage 2 (with nodal 
metastases).
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Table 6.4.
Mean percentage of cells positive for c-erb B-2 in relation to tumour DNA 
ploidy
Tumour cell ploidy Statistical
Diploid Aneuploid significance
(n=14) (n=37)
mean % cells 
c-erb B-2 positive
15 35 p=0.123
The values in the table are given as mean cells positive for the c-erb B-2 protein 
in the diploid and aneuploid tumours
For comparison of two independent groups the Mann Whitney test was used. 
With significance being less than or equal to p= 0.05
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Figure 6.6 Distribution of c-erb B-2 positive cells within diploid (1) and
aneuploid (2) tumours
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6.4.1. p53 expression and stage of the tumour
p53 expression was divided into 26 stage 1 patients and 35 stage 2 
patients. The range of expression was greater in the stage 1 patients 6% to 
84% than the stage 2 patients range 2% to 64% (Figure 6.7). The average 
values reflected the range with stage 1 patients at 39% and stage 2 patients at 
28% (Table 6.5). These changes do not show any statistical significance.
6.4.2. c-erb B-2 expression and stage of the tumour
The expression of c-erb B-2 was divided into stage 1 and stage 2 
categories. The stage 1 tumours expressed on average lower levels of the c-erb 
B-2 protein of 22% than the stage 2 patients 36% (Table 6.6). The range of 
expression within the stage 1 patients 1% to 48% showed a much tighter range 
than that found in stage 2 patients 7% to 89% (Figure 6.8.). However this was 
not statistically significant
6.5. Expression of oncoprotein in relation to the grade 
of tumour differentiation.
The grade of the tumour is a measure of the differentiation within the 
tumour from grade 1 with little differentiation to grade 3 with extensive 
differentiation. The p53 and c-erb B-2 expression was divided into the three 
degrees of tumour differentiation.
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Figure 6.7 Distribution of p53 positive cells within patients with tumour free 
nodes (stage 1)(1) and tumour invaded nodes (stage 2)(2).
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Table 6.5.
Mean percentage of cells positive for p53 in relation to the stage of the tumour 
(lymph node status).
Histopathological staging Statistical
of tumour draining lymph nodes significance
Stage 1 Stage 2
(n=26) (n=35)
mean % cells 
p53 positive
39 28 p=0.187
The values in the table are given as mean cells positive for the p53 protein in 
stage 1 and stage 2 tumours
For comparison of two independent groups the Mann Whitney test was used. 
With significance being less than or equal to p= 0.05
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Table 6.6.
Mean percentage of cells positive for c-erb B-2 in relation to the 
histopathological staging of the tumour
Histopathological staging Statistical
of tumour draining lymph nodes significance
Stage 1 Stage 2
(n=21) (n=30)
mean % cells 
c-erb B-2 positive
22 36 p=0.143
The values in the table are given as mean cells positive for the c-erb B-2 protein 
in stage 1 and stage 2 tumours
For comparison of two independent groups the Mann Whitney test was used. 
With significance being less than or equal to p= 0.05
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Figure 6.8 Distribution of c-erb B-2 positive cells within patients with 
tumour free nodes (stage 1)(1) and tumour invaded nodes (stage 2)(2).
2 0 2
6.5.1. p53 expression and tumour grade
A trend of increasing p53 expression was noted in the change from a 
grade 1 tumour with average expression of 29% to a grade 2 tumour of 31% 
and then finally to grade 3 tumours of 46% (Table 6.7). However due to the 
small numbers of both grade 1 and 3 tumours this trend failed to be of any 
significance as a result of the wide range of expression (Figure 6.9.).
6.5.2. c-erb B-2 expression and tumour grade
When c-erb B-2 was compared with grade a trend of increasing 
expression with increasing grade was observed with grade 1: 24%, grade 2: 
25% and grade 3: 34% (Table 6.8). However this trend was not significant 
(Figure 6.10.).
6.6. Oncogene expression in the primary tumour and 
paired nodal metastases
In some of the cases the expression of p53 or c-erb B-2 was compared 
to the paired metastatic tumour within the tumour draining lymph nodes, to 
deduce if there are changes in expression on the oncoprotein during the 
metastatic process.
6.6.1. p53 expression and metastases
8 tumours were compared with their matched heavily invaded lymph 
nodes containing metastatic tumour (Figure 6.11a). In general the expression 
was similar in the metastases with in three cases little change in expression, 
three other cases an increase in p53 expression and in the two final cases a
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Table 6.7.
Mean percentage of cells positive for p53 in relation to histological grade of 
tumour differentiation
Histological grade of tumour 
differentiation
Grade I Grade n  Grade ID 
(n=8) (n=29) (n=13)
Mean %
cells p53 29 31 46 p=0.197 p=0.097 p=0.086
positive
The values in the table are given as mean cells positive for the p53 protein in 
the three different grades of tumour differentiation.
For comparison of two independent groups the Kruskal-Wallis test was used 
as three independent parameters were compared. With significance being less 
than or equal to p= 0.05
Statistical
significance
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Figure 6.9 Distribution of p53 positive cells within the three different grades 
of tumour differentiation.
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Table 6.8
Mean percentage of cells positive for c-erb B-2 in relation to histological grade
Histological grade of tumour Statistical
differentiation significance
Grade I Grade n Grade in 
(n=8) (n=24) (n=7) I vs II I vs HI II vs III
Mean %
cells p53 24 25 34 p=0.203 p=0.116 p=0.092
positive
The values in the table are given as mean cells positive for the c-erb B-2 protein 
in the three different grades of tumour differentiation.
For comparison of two independent groups the Kruskal-Wallis test was used 
as three independent parameters were compared. With significance being less 
than or equal to p= 0.05
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Figure 6.10 Distribution of c-erb B-2 positive cells within the three different 
grades of tumour differention.
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Figure 6.11a Comparison of p53 positive cells in paired primary and 
metastatic tumour.
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Figure 6.11b Comparison of c-erb B-2 positive cells in paired primary and 
metastatic tumour.
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decrease in the p53 expression. There was no change in the average expression 
of p53 within the tumour and metastases (Table 6.9). The metastases show no 
significant change in expression, thus are similar and reflect the expression in 
the primary tumour.
6.6.2. c-erb B-2 expression and metastases
6 patients with tumour and matched lymph node metastases were 
analysed for c-erb B-2 expression (Figure 6.11b). Little change was noted in 
one patient, an increase in c-erb B-2 expression was observed in three patients 
and in the two remaining patients a decrease in the c-erb B-2 expression was 
noted. The metastases show no significant change in expression, thus are 
similar and reflect the expression in the primary tumour (Table 6.9).
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Table 6.9.
Mean percentage positive cells for p53 and c-erb B-2 in paired primary and 
metastatic tumour
Tissue type Mean percent Mean percent
cells c-erb B-2 cells p53
positive positive
(n=6) (n=8)
Tumour 43 33
Metastases 43 34
The values in the table are given as mean cells positive for the c-erb B-2 protein 
in the three different grades of tumour differentiation.
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6.7. Discussion
This study was initiated to determine whether, within a heterogeneous 
primary tumour genetic changes such as aneuploidy correlate with the 
expression of proto-oncogene (c-erb B-2) or tumour suppressor gene (p53) 
products in the same cell population within the tumour. The degree of 
expression of the two proteins was independently assessed in comparison to 
both metastatic capacity and tumour differentiation.
Flow cytometry of proteins such as p53 and c-erb B-2 has certain 
advantages over traditional techniques such as immunocytochemistry as flow 
cytometry examines objectively a large number of cells in a short period of 
time. This removes the subjective nature often associated with 
immunocytochemistry. The only disadvantage is that the architecture of the 
tumour is lost during processing of the tumour and this is compensated for by 
the use of scatter and marker gating. The use of multiparameter flow cytometry 
described here shows that more than one marker can be examined on one cell. 
This has traditionally been used for lymphocytes but little work has been 
carried out on tumour cells. Using this technique the amount of oncoprotein 
staining can be evaluated simultaneously with DNA profile within the primary 
and metastatic tumour thus providing a greater understanding of what is 
occurring within a heterogeneous tumour population.
The efficacy of the staining procedure was evaluated by 
immunofluorescence staining of the primary tumour using the anti- c-erb B-2 
and anti- p53 antibody. Membrane staining was noted for the c-erb B-2 proto- 
oncogene receptor which was expected and little background fluorescence 
could be noted. The p53 staining was both cytoplasmic and nuclear which has
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also been reported (Section 1.4.4.2.). The HL-60 had negligible expression of 
p53 which corresponded to the null p53 mutation in its genome (Table 6.1).
At the genetic level amplification of genes in cells expressing c-erb B-2 
and p53 has been measured and no correlation was found. Analysis of the 
amplification of the specific oncogene may have limited relevance since ploidy 
analysis shows that the greater part of the entire genome is amplified in the 
majority of breast cancer patients, this being due to aneuploidy of the cell. The 
aneuploidy of the tumour seems to be related to the expression of especially the 
c-erb B-2 protein (Figure 6.6) rather than the p53 protein (Figure 6.5) with an 
example of the expression within aneuploid populations shown in Figure 6.1. 
Reports have linked expression of c-erb B-2 to aneuploidy (Section 1.4.5.) but 
the methods utilised have been immunocytochemistry and a separate DNA 
ploidy analysis. Here the two are simultaneous on one cell showing a direct 
relationship. There have been reports on tetraploid tumours expressing higher 
amounts of c-erb B-2 but in this study this was found not to be the case.
An interesting aspect of this study is the fact that even on cell lines there 
is never 100% expression or 0% expression of either the p53 or c-erb B-2 
protein (Figure 6.2 and Figure 6.3) and this disputes the data obtained from 
immunochemistry. The theory of the tumour being clonal in origin would be 
questioned by this data. However the experience in the study of leukaemia 
suggests that all clonal tumours have the capacity to generate terminally 
differentiated progeny which carry a different complement of cellular markers 
(Greaves 1982). Thus, while the non staining cells may be normal epithelia or 
stroma, it is also possible that they form part of the tumour cell lineage, but at 
another window of differentiation. This being supported by the fact that similar 
expression is often observed in the metastases where stromal or normal 
epithelial cells are not present (Table 6.9).
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The expression of the oncoproteins were compared directly with the 
presence or absence (stage 1 or stage 2) of tumour cells within the tumour 
draining lymph nodes. The p53 gave no significant trends whereas higher 
levels of expression of the c-erb B-2 tended to be greater in stage 2 patients. 
This agrees with results published for p53 and c-erb B-2 (Section 1.3.).
The degree of tumour differentiation was compared to the expression of 
both p53 and c-erb B-2 (Table 6.7 and Table 6.8). There were no statistically 
relevant trends noted. However the grade 3 tumours tended to express more of 
both p53 and c-erb B-2.
Analysis of the expression of oncoproteins such as p53 and c-erb B-2 
within the metastatic tumour population of the lymph node has to date been 
attempted but this is difficult due to the presence of a large quantity of 
lymphocytes. The use of a scatter gate described in Section 2.2.6.2. provides a 
means to eliminate the lymphocytes due to their defined size. The lymph nodes 
contain pure metastatic tumour with no other stromal or epithelial 
contaminating cells. In consequence of this fact the nodal population assessed 
is almost entirely epithelial tumour cells. The percentages of both p53 and c-erb 
B-2 in the nodal metastases is variable (Figure 6.11a and Figure 6.11b) with 
some expression at higher levels than those found in the parent primary 
tumour. Overall,the metastases expressed both the proteins to a high level with 
all the metastases consisting of aneuploid tumour cells with a similar 
expression to the parent primary tumour. The result would suggest that the 
expression of p53 and c-erb B-2 could be involved primarily with the initiation 
of the tumour rather than progression. For the progression of the tumour 
multifactorial events would be necessary for successful metastatic capability.
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From the results it seems that c-erb B-2 has trends associated with both 
stage (presence of metastases in the lymph nodes) and ploidy of the tumour. 
This suggests that c-erb B-2 may play an important role in the possible 
generation of metastatic capability of the tumour. In contrast the p53 has no 
trends, with only a weak tendency for increasing expression in aneuploid 
tumours which may indicate a possible role in early tumour generation.
CHAPTER 7
THE EFFECT OF TUMOUR 
TYPE ON THE IMMUNE 
RESPONSE IN THE TUMOUR 
DRAINING AXILLARY 
NODES
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7. The effect of tumour type on the immune response in 
the tumour draining axillary nodes.
An immune response to breast cancer has been implicated within the 
primary tumour in the form of tumour infiltrating lymphocytes, in the tumour 
draining axillary lymph nodes and to a much lesser extent the blood. The 
changes observed within these areas occur in both phenotype and activation of 
the lymphocytes. The antigen or antigens which are stimulating the immune 
system in breast cancer patients are still as yet unknown. The study of the 
oncology of the disease provides some possible candidates. The p53 nuclear 
protein is found in a mutated form in over 50% of all breast cancers. As it is an 
internal protein a T cell response would normally be elicited. However if the 
protein is released from the cell then a B cell immune response would occur. 
Other possible antigens would include ras with point mutations at position 12 
and 13. Other proteins such as c-erb B-2 over-expressed in 20-30% of all 
breast cancers are normal and should in theory have no effect on the immune 
system.
In this study the p53 protein was measured along with the c-erb B-2 
protein in primary tumour in 22 patients (11 stage I and 11 stage II), 
simultaneously with the immune response within the tumour draining nodes of 
these patients to examine the effect of these two proteins on the nodal immune 
response. The ploidy of the tumour was also compared to the nodal immune 
response in these 22 patients.
These patients were 22 of the patients analysed in Chapters 5 and 6
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The gating and staining of lymph node lymphocytes is illustrated in 
Section 2.2.6.1. and 2.2.6.2. along with the estimation of p53 and c-erb B-2 
expression in primary tumour and also determination of DNA ploidy (Section 
2.2.6.7 and 2.2.6.8).
7.1. Comparison of p53 and c-erb B-2 expression to the 
immune response in the low and high axillary nodes
7.1.1. Phenotypic markers
No significant trends were noted for p53 and c-erb B-2 positive cells in 
the primary tumour in relation to phenotypic change in the low and high nodes 
for both stage I (Table 7.1) and stage II patients (Table 7.2).
7.1.2. Activation markers
No significant trends were found for p53 and c-erb B-2 positive cells 
within the primary tumour in relation to lymphocyte activation in stage I 
patients (Table 7.1). The only trend noted was p53 expression in relation to 
increasing interleukin-2 receptor (IL-2R) on low lymph nodes of stage II 
patients (p=0.009) (Table 7.2 Figure 7.1).
7.2. Ploidy and the immune response in the axillary 
tumour draining nodes.
The low and the high node percentages for phenotype and activation 
were averaged and compared to the ploidy of the tumour (Table 7.3).
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Table 7.1
Effect of p53 and c-erb B-2 expression in primary tumour on the immune 
response in the low and high axilla of stage I patients.
Lymphocyte Statistical significance+
Phenotype/ Tumour cells p53 Tumour cells c-erb B-2
Activation positive positive
CD3 (%T cells) p=0.134 p=0.129
CD 19 (B cells) p=0.110 p=0.125
CD8 (CD8+ T cells) p=0.089 ii o
 
»—»
CD4 (CD4+T cells) p=0.153 p=0.139
CD3/CD19 ratio p=0.122 +3 II O *—
i
CD4/CD8 ratio p=0.167 p=0.117
HLA DR on CD8+ T cells p=0.187 p=0.156
HLA DR on CD4+ T cells p=0.109 p=0.173
Interleukin-2 receptor (Tac) 
on CD8+ T cells p=0.169 p=0.176
Interleukin-2 receptor (Tac) 
on CD4+ T cells p=0.097 +3 II O t—
k 00
slgG on CD 19+ B cells p=0.141 p=0.158
+ Statistical significance was assessed by the Spearman rank correlation with 
significance being less than or equal to p=0.05
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Table 7.2
Effect of p53 and c-erb B-2 expression in primary tumour on the immune 
response in the low and high axilla of stage n  patients.
Lymphocyte
Phenotype/
Activation
Statistical significance+ 
Tumour cells p53 Tumour cells c-erb B-2
CD3 (%T cells) p=0.127 p=0.23
CD 19 (B cells) p=0.162 p=0.142
CD8 (CD8+T cells) p=0.128 p=0.153
CD4 (CD4+T cells) p=0.145 +3 II O to
CD3/CD19 ratio p=0.162 p=0.176
CD4/CD8 ratio p=0.137 p=0.124
HLA DR on CD8+ T cells p=0.098 p=0.155
HLA DR on CD4+ T cells p=0.093 p=0.135
Interleukin-2 receptor (Tac) 
on CD8+ T cells p=0.068 p=0.168
Interleukin-2 receptor (Tac) 
on CD4+ T cells p=0.009* p=0.126
slgG on CD 19+ B cells p=0.098 p=0.132
* Statistical significance to the low node
+ Statistical significance was assessed by the Spearman rank correlation with 
significance being less than or equal to p=0.05
%
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Figure 7.1 The expression of the interleukin-2 receptor (IL-2R) on stage II 
low node in relation to p53 expression in the primary tumour.
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Table 7.3
Distribution of phenotypic and activation markers in lymphocytes from lymph 
nodes of breast cancer patients with diploid and aneuploid tumours.
Phenotypic/
Activation
markers
Diploid
(n=7)
Aneuploid
(n=15)
Statistical
Significance+
CD3/CD19 ratio 1.0 2.4 p=0.152
CD4/CD8 ratio 3.5 3.6 p=0.110
HLA DR on 
CD8+ T cells 44.5 57.0 p=0.139
HLA DR on 
CD4+ T cells 28.7 36.7 p=0.122
Interleukin-2 
receptor (Tac) 
on CD8+ T cells 9.3 16.2 p=0.134
Interleukin-2 
receptor(Tac) 
on CD4+ T cells
18.5 22.1 p=0.158
slgG on CD 19+ 
B cells
19.9 32.6 p=0.04
+ Statistical significance was assessed by the Mann-Whitney U test, with 
significance being less than or equal to p=0.05
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7.2.1. Phenotypic markers
There was no difference in terms of phenotype of T or B cells with the 
ratio of CD3/CD19 and CD4/CD8 being similar in both aneuploid and diploid 
tumours.
7.2.2. Activation markers
Differences were observed in the activation states of both T and B 
lymphocytes compared to ploidy (Table 7.3). However, although not 
statistically significant HLA DR was expressed on a higher proportion of 
CD8+ T cells in the aneuploid tumours (57.0%) than the diploid tumours 
(44.5%). This was also observed for the HLA DR expressing CD4+ T cells in 
the aneuploid (36.7%) and diploid (28.7%) tumours. No significant trends 
were observed for interleukin-2 receptor (IL-2R) expressing T cells. The IL- 
2R+ CD8+ T cells show increased expression within the aneuploid tumours 
(16.2%) than diploid tumours (9.3%). Again this trend was also observed for 
the IL-2R expressing CD4+ T cells in the aneuploid (22.1%) compared to 
diploid tumours (18.5%).
The only significant difference observed for activation of lymphocytes 
was observed in the slgG expression in the aneuploid tumours (32.6%) 
compared to diploid tumours (19.9%) with a significance of p=0.04.
The trend in B cell activation and the higher levels of activation in 
aneuploid tumours compared to diploid may indicate more antigenic 
determinants within aneuploid tumours.
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7.3. Discussion
In this chapter the immune response in the lymph node lymphocytes 
was compared to some of the possible causative factors. p53 is to date the most 
commonly mutated protein in breast cancer with 50% tumours showing 
mutation of this protein. As p53 is an internal protein found mainly in the 
nucleus a T cell response should be initiated. This would involve the 
proteolysis of the protein to peptides which then associate with the MHC class 
I protein in the endoplasmic reticulum eventually to be presented on the surface 
of the tumour cell to the cytotoxic T cell (CD8) arm of the immune system. For 
p53 expression only one trend is observed that of the IL-2R on CD4+ T cells 
in the low node of stage II patients (Figure 7.1), suggesting p53 is stimulating 
the nodal CD4+ T helper cells. Since CD4+ T cells process largely exogenous 
antigen, they may use free p53 released from dying tumour cells.
In Chapter 5 the trend of increasing IL-2R in the low node was the most 
statistically relevant one noted. Thus the change in this subset may be an 
important indicator of an immune response in stage II patients with high p53 
expression. A B cell response to p53 has been shown as the presence of anti- 
p53 IgG in sera of 10% of patients (Crawford et al 1979). This would be due 
to the tumour cell releasing its contents allowing the mutant p53 protein to be 
seen by the B cell arm of the immune system. This response would possibly be 
clinically ineffective due to the internal location of the mutant p53 as antibodies 
generally cannot enter live cells. Apart from this, other activation markers 
failed to reach significance and this may be possibly due to the loss of MHC 
expression in the tumour thus making a response in these patients more 
difficult. Also the mutation in the p53 protein may not allow presentation of
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peptides derived on the MHC groove as only certain types of peptides can be 
presented by each MHC molecule to elicit an immune response.
No response to c-erb B-2 was noted for either T or B cells. This protein 
is normal and over-expressed in breast cancers. Thus no response may be 
initiated. If a functionally useful response was formed it would be seen in the 
form of IgG as c-erb B-2 is a receptor found on the surface of tumour cells.
Alterations in activation were noted in the lymph nodes in relation to 
ploidy. No changes were observed in the phenotype of lymphocytes when 
nodal lymphocytes from diploid and aneuploid patients were compared. The 
only significant trend was associated with the expression of slgG on B cells 
which was higher in the aneuploid patients. Although no significant trends for 
T cell activation were observed HLA DR and IL-2R expression were higher in 
all cases in the aneuploid tumours. The data would possibly suggest that 
aneuploid tumours may express more antigens than diploid tumours. Chapter 6 
indicated weak but not significant trends for both p53 and c-erb B-2 and 
aneuploidy. However the presence of a mutant protein does not necessarily 
mean an immune response as the full mechanism for antigen processing and 
presentation must be intact to initiate this response.
CHAPTER 8 
GENERAL DISCUSSION
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8. General Discussion
During this study a number of aspects of breast cancer oncology and 
immunology have been investigated by flow cytometry. For this to be 
accomplished samples of patient tumour, blood and tumour draining lymph 
nodes were obtained for investigation. The expression of the y/8 T cell receptor 
was investigated in the blood, nodes and tumour infiltrating lymphocytes of 
breast cancer patients (TILs) (Chapter 3). The axillary tumour draining lymph 
nodes were investigated for the effect of metastatic tumour on their 
immunological function (Chapter 4) and the two factors of distance and 
presence or absence of tumour were also investigated as possible modulating 
factors (Chapter 5). The expression of two oncoproteins p53 and c-erb B-2 
were estimated in the tumour and related to tumour type and stage of the 
tumour (Chapter 6). Finally the expression of c-erb B-2 and p53 were 
interrelated to the changes occurring in the lymphocytes within the tumour 
draining axillary lymph nodes (Chapter 7).
8.1. Flow cytometry
Flow cytometry has been used throughout this study. It has certain 
advantages over other techniques such as the more commonly used 
immunocytochemistry. The machine is run by computer which allows 
objective collection of data. The number of cells analysed can be as high as 
50,000 for each sample in a relatively short space of time. Another advantage 
is that dead cells can be excluded from the analysis, as often these cells will 
bind the antibody non specifically and removal of these cells from the analysis 
will increase accuracy. Also it is possible to select for populations of defined 
size on the basis of FSC (forward scatter) and SSC (side scatter) such as
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lymphocytes. An exclusion gate for lymphocytes can also be set as tumour 
infiltrating lymphocytes (TILs) which can make up 80% of the tumour cell 
bulk (Whitford et al 1992a). Different parameters can be studied on the same 
cell such as phenotype and activation of lymphocytes or oncoprotein 
expression in relation to DNA ploidy. The sensitivity of the technique with 
respect to immunochemistry became particularly evident in this study where 
several times flow cytometry detected tumour cells in nodes where 
conventional pathology did not. This was also shown for the detection of p53 
and c-erb B-2 positive cells in the tumour, when a certain percentage was 
positive in almost every case. Some of these weak positives may be clinically 
relevant yet score negative in immunochemistry. However useful flow 
cytometry can be, there are certain drawbacks such as the sample to be 
analysed has to be completely disaggregated. This disrupts normal inter­
cellular architecture and unlike histochemistry it is not possible to observe the 
relationship between staining cells and the rest of the tissue.
8.2. The immune response to breast cancer
Tumour immunology is a complex and fast moving field and one which 
becomes more complex as further advances are made in both immunology and 
oncology. Primary tumours are heterogeneous in cell population, with the 
sequence of genetic events leading to tumour development and metastasis 
probably differing between patients. On top of this, the patients’ own immune 
response to any oncoprotein will depend on their genetic makeup, especially 
the HLA antigens. Thus one patient may respond to mutant p53 protein while 
another may not. This heterogeneity of both tumour and response capability 
means that, ideally, a study such as this should have used more parameters and
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many more patients. Yet even if the cost and man hours had been available, 
modem clinical diagnostic techniques have resulted in smaller tumours due to 
earlier treatment. In addition the sampling of the tumour takes place at a fixed 
point during the progression of the disease and this will obviously vary among 
patients. More importantly, the full complement of oncogenes and potential 
immune defence mechanisms are probably not yet known. To give relevant 
examples it is exceedingly difficult to find "new” oncogenes and "gene 
knockout" mice lacking major components of the immune system which do not 
have accelerated rates of tumour development.
The y/8 T cell receptor has not yet been found a well defined role in 
immunology and tumour immunology. The presence of the y/8 T cell receptor 
varied between tissues of the immune system of the breast cancer patients 
(Chapter 3). Within the Tumour Infiltrating Lymphocytes (TILs) the median 
value was highest for the CD3+ CD8+ y/8 subset. The presence of this (the y/8 
T cell receptor) on the CD8+ cytotoxic T cells may indicate a possible cytolytic 
function, as within the TIL population of breast cancer patients the majority of 
lymphocytes are CD8+. The lymph node lymphocytes showed a trend of 
increasing CD3+ CD4+ y/8+ lymphocytes compared to the TILs and the 
peripheral blood lymphocytes (PBL). This corresponds to the study by 
Whitford et al (1992b) suggesting that the CD4+ T cells make up the majority 
of lymph node lymphocytes. These CD3+ CD4+ y/8+ cells may play a role in 
the regulation of the immune response in these nodes. More interestingly, the 
double negative cells (CD3-, CD4-) make up the majority of the y/8 subset 
indicating that these cells may function without the need for MHC molecules 
and thus, since tumours often lack MHC expression, these cells may have an 
important role to play.
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The axillary nodes occupy an important position in breast cancer, as 
they are a potential site of an immune response against the cancer and also 
usually the first site of secondary metastatic tumour. Thus it is important to 
determine the role of these nodes in generating an immune response against the 
tumour and whether metastases affect this in any way. Earlier flow cytometric 
studies have indicated host mediated immune responses occur in some 
patients,.with both phenotypic and activation changes in the lymphocytes 
observed in the nodes (Whitford et al 1992b; Morton et al 1986). These studies 
involved both stage I and stage II patients, in general, using only tumour free 
nodes. The present study analysed the difference between a tumour invaded 
and a tumour free node taken from the same patient to compare intra patient 
variability in respect to the possible host tumour interactions taking place.
The presence of metastatic tumour altered both phenotype and activation 
of the lymphocytes. The CD8+ T cell population was found to be raised in the 
tumour invaded node. This reflects the observation in breast cancer TILs as 
here the CD8+ population make up the majority of lymphocytes. Thus in the 
tumour and the tumour invaded lymph node the close proximity of tumour may 
cause proliferation of these lymphocytes. Along with the increase in CD8+ T 
cells the proportion of CD4+ T helper cells decreases in tumour invaded nodes. 
This may indicate that although certain populations are proliferating others are 
possibly being actively suppressed. For example most breast cancer cells 
secrete TGFp, a powerful immunosuppressant.
The indication of the changes occurring in the tumour invaded lymph 
nodes compared to the tumour free raised the question of proximity. How 
close did the tumour need to be to elicit an immune response? Distance from 
tumour was taken into account with a low node and a high node removed from 
the breast cancer patients for both stage I and stage II patients (Chapter 5).
227
There were significant phenotypic changes for T and B lymphocytes but only 
in stage I nodes. However the most significant trends were for lymphocytic 
activation and stage II nodes. The trend of increasing activation in a low node 
occurred in all cases being very significant for expression of IL-2R on CD4+ T 
helper cells. The presence of increased levels of the IL-2R on CD4+ T cells 
could indicate that these cells may be mediating a local response against the 
tumour in the stage II nodes where tumour has metastasised. This result must 
be treated with caution as down regulation of this receptor occurs soon after 
binding of the ligand. Thus lack of the receptor does not necessarily mean an 
inactive state. Fisher et al (1980) reported that a subset of stage II patients, 
survived even with suspected nodal metastases. This would suggest that the 
stage II patients could be divided into 4 further subgroups depending on the 
nodal tumour invasion in the low or high nodes. The subgroup having low 
node tumour invaded and high node tumour free showed some trends for both 
phenotype and activation. The phenotypic change was with the T cell subsets, 
showing a decreased CD4/8 ratio in the low node with respect to the high 
node. This was due to the presence of increased amounts of CD8+ T cytotoxic 
lymphocytes in the tumour invaded node possibly involved in an effective local 
response against the tumour. The same trend was observed in the study carried 
out on tumour invaded and tumour free nodes in Chapter 4. This subgroup 
also showed activation trends for both IL-2R and HLA DR with the low node 
having significantly higher expression. The level of HLA DR, IL-2R and IgG 
on B cells was also shown to be higher than the mean stage II expression 
possibly indicating a greater immune response against the tumour in this stage 
II subgroup.
This notable difference within the nodal immune response for both 
phenotype and activation may reflect differences in host immunity or it may 
reflect different tumour types. The measurement of the immune response in
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relation to the tumour type may provide clues of the origin of this response. 
For a response to occur an antigenic protein must be presented to the immune 
system. The B cell arm may only be effective if the antigenic protein is external 
or soluble (Chapter 1). Although a B cell response to internal antigens may be 
generated, it is difficult to envisage any functional utility. The T cell arm main 
requirement is for the antigen to be presented either after internal synthesis and 
assembly on MHC class I antigens (CD8+ cytotoxic T cells) or after internal 
degradation and presentation on MHC class II antigens (CD4+ T helper cells). 
To date, no mutant external antigen has been recognised in breast cancer*. 
However, the first well characterised internal antigen has been identified by 
van Der Bruggen et al (1991). This was identified from melanoma and called 
MAGE. The function of this protein is as yet unknown, but it is expressed on 
40% of all melanomas and on a smaller proportion of breast cancers. The most 
commonly mutated protein in breast cancer is p53 with mutations reported in 
50% of all tumours (Bartek et al 1990). p53 being expressed within the cell 
therefore, could initiate an effective T cell response. In contrast to this another 
common protein in breast cancer c-erb B-2 is a receptor protein overexpressed 
in 20-30% of all breast cancers (Clark and McGuire, 1991). This is "self’ but 
overexpressed and in theory unlikely to elicit a B cell response.
The p53 (mutant) and c-erb B-2 (normal) proteins were measured by 
flow cytometry to assess their importance in both oncology and immunology 
of breast cancer. The p53 protein was not associated with any tumour variable. 
The c-erb B-2 protein although not significantly associated with any variable 
had weak trends to increased expression in aneuploid and stage II tumours 
possibly indicating tumour aggressiveness. The paired metastases compared to 
the primary showed little change in expression thus possibly indicating a role 
in tumour generation rather than progression for both p53 and c-erb B-2.
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The values obtained for percent c-erb B-2 and p53 positive cells along 
with tumour ploidy were compared to the immune response in the 
corresponding tumour draining lymph nodes. No trends for c-erb B-2 were 
noted for either lymphocyte phenotype or activation suggesting that c-erb B-2 
was not stimulating a B or T cell immune response as the protein is normal and 
overexpressed. The p53 protein was also compared to the nodal response and 
only one trend was observed, that of increasing p53 expression with increasing 
IL-2R expression on CD4+ T helper cells. This trend indicated a possible link 
between p53 and the immune system. Aneuploid tumours were associated 
with an increase in IL-2R, HLA DR and slgG expression with the slgG 
showing significance (p=0.04). It appears that there may be some antigenic 
determinants in aneuploid tumours that are absent in diploid tumours. This 
would suggest an antigenic protein(s) expressed in some aneuploid tumours 
may be mediating an immune response. This protein may not be p53 as it is not 
associated with aneuploidy thus some unknown proteins may be stimulating 
the immune system.
If the antigenic proteins can be determined then the hope lies for directed 
immunotherapy. The only defined antigen so far is MAGE (van Der Bruggen 
et al 1991) expressed on 40% of melanomas and 25% of breast cancers. It 
would be possible soon after surgery to test for this antigen. If it was present a 
suitable vaccination strategy could be prepared. However the MAGE antigen is 
only presented to the immune system in the 25% of melanoma patients who 
carry HLA Al. Thus with 40% total expression of MAGE and only 25% 
suitable, this gives only 10% of melanoma patients the possibility for 
vaccination. Even then an intact immune system would be be necessary to elicit 
an effective immune response. Tumours have been shown to have reduced 
expression of the MHC class I molecule necessary for a CD8+ cytotoxic T cell
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response (Whitford et al 1992a). Thus even in this 10% subset steps may be 
needed to bolster the immune system.
8.3. Surgery and treatment of breast cancer
The treatment of breast cancer involves the removal of the primary 
tumour and the axillary lymph nodes in an attempt to limit secondary metastatic 
spread of tumour. As knowledge has increased, the type of surgery has 
changed from the Halsted radical mastectomy which favoured en bloc removal 
of the breast and the surrounding area. Today more conservative surgery is 
advocated with a simple mastectomy or even a lumpectomy followed by 
chemotherapy or radiation therapy. There still remains some controversy over 
breast cancer treatment with each surgeon often performing different 
procedures. Most surgical debate lies in the treatment of the axillary tumour 
draining lymph nodes. The surgeon has a number of options; either sample the 
low axilla for tumour, leave the axilla intact or remove the entire axillary nodes. 
However removal of the entire axilla is a skilled operation and in many cases 
only surgeons in large centres attempt it. Other surgeons argue that to leave the 
axilla intact will not compromise the patients survival. This is based on the 
Fisher trial (Fisher et al 1980) which showed that survival was not adversely 
affected in some patients in whom no axillary clearance was performed, but 
who statistically may be presumed to have had lymph node metastases. Thus 
lack of axillary clearance does not affect the survival in some breast cancer 
patients. However this has been disputed by others (Fentiman and Mansel, 
1991), who point out that this trial was performed before the successful use of 
systemic adjuvant chemotherapy had been established and as such the findings 
are not valid. Recent trials have reinforced this, indicating that adjuvant chemo- 
endocrine therapy can significandy reduce both recurrence and death in breast
23 1
cancer patients (Early Breast Cancer Trialists Collaborative Group, 1992). 
However if any breast cancer patient is immunologically responding to the 
tumour, removal of the axillary lymph nodes may be detrimental.
In conclusion, a fuller understanding of the immune response and its 
target of of tumour specific antigens is necessary before treatments can be 
designed to utilise this response.
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